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ABSTRACT
Numerous linear, water-soluble polymers (particularly polyanions) are 
biologically active and can induce cytokines such as tumour necrosis factor-alpha 
(TNF-a), interferon-gamma (IFN-y) and interleukin-2 (IL-2) from cells depending on 
their molecular weight (MW), and composition. The proinflammatory cytokines 
TNF-a and IFN-y are able to permeabilise epithelial barriers by affecting the protein 
composition of the tight junctions (TJ) (Walsh et al., 2000). The aim of this work 
was to identify polymers that would promote enhanced drug delivery due to their 
inherent ability to stimulate TNF-a, IFN-y and IL-2 release, and therefore transiently 
permeabilise epithelial barriers. Several linear polyanions already used as excipients, 
including alginate, hyaluronic acid (HA), and polyacrylic acids (PAcA; MW 30,000, 
100,000, or 450,000 Da), were chosen as the first polymer library to investigate. 
Branched polymers including polyamidoamine (PAMAM) generation 3.5 dendrimers 
and the polycation polyethylenimine, PEI (MW 750,000 Da), were also studied.
Polyanions showed little cytotoxicity towards B16F10 cells and ECV304 cells 
at 72 h except PAcA of MW 100,000 Da in both cell lines, and 450,000 Da in 
B16F10. PEI was cytotoxic at low concentrations. Decreasing the incubation time to 
1 h reduced polymer cytotoxicity (IC50 > 1 mg/mL) with the exception of PEI. 
Highest amounts of TNF-a, IL-2 and IFN-y release from B16F10 and RAW 246.7 
cells were seen with PEI (1 mg/mL). HA and HA sodium salt induced TNF-a release 
from DU937 cells in concentration-dependant manner. In transport studies, FITC- 
dextran transfer was greatest in the Ap-*Bas direction, and in the absence of Peyer’s 
patches. Cytokines had no significant effect on FITC-dextran transport, at either 
physiological or ng/mL concentrations. Polymers appeared to inhibit FITC-dextran 
transport in all directions and tissue types, though apically applied PAcA (MW 
30,000 Da) and HA (1 mg/mL), showed some increase. This data was not significant. 
Lastly, PAcA (MW 30,000 Da) and PAMAM generation 3.5 dendrimers were 
labelled with OG cadaverine (OGcd) to monitor their transport across rat intestinal 
tissue (with or without Peyer’s patches) also using the vertical diffusion system. The 
uptake of the polymers into Caco-2eBe cells (chosen as an enterocyte model) was 
investigated using flow cytometry. Fluorescently-labelled PAcA- (MW = 30,000 Da) 
and PAMAM-OG conjugates showed a greater rate o f transport in the Bas-»Ap 
direction. The conjugates did not appear to be taken up by Caco-2BBe cells.
Although the scientific literature had suggested that certain polymers promote 
cytokine release, and that specific cytokines increase gastrointestinal permeability, it 
proved difficult here to validate the hypothesis that polymers might be designed to 
enhance transport in a reproducible and safe manner.
i
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CHAPTER 1:
General Introduction
CHAPTER 1: General Introduction
1.1 INTRODUCTION
The idea of using ‘nanomedicines’ as contemporary therapeutics has been the 
subject o f much debate over recent years, and is often stigmatised as science fiction 
(The Lancet, 2003). However, research into the development of nano-sized, water- 
soluble polymers and polymer-constructs to use as drugs and pro-drugs rather than 
drug delivery systems, has a well-established history (Figure 1.1).
Natural polymers have unknowingly been used in herbal remedies for several 
millennia. Hermann Staudinger first discovered polymers in the 1920’s (reviewed in 
Miilhaupt, 2004). Synthetic polymers (i.e. polyvinylprrolidone) first appeared in 
medicine as plasma expanders during World War II, and were later developed into 
polymer-drug conjugates in the 1950’s (Jatzkewitz 1954). Later still, a rapid 
advancement in polymer chemistry in the 1960’s and particularly 1970’s, brought the 
concepts o f block copolymer micelles (Gros et al., 1981) and PEGylated proteins 
(reviewed by Davis, 2002) into light, and fuelled the synthesis of new polymeric 
drugs. Around this time increased attention was also paid to the biological properties 
o f both natural and synthetic polymers (reviewed in section 1 .1 .1).
In the m id-1970’s it was noted that endocytosis (process by which materials 
enter a cell without passing the membrane) could be used for lysomotropic drug 
delivery (DeDuve, 1974), and that soluble, synthetic polymer-drug conjugates could 
be tailor-made into targeted drug carriers (Ringsdorf, 1975). These ideas inspired 
Duncan, Kopecek and their co-workers to produce Prague-Keele 1 (PK1), the first 
polymer-anticancer drug conjugate to enter clinical trials (Vasey et al., 1999), and 
later PK2, the only targeted polymer-anticancer drug conjugate to enter clinical trial 
to-date (Seymour et al, 2002).
Next, research towards the molecular basis o f disease in the 1980’s and 1990’s 
saw increased interest in polycationic non-viral vectors to deliver genetic material 
(Wagner, 1990; Boussif et al., 1995). It was also the time that Maeda and colleagues 
discovered the enhanced permeability and retention (EPR) effect within tumours 
(Matsumara and Maeda, 1986), a phenomenon which is now used to passively target 
“polymer therapeutics” into tumours from the vasculature (Figure 1.2).
Polymer therapeutics is a descriptor founded by Duncan (1997), to encompass 
the wide range o f polymeric nanomedicines previously described, and has now grown 
to include new polymers with increasingly intricate structures, tailored surface multi­
valences and defined architectures (reviewed in Duncan, 2003).
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However, as the new millennium progresses, current polymer research is 
turning once again to biologically active molecules, focusing on the relationship 
between their structure and properties, in an attempt to understand the structure- 
activity relationships that govern their behaviour. In light of this trend, biologically 
active polymers were investigated here as potential tools to enhance barrier 
permeability.
The overall aim of this project was to identify polymers capable of transiently 
permeabilising biological barriers such as the epithelial mucosa of the gastrointestinal 
tract, or endothelial barriers of the vasculature. Polymers capable of promoting drug 
transfer across these tissues, either directly, or through their ability to induce cytokine 
release (discussed below), could then be used to enhance the delivery of poorly 
absorbed drugs and macromolecules. In addition, they could also be used to increase 
drug accumulation in tumours by exaggerating the EPR effect (see Figure 1.2), and at 
the same time, initiate a local immune response towards it.
More specifically, rat intestinal tissue was chosen as an epithelial model for 
these studies, and the vertical diffusion system was used to measure the effects of 
cytokines or polymers on the transport of a fluorescent marker across this barrier. 
The polymers and cytokines chosen for this project are described in detail in the 
following sections, and as this work encompasses several disciplines, biologically 
active polymers, the immune system, cytokines and the intestine are also described. 
The specific aims of the project will be discussed at the end of this Chapter.
1.1.1 Biologically active polymers
Unlike the chemically inert polymers that have been chosen for conjugation to 
proteins and drugs (such as N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers, which are non-immunogenic and non-toxic in the body at doses of up to 
20 g/patient (Vasey et al., 1999)), biologically active polymers elicit pronounced 
effects in living systems and can be thought of as polymeric drugs (reviewed by Liao 
and Ottenbrite, 1997). In a broad sense, the term biologically active can include a 
number of inherent activities such as the ability to mediate an immune response, 
and/or to inhibit enzymes, bacteria and viruses, or to act as antitumour agents (De 
Somer, 1968). Examples of biologically active polymers are shown in Table 1.1.
4
Table 1.1 Biologically active polymers with immunomodulatory or other biological properties.
Polymer Type Charge Activity References
Acetyl lignin Polysaccharide Anionic Induce cytokines from macrophage (Sorimachi e ta l, 1999)
Bacteroides fragilis Polysaccharide Zwitterionic Induces IL-2, and activates T-cells (Stingele et al., 2004)
polymers A and B
Calcium spirualn Polysaccharide Anionic Anticancer activity (Mishima et al., 1998)
Carbetimer Synthetic Anionic Anticancer activity (Hanauske et al., 1988)
Activates T cells
Chitosan Polysaccharide Cationic Induces cytokines from macrophage (Zhijun et al., 2004)
CT-1 Polysaccharide Anionic Anticancer activity (Fernandez et al., 1989)
Dextran carboxylate Polysaccharide Anionic Inhibit tumour metastasis (Bastias, 2002)
Dextran sulphate Polysaccharide Anionic Block intracellular virus replication (Takemoto and Fabish, 1963)
Antiangiogenic activity (Thornton et al, 1999)
Ethylene maleic anhydride Synthetic Anionic Block intracellular virus replication (Feltzetal., 1962)
copolymers
Ginsan Polysaccharide Anionic Activates immune system (Lee etal., 1997)
Anticancer activity (Song et al., 2003)
Grifolan Polysaccharide Anionic Induces cytokines from macrophage (Ishibashi et al., 2001)
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Table 1.1 continued
Polymer Type Charge Activity References
Heparan sulphate Polysaccharide Anionic Generate primary immune responses (Kodaira et al., 2000)
Lentinan Polysaccharide Induce cytokines & antitumour activity (Ng,2002)
Lysine polypeptide Peptide Cationic Inhibit virus infectivity (Burger et al., 1951); (Green et al., 
1953); (Rubini et al., 1951)
Maleic anhydride divinyl 
ether
Synthetic Anionic Enhances natural killer cell and 
macrophage response towards tumours
(Piccoli etal., 1984)
Novispirin G-10 Peptide Cationic Antimicrobial activity (Yasin et al., 2003)
Polyacrylamide Synthetic Amphiphilic Antimicrobial activity (Tew et al., 2002)
PolyETCA-co-VAc Synthetic - Anticancer activity (Neung-Ju et al., 2001)
Polymethacrylic acid Synthetic Anionic Induce IFN in animals (De Somer, 1968)
Polysodium acrylate Synthetic Anionic Slows tumour cell growth (Hodnett and Tai, 1974)
Polystyrene sulphonate Synthetic Anionic Block intracellular virus replication (Christensen, 2001)
Schizophyllan Polysaccharide Neutral Induces cytokines from leukocytes (Kubala et al., 2003)
Sulphated glucan Polysaccharide Anionic Anticancer activity (Zhang et al., 2000)
Yam mucopolysaccharide Polysaccharide - Induce cytokines from macrophage (Choi etal., 2002)
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The activity they elicit is highly dependant on chemical composition and 
characteristics including tacticity, molecular weight and cross linking (reviewed in 
Donaruma, 1975). The ability of polymers to induce cytokines is generally 
dependent on polymer molecular weight (Breslow et al, 1973), conformation, and 
ionic charge distribution (Hunt et a l, 1996).
Polyanions have been used clinically and have a wide spectrum of effects on 
the immune system and have shown great clinical potential in the areas of oncology, 
virology and immunology (reviewed in Liao and Ottenbrite, 1997). In 1910, 
Oestreich was the first to clinically apply polyanions (chondritin sulphate connective 
tissue extracts) as a treatment for cancer (cited in Liao and Ottenbritte, 1997). Since 
then, a large number of polyanions including polymaleic anhydride (Goodell et al, 
1978) and carbetimer (Fields et al, 1982) have shown antitumour effects. This 
activity is probably due to their ability to modulate the immune system.
Several polyanions such as polyacrylic acids (PAcA) (De Somer, 1968), 
polyacetal carboxylic acids (Claes, 1970), and many polysaccharides (Artursson et 
al, 1987; Tzianabos, 2000) including alginates (Son et al, 2001) and hyaluronic acid 
(HA) (Boyce et al., 1997) have shown an ability to induce cytokine release.
Pyran copolymer of ethylene maleic anhydride and divinyl ether (DIVEMA) 
was the first polyanion to enter clinical trials as an anticancer agent (Butler, 1960). 
DIVEMA is an inducer of interferon-gamma (IFN-y) in mice, and displays 
antineoplastic, antibacterial and antiviral activity. However, the clinical trials 
involving DIVEMA were stopped due to toxic effects that were later found to be 
associated with a higher molecular weight fraction in the preparation (Breslow, 
1976). Nevertheless, a number of new biologically active polyanions including 
copolymer-1 (Ampligen®, Hemisphere Biopharma) (Fellay, 2001) dextrin 2-sulphate 
(Shaunak et al, 1998) and the cationic poly(lysine) dendrimer VivaGel™
•  •  •  •  •  TM(Starpharma) have successfully entered clinical trials for the prevention (VivaGel ) 
or treatment (dextrin 2-sulphate) o f human immunodeficiency virus type 1 (HIV-1), 
or chronic fatigue syndrome (Ampligen®).
Some polyanions also appear to behave similarly to specific proteins,
glycoproteins and polynucleotides that modulate biological responses (Liao and
Ottenbritte, 1997). Polymers formed from poly(N-acryl amino acids) for example,
have shown potential use in the inhibition of heparanase-mediated degranulation of
basement membranes associated with tumour metastasis, inflammation and
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autoimmunity (Bentolila et al., 2000). Another example is Copaxone® (Teva 
Pharmaceuticals), an amphoteric polypeptide used to treat multiple sclerosis, which 
inhibits neuron degradation through its ability to mimick myelin-1 basic protein 
(Fridkis-Hareli et al., 2002).
Unlike polyanions, polycations have shown direct antitumour activity. It has 
been suggested that they neutralise the enhanced negative charge on the tumour cell 
membrane, but it is clear they also have a number of other toxic effects (James et al, 
1956). Because polycations would also bind to other negatively charged mammalian 
cells (causing cell distortion, lysis and agglutination), the clinical use of these 
molecules is limited due to their extreme toxicity. In addition, it should be noted that 
polycationic amino acids such as poly(lysine) (PLL) can induce IFN-y (Wild et al, 
1994; Giantonio etal., 2001).
The chemical structure o f polyelectrolytes is thought to determine the 
mechanism of cytokine induction. Naturally occurring anionic polyelectrolytes (and 
their synthetic analogues) often exhibit antigenic properties. As one aspect of this 
study was to determine the ability o f polymers to initiate cytokine release, the 
following sections aim to briefly review the immune system.
1.2 The immune system
Multicellular organisms possess an innate immune system to protect them 
against pathogenic invasion, and all vertebrates also possess more specific and 
specialised defence mechanisms (termed adaptive immunity) that are superimposed 
on innate immunity to improve host defence against infection. Both types of 
immunity are briefly described below.
1.2,1 Innate immunity
Innate immunity (reviewed in Roitt et al., 2001) is the first line o f defence
against microbes and the underlying mechanisms are present from birth. It relies on
epithelial (epidermal and mucosal) barriers to protect against microbial entry,
circulating leukocytes, specific proteins (expressed in the blood and tissues; see
below), and cytokines (reviewed in Abbas et a l, 2000). Phagocytic (neutrophil and
mononuclear phagocyte) and natural killer (NK) cells are the principal effector cells
o f this system, and attack microbes that have entered the circulation from breached
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epithelia. Each cell type plays a distinct role. Phagocytes ingest and destroy 
microbes, whilst NK cells kill microbe-infected cells by direct lytic mechanisms 
(reviewed in Abbas et al, 2000; reviewed in Roitt et a l , 2001). Macrophage and NK 
cells also secrete cytokines that activate phagocytes and stimulate the cellular reaction 
of innate immunity called inflammation. This involves the recruitment of leukocytes 
into a site of infection, and activation of the leukocytes to eliminate the infectious 
agent (reviewed in Oppenheim et al, 2001).
Circulating microbes are also bound by plasma proteins (complement proteins, 
mannose-binding lectin, C-reactive protein, collectins, pentraxins and coagulation 
factors) that recognise specific binding sites shared by particular classes of infective 
agent, but that are not present on mammalian cells. These recognition sites include 
chemically distinct carbohydrates (e.g. lipopolysaccharide (LPS), mannans) lipids 
(e.g. lipoteichoic acid) and nucleic acids (double stranded RNA from certain viruses 
or DNA with unmethylated cystosine and guanine nucleotides (CpG) from bacteria) 
(reviewed in Abbas et al, 2000; reviewed in Roitt et a l , 2001).
1.2.2 Acquired immunity
The acquired immune system is complex, intricately regulated and is mediated 
by lymphocytes. It is able to discriminate between self and non-self proteins 
(expressed by foreign organisms tissues or cells) and also has memory, so that 
resistance that is weak or absent on first exposure to an immunogen, gives a more 
effective response on repeated exposure (reviewed in Abbas et a l, 2000). 
Contemporary usage of the terms ‘immunology’ and ‘immune response’ refers 
primarily to this type of immunity, thus an overview of this process is given below.
Immune response
The immune response (reviewed in Abbas et al, 2000; reviewed in Roitt et al., 
2001) involves several cell types and is triggered when a foreign agent enters the 
body (see Figure 1.3). The first cells to recognise 'foreign' material are the antigen 
presenting cells (APC) such as macrophages and dendritic cells that constantly patrol 
their environment. These cells phagocytose foreign material and display the digested 
peptide fragments (antigens) on their cell-surface via the major histocompatibility 
complex (MHC) to be presented to T-lymphocytes (T-cells). Only lymphocytes
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carrying the extracellular-membrane receptors specific to the antigen will bind the 
APC and proliferate to mount an immune response, and this is dependent on the type 
of T-cell activated (reviewed in Abbas et al, 2000; reviewed in Roitt et al., 2001).
There are two major subsets of T-cell, and each recognises one of two different 
classes o f MHC proteins. Cytotoxic cluster designation-8 positive (CD8+), T-cells 
recognise class I MHC proteins that are expressed by virtually all somatic cells. 
Class II MHC proteins are only expressed by macrophages, dendritic cells and B- 
lymphocytes (B-cells), that endocytose antigens bound to their surface 
immunoglobulins or other receptors. These cells present antigens to CD4+ T-cells 
that are necessary for virtually all immune responses. However, in addition to MHC 
class II activation, co-stimulatory signals are also required by CD4+ T-cells in order 
to achieve activation. This is provided through the close contact of the CD4+ T-cell 
and APC, and through the binding of the CD28 protein on the CD4+ T-cell surface, 
with the B7 proteins on the surface of the APC. Together these signals cause the T- 
cell to begin secreting a cytokine called interleukin-2 (IL-2; see section 1.7.2), and to 
begin expressing specific high affinity IL-2 receptors on its surface.
Activated CD4+ T-cells also secrete other cytokines that promote the growth, 
differentiation and functions of B-cells, macrophages and other cell types (reviewed 
in Abbas et a l, 2000; reviewed in Roitt et a l , 2001).
The following sections introduce cytokines and discuss their role in disease and 
disease therapy. The cytokines explored in detail in this study are described later.
13 Cytokines
Cytokines are a diverse group of intercellular signalling peptides and 
glycoproteins with a molecular weight of 6,000 - 60,000 daltons (Da) (reviewed in 
Oppenheim et a l, 2001). They are produced by all nucleated cells in response to 
various (mainly inflammatory or antigenic) stimuli. In man, several hundred types of 
genetically and structurally unrelated cytokines (interleukins, interferons, tumour 
necrosis factors, growth factors, colony stimulating factors and chemokines) have 
been identified (reviewed in Roitt et a l , 2001).
The biological properties of cytokines include the ability to mediate cell 
growth, division, differentiation, and apoptosis. They also mediate inflammation, 
immunity (reviewed in Abbas et al, 2000), wound repair (reviewed in Werner and
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Grose, 2002; Boniface et al., 2005) and fibrosis (Oh et al., 2005). Cytokines activate 
cells through specific, high-affinity cell surface receptors at micromolar, picomolar or 
femtomolar concentrations in either a paracrine or an autocrine way. Transforming 
growth factor-beta (TGF-P), erythropoietin (EPO), stem cell factor (SCF) and 
monocyte-colony stimulating factor (M-CSF), affect distant target cells (reviewed in 
Oppenheim et al., 2001).
Most cytokine receptors belong to a family of proteins called the hematopoietin 
receptor family that share an extracellular domain, with a similar three-dimensional 
structure, that has common amino acid residues at key positions (reviewed in 
Oppenheim et al., 2001). Each receptor that is a multiprotein complex comprising 
two or more integral membrane polypeptide subunits has different ligand 
specificities. Each subunit also has an extracellular domain that participates in 
cytokine binding, a transmembrane domain, and a cytoplasmic tail involved in signal 
transduction. An a -  and p-subunit are found in all cytokine receptors, though 
trimeric receptors (such as the IL-2 receptor) may also have a y-subunit. The sharing 
of subunits between different cytokine receptors is thought to explain their pleotropic 
actions upon cells, by enabling them to trigger identical signalling events inside the 
cell (reviewed in Abbas et al, 2000; reviewed in Roitt et a l, 2001; reviewed in 
Oppenheim et al, 2001).
Normally cytokines are not stored pre-formed in cells (except in mast cells and 
platelets which release cytokines during degranulation), but they are synthesised by 
transient gene transcription following cell activation. The messenger RNA encoding 
most cytokines is also unstable, so cytokine production is transient. In addition, 
cytokine release from cells is also subject to tight regulation, and it often involves 
cleavage o f a pro-form (reviewed in Abbas et al, 2000).
The production cycle o f a given cytokine lasts only a few hours to a few days in 
a normal state, and the deregulation o f this process is the cause of many diseases. 
Some o f these diseases are discussed in the next section.
1,3.1 Aberrant cytokine expression and disease
The deregulation of cytokines and/or their receptors within biological systems
12
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is a common cause of many inflammatory diseases, which often appear as sites o f cell 
activation, with an inflammatory and/or immune response. In normal physiology, 
cytokine cascades are key mediators of disease, and the cytokines released are 
diverse. They can be pathogenic or act merely as innocent bystanders. A stimulus 
can cause prolonged cytokine production, altering local cell behaviour (reviewed in 
Feldmann et al., 1996). For example, Crohn’s disease and rheumatoid arthritis are 
associated with a persistent up-regulation of tumour necrosis factor-a (TNF-a). In 
Crohn's disease this causes chronic inflammation and a high infiltrate of 
inflammatory cells (reviewed in Aggarwal, 2000), which results in hyperpermeable 
epithelia and granulomas in the intestine. In arthritis, high levels of TNF-a cause 
increased degradation of bone and cartilage in rheumatic joints (Zwerina et a l, 2004).
Overproduction of IL-6 has also been observed in rheumatoid arthritis, and this 
leads to Castleman's disease (Kishimoto, 2005). High levels of IL-6 cause several 
other pathological conditions such as multiple myeloma (Xiao et al., 2004), 
histiocytic lymphoma (reviewed in Knowles and Eriksson, 2001), cardiac myxomas 
(Mendoza et a l, 2001) and liver cirrhosis (Eriksson et al, 2004).
Aberrant expression of IL-2 or its receptors has been associated with Hodgkin's 
disease, graft-versus-host reaction, multiple sclerosis, rheumatoid arthritis, systemic 
lupus erythem atosis, type-1 diabetes, lepromatous leprosy, acquired 
immunodeficiency syndrome (AIDS), severe bum traumas and allogenic bone 
marrow transplantation (reviewed in Thorpe, 1998). Current research is focusing on 
the identification of mechanisms able to correct the deviant expression of these 
cytokines and/or their receptors to allow development of new therapies.
Monoclonal antibodies (e.g. Infliximab®) have been developed to neutralise 
cytokines in relation to specific disease conditions. Infliximab® binds TNF-a and it 
has been approved for the treatment o f Crohn’s disease (Agnholt et a l, 2003) and 
rheumatoid arthritis (reviewed in Schottelius et a l, 2004). Enbrel® (known as 
etanercept) is a soluble TNF-a receptor-fusion protein that has also shown promise as 
a treatment o f these diseases (Agnholt et a l, 2003; reviewed in Schottelius et al, 
2004). Anti-IL-2-receptor monoclonal antibodies specific for the IL-2 receptor a -  
subunit, unmodified or bound to toxins, have been used for the treatment of 
Hodgkin’s lymphoma (Engert et a l, 1991) and T-cell leukemia (Kreitman et a l, 
1992).
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Although cytokines can play an important role in causing diseases, they have 
also been used to treat viral infections and certain types of cancer. As biologically 
active polymers have been shown to induce cytokines, the role of cytokines and 
biologically active polymers in therapy are therefore discussed in the following 
sections.
1,3,2 Cytokine therapy
Several cytokines have undergone clinical trials. TNF-a has been used for the 
treatment o f sarcoma and melanoma when given locally by isolated limb perfusion 
(Eggermont et al., 1997; DiFilippo et al., 2004). IFN-y has been used for the 
treatment o f warts caused by the human papiloma virus (HPV), and IL-2 (Proleukin®) 
for the treatment of renal and colon cancer (Emery et al., 2002). Interleukin-12 is 
currently in phase II clinical trails as a treatment for non-Hodgkin’s lymphoma and 
Hodgkins disease. However, the clinical application of these, and other cytokines, is 
often limited by their short half-life and toxic side effects. High concentrations of 
T N F-a can cause septic shock syndrome (Tracey, 2004), IFN-y can give rise to 
malaise, weakness and lethargy (Oppenheim et al., 2001), IL-2 can cause vascular 
leak, shock and pulmonary odema (reviewed in Vial, 1995), and IL-12 can give rise 
to abnormal liver function (reviewed in Abbas et al, 2000).
Since low concentrations, or locally administered cytokines have a beneficial 
role towards disease and tumour regression (see following section), attempts to 
prolong the half-life of some cytokines have been made. IL-2, TNF-a and IFN-a for 
example, have been “PEGylated” by covalently linking the proteins to polyethylene 
glycol (PEG) chains (Harris, 2003). However, although PEG is non-immunogenic 
itself (Chinol et al., 1998), high doses of PEGylated cytokines still have significant 
toxicity. Recent reports have also shown that cytokines can be stabilised and 
designed to become bioactive fusion proteins, such as Hyper-IL-6. This protein 
consists o f IL-6 and a soluble IL-6 receptor, and synergises with murine stromal 
elements to promote the long-term survival o f primitive human hematopoietic 
progenator cells (Gotze et al., 2001).
1.4 Biologically active polymers as modulators for cytokine therapy
Normally, the ability of tumour cells to trigger an effective immune response is
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limited due to their weak expression of MHC antigens, adhesion molecules and 
costimulatory signals. Some tumours may also secrete immunosuppressive cytokines 
such as IL-10 (Monti et al., 2004), TGF-0 (Kao et al., 2003; Blanchere et al., 2002), 
and platelet-derived growth factor 2 (Zhou et al., 2005), or fail to express the 
cytokines that activate local immune responses. However, these evasive strategies 
can be overcome by directly introducing cytokines or other immunomodulatory 
molecules (e.g. biologically active polymers) into the tumour milieu, or through 
tumour ceil transfection. Biologically active polymers (particularly polyanions) 
capable of increasing the local production of therapeutic cytokines can therefore be 
used to initiate acquired immunity, enabling identification and destruction of tumour 
cells, and eliciting a long-lasting memory of this interaction. It has been proposed 
that this can also be used to treat local viral or bacterial infections, or immune- 
deprived conditions e.g. chronic non-healing leg ulcers, which respond to treatment 
with TNF-a. Here it was postulated that as a result o f local cytokine release, 
biologically active polymers might also be exploited as a means to permeabilise 
epithelial and/or endothelial barriers.
1.5 Biologically active polymers and cytokines as permeability enhancers
Several polyanions are known to induce the production of TNF-a and IFN-y in 
vitro and in vivo. Besides their role in the immune response, these cytokines can 
mediate the permeability o f epithelial and endothelial cells, by permeabilising their 
tight junctions (Walsh et al., 2000; Nusrat et al., 2000) (Figure 1.4). Tight junctions 
(TJ) are highly regulated, apical, multiprotein complexes (Figure 1.5) that act as a 
dynamic physical barrier to prevent the diffusion o f fluids with different molecular 
compositions (e.g. urine, milk, gastric juice, blood) through the paracellular pathway 
into surrounding tissues (see Figure. 1.4). This is referred to as the gate property of 
TJ and is commonly affected by a variety of exogenous agents such as calcium ions 
(Ca2+) bacterial toxins, and glucose. Permanent disruption o f TJ function drastically 
alters permeability and is the hallmark of many pathologic states (Walsh et al., 2000). 
However, changes in permeability caused by TNF-a, IFN-y, and hepatocyte growth 
factor (HGF), are transient, reversible (unless the cytokine persists as in disease), and 
involve alterations in the distribution of individual TJ proteins, or the actin 
cytoskeleton. The structure of the TJ is discussed in the following section.
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1.5.1 Structure andfunction o f tight junctions
Formation of the TJ requires the assembly of several proteins that are anchored 
directly or indirectly to the actin cytoskeleton (Han et al., 2002), or intracellular 
proteins (e.g. zonulae occludins proteins, catenins and cytoskeletal proteins 
(microtubules and microfilaments)). Recent work has uncovered a constellation of 
molecules, several o f which comprise three unique families of transmembrane 
proteins (see Figure. 1.5). Each family is described below.
Occludin
The first TJ integral protein to be characterised was occludin. It is 65,000 Da in 
size, possesses two extracellular loops, four transmembrane domains, three 
cytoplasmic regions and a large cytosolic C-terminal (Furuse et al., 1993). Both 
extracellular loops of this protein are o f similar size, and are enriched in glycine (one 
loop is also rich in tyrosine). Unlike other TJ integral proteins, occludin possesses a 
conserved 150 amino acid sequence in its carboxyl tail domain, which allows it to 
bind directly to filamentous (F)-actin (Wittchen et al., 1999), and not rely upon 
scaffolding proteins for association. Moreover, the same carboxyl segment of 
occludin is also capable of binding to other TJ related proteins such as the membrane 
associated guanylate kinase homologues (MAGUK) proteins, zonulae occludins-1 
(ZO-1) (Furuse et al., 1994), ZO-2 (Itoh et al., 1999), and ZO-3 (Haskins et al., 
1998).
The role o f occludin in TJs seems to be an important one, as over expression of 
mutant forms of the protein leads to changes in the gate function of epithelia (Baida 
et al., 1996; McCarthy et al., 1996). Occludin also has the ability to form TJ 
filaments in L-fibroblasts (which lack TJ) when transfected (Furuse et al., 1998). 
However, the precise role o f occludin in the TJ is unclear, especially since the 
discoveiy that occludin knockout mice still display well developed TJ (Saitou et al., 
2000).
Claudin
Claudins are a family o f 17,000 - 27,000 Da integral TJ proteins, with four
transmembrane domains, short carboxyl intracellular tails and two extracellular loops,
one of-which is larger than the other. Like occludins, the amino acid tails of these
proteins are highly conserved within the family and constitute PSD95/disc large/ZO-1
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homology domain (PDZ) binding motifs (Furuse et al., 1998), which connect to the 
PDZ containing proteins ZO-1, ZO-2, ZO-3, PALS 1-associated TJ protein (PATJ) 
(Roh et a l, 2002) and the scaffolding protein, multiple PDZ domain protein 
(MUPP1) (reviewed in Mrsny, 2005). The PDZ binding motifs are 80 - 90 amino 
acid modules that bind to specific motifs found at the carboxyl terminal ends of 
several proteins, and are crucial for the clustering and anchoring of transmembrane 
proteins (reviewed in Mrsny, 2005).
Claudins appear to help constitute the backbone of TJ strands, as cells that are 
devoid of TJ (murine L-fibroblasts) can generate intramembrane strands following 
claudin addition (Furuse et al., 1998; Morita et al., 1999). Down-regulation of 
claudin proteins is often a contributory factor for various disease conditions and 
cancers. Different species of claudin are found in different epi- and endothelia, and 
are responsible for the ample variety in electrical resistance and paracellular ionic 
selectivity (reviewed in Gonzalez-Mariscal et al., 2003). This is because the different 
species of claudins are capable of generating different intramembrane strand patterns 
(Furuse et al., 1999; Morita et al., 1999).
Junctional adhesion molecule and coxsackievirus and adenovirus receptor
The third transmembrane protein involved in the TJ complex of epithelial and 
endothelial cells, is a 43,000 Da, glycosylated protein termed, junctional adhesion 
molecule (JAM). Like the coxsackievirus and adenovirus receptor (CAR), this 
protein belongs to the immunoglobulin superfamily. Both proteins have only one 
transmembrane domain, possess a large extracellular region with two 
immunoglobulin (Ig) domains and share similar function.
CAR is a 46,000 Da integral membrane protein with a long cytoplasmic tail that 
increases transepithelial electrical resistance (TEER) when over expressed in 
epithelial cells (Cohen et al., 2001). It is also believed to be involved in diapedesis, 
and is over expressed at sites o f inflammation (Ito et al., 2000; reviewed in Gonzalez- 
Mariscal et al., 2003).
Compared to CAR, JAM possesses a short intracellular tail featuring a PDZ
binding motif that interacts with a number of TJ proteins such as ZO-1 (Bazzoni et
al., 2000) AF6 (Ebnet et al., 2000) and cingulin (Bazzoni et al., 2000; Ebnet et al.,
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2000). Freeze-fracture immunoreplicas have shown this protein to reside near the TJ 
strands, and it is thought to associate laterally as homodimers, which may interact 
with occludin and claudin (reviewed in Gonzelez-Mariscal et al., 2003). Fresh 
evidence also suggests that JAM is involved in the closure of the TJ, as antibodies 
against the protein prevent the recovery of the gate function of epithelia transiently 
deprived of calcium (Liu et al., 2000). The presence of JAM is also known to be 
required for leukocyte migration across vascular endothelia (Lechner et al., 2000).
Plaque proteins
Plaque proteins are cytosolic proteins associated with the TJ. The MAGUK 
proteins are a family recognised for having structurally conserved PDZ, src homolgy 
3 (SH3) and guanylate kinase (GK) domains. O f these proteins ZO-1 is most 
important.
ZO-1 is a phosphoprotein found at the submembranous domain in the TJ. It is 
linked to several other proteins including claudins (Itoh et al., 1999), JAM (Ebnet et 
al., 2000), occludin (via its GK module) and CAR. It independently associates with 
ZO-2 and ZO-3, and is also linked with the actin-binding protein 4.1, and the actin 
cytoskeleton (Fanning et al., 1998; Itoh et al., 1997). Interestingly, it is thought to 
shuttle between the nucleus and plasma membrane (Islas et al., 2002).
Sequencing o f ZO-1 has recently revealed its possession of reputed nuclear 
export signals (NES) (Gonzalez-Mariscal et al., 1999). In mechanically injured cells 
(with decreased TJ), ZO-1 is located in the nucleus (Gottardi et al., 1996), where it 
interacts with a transcription factor termed ZONAB (Baida et al., 2003). The 
interaction o f ZO-1 with ZONAB regulates paracellular permeability and gene 
expression in reporter assays (Baida and Matter, 2000). Therefore, the function of 
ZO-1 can be thought of as a protein that establishes a cross talk between the nucleus 
and the TJ that balances epithelial cell differentiation and growth. High levels o f ZO- 
1 are associated with an increase in barrier function, and are seen in intestinal 
epithelia after IL-15 treatment (Nishiyama et al., 2001). Low levels o f ZO-1 and 
occludin are found in lung epithelia following the addition of IL-4 and IL-13, though 
this can be reversed with IFN-y (Ahdieh et al., 2001).
As TJ play an important role in the intestine, which was chosen as a model 
epithelial barrier for these studies, the following section aims to introduce this tissue.
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1,5,2 Small intestine as a model epithelial barrier
The small intestine presents one of the most complex biological barriers for 
drug delivery, and can loosely be divided into three regions stretching from the 
stomach to the anus that are: the duodenum, jejunum and ileum (see Figure 1.6). The 
wall of the small intestine has a basic arrangement of tissues that from the inside out 
are: the mucosa (see below), submucosa (dense connective tissue and submucosal 
plexus), muscularis (two sheets of thin muscle) and serosa (connective tissue) 
(reviewed in Tortora and Grabowski, 2003) (Figure 1.7a).
The small intestinal mucosa is covered by villi (Figure 1.7b), which increase 
the surface area for absorption. The core of each villus is an extension of the lamina 
propria, (connective tissue layer of the mucosa), and its surface is covered with 
simple columnar epithelial cells. Opening into the luminal surface at the bases of the 
villi are intestinal glands termed the crypts of Lieberkuhn, which extend downward 
toward the muscularis mucosae (a thin layer o f muscle that supports the laminar 
propria). The simple columnar epithelial lining them is continuous with that covering 
the villi. This cell layer comprises diffuse neuroendocrine cells (paracrine and 
autocrine hormone-producing cells that form approximately 1 % of the total cell 
population), goblet cells and surface absorptive cells (reviewed in Tortora and 
Grabowski, 2003). Goblet cells are unicellular glands that secrete mucinogen, which 
hydrates to form mucin (mucus), and acts as a viscoelastic barrier to reduce shear 
stresses on epithelia. Mucus also binds bacteria to prevent epithelial colocalisation, 
and from a drug delivery perspective, has important implications as a physical barrier 
through which drug molecules must diffuse before reaching the absorbing surface.
The most numerous cell-type in the small intestinal mucosa are the surface 
absorptive cells, termed enterocytes (reviewed in Hillery et a l, 2001; reviewed in 
Tortora and Grabowski, 2003), which are responsible for the terminal digestion and 
absorption of nutrients and water (mentioned above). These cells are responsible for 
transporting the bulk o f the absorbed nutrients into the lamina propria to be 
distributed throughout the body. Their apical surface presents a brush border of 
microvilli (approximately 1 p.m long), whose tips contain a glycocaylx coat to protect 
against auto-digestion, and to hold enzymes that digest dipeptides and disaccharides 
(into their monomers), and re-esterify fatty acids (into triglycerides from 
chylomicrons). Drug metabolising enzymes such as cytochrome P450 3A (CYP3A),
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urdine diphosphate (UDP)-glucuronyl transferases, sulphotransferases, glutathione S- 
transferases, N-acetyl transferases, are also found on the apical surface of these cells, 
along with the efflux transporter P-glycoprotein (P-gp) (reviewed in Hillery et al,
2001). P-gp confers multi-drug resistance by acting as an ATP-dependant efflux 
pump that reduces intracellular accumulation and/or transcellular flux of several 
drugs and some peptides (reviewed in Oude-Elferink and Paulusma, 2006).
Drugs that are not affected by the above cross the mucosal barrier (enterocytes) 
via (1) transcellular mechanisms that involve transport across the plasma membrane 
e.g. passive diffusion, or active processes such as cell type specific transporters or 
channels, (2) transcellular transport by endocytosis and exocytosis (transcytosis) 
mechanisms, or (3) paracellular routes if the drug is small enough or when the TJ are 
open (see Figure 1.4). However, passage through the TJ is dependent upon the 
magnitude of the barrier (the permeability) as well as the molecular size and ionic 
charge of the molecule (reviewed in Hillery et al., 2001). Currently a succession of 
absorption enhancers (e.g. N-trimethyl chitosan chloride) has been researched by the 
pharmaceutical industry, to enchance delivery through this pathway.
The gastrointestinal tract also contains various leukocyte cells that form the 
mucosal immune system.
1.5.3 Mucosal immune system
The mucosal immune system is one of the most dispersed, diverse and 
complicated systems in the body (reviewed by MacDonald, 2003; Kiyono and 
Fukuyama, 2004). As it is continuously presented with antigenic challenges from 
food and the native bacterial flora and pathogens it is highly specialised to rapidly 
respond to 'foreign' materials.
Scattered throughout the mucosal epithelia are T-cells, thought to have evolved 
to recognise commonly encountered inter-luminal antigens. In the underlying lamina 
propria there is a mixture of leukocytes including activated T-cells (thought to have 
responded to antigens in regional mesenteric lymph nodes and to have migrated to the 
intestine), B-cells, plasma, macrophage, dendritic, mast and eosinophil cells 
(reviewed in Abbas et a l, 2000). These collected cells form visibly distinct, dome­
like lymphoid follicles termed Peyer’s patches (Figure 1.8).
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Peyer’s patches (reviewed by Bray den et al., 2005) were first described by 
Johann Peyer more than 300 years ago. They reside on the luminal surface in the 
intestine, and are an example of organised gut-associated lymphoid tissue (GALT). 
They do not bear afferant lymphatics, and they function to induce tolerance towards 
common antigens. Some of the epithelial cells that overlay Peyer’s patches are 
specialised membranous (M)-cells that lack microvilli, are actively pinocytic, and 
transport lumenal antigens into the sub-epithelial tissues of the patches. These 
regions are rich in B-cells, B-cell germinal centres, and small numbers of CD4+ T- 
cells in the interfollicular regions. Tissues containing Peyer's patches were used later 
in some of the transport studies conducted here (see Chapter 4 and Chapter 5).
1.6 Biological rationale for the choice of polymers selected for these studies
A range of synthetic and linear polymers of different molecular weight and 
architecture were used in these studies, and their structure and current uses are briefly 
discussed here.
1.6,1 Alginates
Alginates were selected for this project because they are abundant, 
biocompatible, polysaccharides that are widely used e.g. as pharmaceutical excipients 
and food additives (reviewed by Simsrod and Dragnet, 1996). Some alginates have 
been shown to induce cytokine production from immune cells in vitro (Espevik et al., 
1993; Jahr et al., 1997; Flo et al., 2000).
In their natural state, alginates can form insoluble complexes with calcium, 
magnesium, sodium and potassium salts. They are found in the cell walls and 
intracellular spaces o f brown seaweed where they serve to provide the flexibility and 
strength needed for mechanical support during growth in the sea (reviewed by 
Simsrod and Dragnet, 1996). They also occur in some soil bacteria (Espevik et al., 
1993; Jahr et al., 1997; Flo et al., 2000). Alginates are composed of unbranched 
linear chains of P-D-mannuronate (M) and a-L-guluronate (G) acid monomers that 
link together in a 1—*4 direction (Figure 1.9).
Alginates containing the high G-blocks possess the greatest ability to form gels, 
as the G monomers become cross-linked by means of calcium, or other multivalent 
cations (Figure 1.9), forming the so-called egg-box structure. These alginates have 
been exploited for stabilising and thickening agents in food, or as films and coatings
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for medicines. Alginate gels have also recently been used as microspheres, to 
encapsulate cells for transplantation (Lanza et al, 1999). These structures act as a 
barrier between the transplanted tissues (e.g. chondrocytes, pancreatic cells and 
hepatocytes) and the immune system of the host (Loty et al, 1998; Heald et al, 1994; 
Haque et al, 2005). Drugs can also be encapsulated within an alginate matrix or 
calcium alginate gels as a mechanism for sustained and controlled drug release. In 
addition, Duncan and colleagues (1995) developed alginate as water-soluble drug 
carriers e.g. for daunomycin (Al-Shamkhani and Duncan, 1995), and for the oral 
delivery of a human rhino virus peptide (VP2) for oral immunisation (Morgan et al, 
1995). The group showed a reduction in the immunogenicity of the conjugated 
peptide, thought to be caused by the steric hindrance of the antigenic determinants 
from immune surveillance, and by the inhibition of the peptide epitopes from their 
matching immune receptors.
Conversely, alginates composed mainly of M monomers are inherently 
immunogenic and were used for these studies (Figure 1.9c). Otterlei and colleagues 
(1991) were the first to demonstrate that alginates stimulate human monocytes to 
produce TNF-a, IL-1 and IL-6. They found that only the M-blocks, not MG- or G- 
blocks of alginate were capable of producing high levels of all cytokines. Later, 
Otterlei et a l (1993) and Espevic et a l (1993) showed that binding of high M 
alginate to the CD 14 receptor on monocyte cells, initiates TNF-a production. The 
CD 14 receptor also binds lipopolysaccharides (LPS) (this is further discussed in 
Chapter 3), and uronic acid containing polysaccharides released from (and in the cell 
well as teichuronic acid) gram-negative bacteria (Jahr, 1997).
Optimal cytokine induction was induced by high M alginates MW ^ 200,000 
Da (Otterlei et al., 1993). This implies that effects can only be obtained if the 
polymer presents a certain macromolecular conformation that results in a co­
operative multiple-receptor aggregation (Bemtzen et al, 1998). To test this, 
Bemtzen et a l (1998) covalently linked M-blocks to biodegradable bovine serum 
albumin (BSA) particles and found that the TNF-inducing potency of alginate was 
greatly enhanced in monocytes. The immunomodulatory effect of high M alginate 
has also been seen in murine peritoneal macrophages in vivo. Son et al (2001), 
showed that macrophages isolated from high M alginate-treated mice, produce large 
amounts of the cytotoxic agents; nitric oxide, hydrogen peroxide and TNF-a. These
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activated cells significantly inhibited the growth of tumour cells when compared to 
the effects seen for macrophages taken from control mice. In addition, Thomas et al, 
(2000) have shown that alginates used in some wound dressings can activate 
macrophages leading to secretion TNF-a within the wound, and this aids wound 
healing.
1.6.2 Hyaluronic acid
HA is a unique, ubiquitous, linear, glucosaminoglycan (Figure 1.10). This 
polymer occurs as a hydrated gel in the extracellular matrix of higher organisms and 
streptococci, primarily as sodium hyaluronan. The polymer was chosen for these 
studies because o f its documented immunological properties. Unlike other 
glucosaminoglycans, HA is synthesised at the inner face of the plasma membrane by 
hyaluronic acid synthases (HAS) 1, 2 and 3. It is not bound by protein, nor does it 
contain sulphuric groups. In animals, the highest concentrations of HA are found in 
connective tissue, hyaline cartilage, synovial fluid, the heart valve, fluids of the inner 
ear, and in the vitreous humor of the eye. The main source of HA is rooster combs, 
which contain the polymer at high concentration with respect to other tissue 
components. HA is also prepared from microorganisms, through a fermentation then 
isolation process.
The basic chemical structure of HA is repeated D-glucuronic acid and N-acetyl- 
D-glucosamine disaccharide units (linked together by p 1—*3 and p l-*4  glycosidic 
linkages) (Figure 1.10). In solution, HA adopts a three-dimensional structure 
showing extensive intramolecular hydrogen bonding (Scott and Heatley, 1999). This 
restricts the conformational flexibility of the polymer chains, which gives hydrated 
HA its pseudoplastic and mucoadhesive properties, enabling it to function as a 
mechanical, transporting, or a water-retaining material.
Commercially, HA is used in a large number o f applications including as 
components of cosmetics, and as treatment for rheumatology, orthopaedics and in 
ophthalmology. For example, the rooster comb HA, Healon® is used to protect 
exposed tissues during the insertion of an intraocular lens during eye surgery. 
Solutions of HA are also used as a vehicle for topical delivery of opthalmic drugs, 
and to produce synthetic tears. In osteoarthritis, HA is given to patients via intra- 
articular injections to reduce inflammation in the joints.
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At the cellular level, protein-to-protein interactions with HA have been shown 
to play crucial roles in cell adhesion, cell motility, inflammation, wound healing, and 
cancer metastasis (Suzuki et al., 2002; Kim et al, 2004). More recently HA has been 
found to possess APC-stimulating activity (Mummert et al., 2002) and the ability to 
induce cytokines (such as IL-12) from macrophage cells. Termeer et al. (2000) have 
recently shown that high molecular weight HA in the extracellular matrix is cleaved 
at sites of inflammation when it comes into contact with dendritic cells. In contrast, 
low molecular weight HA accumulates at sites of inflammation and can induce 
cytokine and/or chemokine production by alveolar and bone marrow derived 
macrophages (Hodge-Dufour et al., 1997). These effects are highly specific for low 
molecular weight HA, as they are not induced by other glucosaminoglycans such as 
chondrotin sulfate, heparan sulfate or their fragmentation products (Termeer et al., 
2000).
Only small HA fragments of tetra- and hexasaccharide size, but not of 
intermediate size (80,000 -  200,000 Da) or high molecular weight (1000,000 -  
6000,000 Da) induced immuno-phenotypic maturation of human monocyte-derived 
dendritic cells (Termeer et al., 2000). This process is initiated by the Toll-like 
receptor 4 (TLR 4), a receptor complex associated with innate immunity and host 
defense against bacterial infection (Termeer et al., 2002). Studies in mice have also 
shown HA to interact with CD44, the receptor for hyaluronic acid mediated motility 
(RHAMM) and intracellular adhesion molecule (ICAM) receptors. Binding of HA to 
CD44 induces murine B-cell activation, thus HA may play an important role in the 
regulation of autoimmune responses (Rafi et al., 1997). The CD44 receptor is often 
up-regulated in cancerous cells, and has been shown to enhance the expression of c- 
Met, a proto-oncogene that encodes for a tyrosine kinase receptor, and thus tyrosine 
phosphorylation in human chondrosarcoma cells when stimulated by HA (Suzuki et 
al., 2002).
1,6,3 Poly aery lie acid
PAcAs are synthetic, linear, mucoadhesive, homopolymers (Figure 1.11). They 
were chosen for these studies because besides their immune-stimulating activity, 
PAcA has also shown potential for enhancing drug delivery via the TJ pathway 
(discussed in Chapter 5, section 5.1). An overview of these polymers is given below.
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In the 1960’s PAcAs were subject to intense interest as potential antiviral 
agents. De Somer and colleagues (1968a) were the first to demonstrate this 
phenomenon, initially using tissue culture, and later mice (De Somer et al., 1968b). 
When investigating the mechanism of activity, De Somer and colleagues realised that 
the antiviral activity induced by PAcA was due to the induction of IFN (De Somer et 
a l, 1968b; De Clercq and De Somer 1969). The anionic nature of PAcAs appeared 
to be crucial for activity. Partially or completely neutralised PAcAs (containing < 85 
% carboxyl groups) were inactive (De Somer et al, 1968b). Another interesting 
observation is that the antiviral activity of PAcA persists in mice for at least 8 days 
after injection (De Clercq and Somer, 1969), suggesting the continuous presence of 
PAcA in the body. On another note, PAcA has also been found to be a mitogen for 
B-cells (Diamantstein et a l, 1976). Studies on the antiviral or immunomodulatory 
activity of PAcAs seem to have since ceased.
Today PAcAs are often cross-linked with an allyl ether pentaerythritol, allyl 
ether of sucrose, or allyl ether o f propylene to be used as viscosity increasing, 
suspending, release modifying, tablet binding, or bioadhesive agents in 
pharmaceutical formulations. Recent studies with PAcAs have mainly focused on its 
use in oral drug delivery systems, particularly as a mucoadhesive (Smart et al, 1984). 
Commercially available cross-linked PAcAs are marketed under the names 
Carbopol®, Carbomer® and Polycarbophil®, and have been used to aid gastrointestinal 
residence time and thus enhance drug uptake.
Microparticulate systems consisting of lightly cross-linked PAcA have also 
been found to widen the paracellular spaces between intestinal epithelial cells in 
vitro, by affecting their TJ (Kriwet and Kissel, 1996; this is discussed in more detail 
Chapter 5, section 5.1). This may be due to the chelation of extracellular calcium 
ions by the polymer, not its bioadhesive properties. Moving away from 
microparticles, PAcA has also recently been cross-linked with polyethyleneoxide and 
polypropylene, to form a new pH- and temperature-sensitive microgel that is suitable 
for drug delivery via the gut (Bromberg and Alakov 2003).
Once again, as with IFN induction, the density of carboxyl groups on the 
polymer chain also appears to be important for mucoadhesion. Park and Robinson 
(1987) have concluded that for mucoadhesion to occur, PAcA must have at least 80
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% protonated carboxyl groups, and that adhesion occurs through hydrogen bonding. 
However, as these interactions are affected by ionic strength and pH, modified 
PAcAs have been created. For example, PAcA modified by the introduction of 
cysteine moieties has displayed excellent mucoadhesive properties (Nafee et al, 
2004). In addition, thiolated PAcA showed the ability to form covalent bonds with 
cysteine-rich subdomains of mucins (Gum et al, 1992). It has been suggested that 
these polymers also enhance oral bioavailability by inhibiting the serine protease, 
trypsin (Anlar et al, 1993).
1.6.4 Polyamidoamine dettdrimers generation 3.5
Polyamidoamine (PAMAM) dendrimers are a family of well defined, highly 
branched, hydrophilic, globular macromolecules, that were first created by pioneering 
chemistry of Tomalia and colleagues during the 1980’s (Tomalia, 1985). The 
production of these molecules (known commercially as Starburst® dendrimers) 
occurs via a procedure known as divergent synthesis, a process in which dendritic 
structures are grown by repetitive reaction steps starting from a multifunctional core 
(to give increasing ’generations'). The core of PAMAM dendrimers consists of 
ethylenediamine, and the number and charge of their dendritic end-groups (at neutral 
pH) differs depending on the generation of the molecule (Tomalia, 1995).
Half-generation PAMAM dendrimers e.g. generations 1.5 - 7.5, have anionic 
carboxyl terminal groups, whilst full generation PAMAM dendrimers e.g. generations 
1 - 1 0 ,  have amine terminal groups (www.sigmaaldrich.com/Area_of_interest/ 
Chemistry/Materials_Science/BiocompatibleBiodegradable/Polymers.html, accessed 
13/12/02). Furthermore, the molecular size of each full generation PAMAM 
dendrimer increases by approximately 1 nm per generation (Tomalia et al, 1993).
The unique chemistry of PAMAM dendrimers has enabled them to be applied 
to several disciplines within the pharmaceutical industry. The central core (dendritic 
box) regions of PAMAM dendrimers are relatively hollow compared to their densely- 
branched outer layers, and can thus be used to encapsulate (therapeutic or poorly 
soluble) molecules for drug (Kannan et al, 2004) and gene (DeLong et al, 1997; 
Bielinska et al, 1997) delivery. Cationic PAMAM dendrimers have primarily been 
used for this purpose. Furthermore, the surface chemistry of PAMAM dendrimers, 
with their high number of end-groups, can be used to attach a variety of moieties for
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targeting or bioadhesion. As a result, PAMAM dendrimers have also been used as 
platforms for the development of cancer therapeutics (Malik et al, 1999).
More recently the use of PAMAM dendrimers as drug carriers for 
transepithelial and -endothelial transport has also been explored using a variety of 
epithelial and endothelial monolayer models (reviewed in Chapter 5, section 5.1). 
These dendrimers have shown the ability to cross epithelial barriers via both 
paracellular (El-Sayed et al, 2003) and transcellular (Jevprasesphant et al, 2003) 
pathways (see Figure 1.4, as discussed in Chapter 5, section 5.1).
The PAMAM generation 3.5 dendrimers (PAMAM 3.5) chosen for these 
studies have 64-carboxylate end groups (Figure 1.12), and are approximately 4.5 nm 
in size. They have been found to cross the rat intestine in an extremely rapid and 
efficient manner (Wiwatanapatapee et al, 2000), making them of particular interest 
for the drug delivery objectives in this project (see section 1.12). Furthermore, the 
high number of anionic terminal end groups of these dendrimers may also enable 
them to induce cytokines.
1.7 Biological rationale for the cytokines chosen for this work
The majority of polymers selected for this project have been shown to be able 
to induce cytokine production from a range of cells including macrophage, mast, 
dendritic, NK, T- and B-cells (as summarised in Table 1.2). These cells are the main 
producers of cytokines, and are capable of making a wider spectrum of these proteins 
compared to all other cells. However, each nucleated cell has its own cytokines that 
it can synthesise. Furthermore, the particular cytokines made by a cell are dependant 
upon the type of stimulus, its nature, duration and intensity, as well as the presence of 
other factors (e.g. other cytokines, hormones, cell contact interaction etc).
Three cytokines were selected for these studies as each has been implicated in 
inducing TJ permeability or for its antitumour properties.
1.7.1 Interferon-gamma
IFN-y is an interesting antiviral cytokine that plays an essential 
immunomodulatory role in virtually all cells. It is hugely upregulated in patients 
suffering from trauma, infections, cancer and autoimmune diseases (reviewed in 
Billau, 2000). The main sources of this lymphokine are CD4+ and CD8+ T-cells and
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Figure 1.12 Molecular structure of the polyamidoamine generation 3.5 dendrimer
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Table 1.2 Summary of the immunological properties of the polymers chosen for this work.
Polymer Type Charge Immunomodulatory Activities Reference
Alginic acid Natural Anionic Binds CD 14 receptors (Jahr et al,  1997); (Flo et al,  2000)
polysaccharide -IL-1, IL-6 & TNF-a from monocytes (Otterlei et al,  1991); (Jahr et al,  1997)
- TNF-a from macrophage (Thomas et al,  2000)
Binds Toll-like receptor 2 & 4 in macrophages (Flo et al,  2002)
Hyaluronic acid Natural Anionic Binds CD44 receptors (Noble et al,  1993)
polysaccharide -  TGF-f from eosinophils (Ohkawara et al,  2000)
- IL-8 from lung epithelia (Mascarenhas, 2004)
- TNF-afrom macrophage (Boyce et al,  1997)
Induce B-cell activation (Rafi, 1997)
Involved in antigen presentation (Mummert et al,  2002)
Activates dendritic cells via Toll-like receptor 4 (Termeer et al,  2002)
PAcA Synthetic, linear Anionic -  IFN-y production from serum of mice (De Somer, 1968a); (De Somer, 1968b);
(De Clercq, 1969); (Claes, 1970)
PAMAM 3.5 Synthetic, Anionic Rapid transcellular transport across rat gut§ (Wiwatanapatepee et al,  2000);
branched Increase permeability of Caco-2 cells§ (El-Sayed et al,  2003)
PEI Synthetic, Cationic Thought to stimulate the immune system (Moroson, 1971)
branched Induces IL-2, & TNF-afrom Caco-2 cells (Goricha, 2001); (Puckey, 2002)
5 Cytokines may play a role in this process
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NK cells, although production has also been observed in B-cells (reviewed in Abbas 
et al., 2000). The biological function of IFN-y in vitro and in vivo is cell-type 
specific, and differs in the presence of other cytokines. Generally, both TNF-a and 
IL-1 synergise with IFN-y, whilst IL-4 antagonises its actions (reviewed in Billau, 
2000).
An important role of IFN-y is as a modulator of the cellular activities 
responsible for inflammation, as it induces macrophages to release reactive oxygen 
intermediates, hydrogen peroxide (Nathan, 1985) and TNF-a. Macrophages and 
monocytes are also induced to transcribe the genes encoding granulocyte-colony 
stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF). 
This series of events enhances the intracellular killing of parasites and tumour cells 
and is antagonised by IFN-a and -p (De Maeyer, 1998). Moreover, IFN-y is a well- 
known activator for endothelial cells, T-cell proliferation, and the cytolytic induction 
of NK cells. Many cells including B-cells, T-cells, macrophages and tumour cells are 
induced by IFN-y to express MHC class II antigens, thus IFN-y is also responsible for 
regulating the antigen-specific immune response. However, it takes several hours for 
this to occur. IFN-y also stimulates the expression of CD4 in T-helper cells and the 
expression of high-affinity receptors for IgG in myeloid cell lines, neutrophils, and 
monocytes (reviewed by Billiau and Vandenbroeck, 2000; reviewed by Tsanev and 
Ivanov, 2002).
Although immuno-modulation is undoubtedly the primary role of IFN-y, it also 
exhibits a direct antiviral action by stimulating specific genes that are also involved in 
the antiviral activity of IFN-a and IFN-p (De Maeyer, 1998). Some of these genes 
contain the regulatory sequences; interferon-stimulated response elements (ISRE) and 
interferon response sequences (IRS), within their promoter regions that function as 
binding sites for a number of transcription factors.
1,7,2 Interleukin-2
This important lymphokine (mainly produced by CD4+ T-cells) was chosen for 
this work not only because it is responsible for T-cell clonal expansion following 
antigen recognition (see Figure 1.3), but also because it plays a key role in regulating 
cellular immune responses by augmenting B-cells and macrophages to secrete
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p r o d u c e  e n o u g h  I L - 2  t o  s t i m u l a t e  t h e i r  o w n  p r o l i f e r a t i o n  ( s e e  F i g u r e  1 .3 ) .
T h e  s y n t h e s i s  o f  I L - 2  i s  t i g h t l y  r e g u l a t e d  a t  b o t h  t r a n s c r i p t i  
t r a n s l a t i o n a l  l e v e l s .  T h e  p r o m o t e r  f o r  I L - 2  c o n t a i n s  s e v e r a l  s p e c i f i c  b i n d i n j  
s p e c i f i c  t r a n s c r i p t i o n  f a c t o r s  ( e . g .  N F - A T  a n d  T C F - 8 )  t h a t  r e g u l a t e  i t s  p r o d i  
v a r i a b l e  r e p r e s s o r  a l s o  m o d u l a t e s  t h e  p o s t - t r a n s c r i p t i o n a l  p r o c e s s i n g  o f  I L -  
s o  t h a t  a p p r o x i m a t e l y  9 8  p e r c e n t  o f  t h e  I L - 2  m R N A  r e m a i n s  u n p r o c e s s e d .  E 
i s  r e c o g n i s e d  b y  t h e  I L - 2  r e c e p t o r  ( I L - 2 R ) ,  w h i c h  c o n s i s t s  o f  t h r e e  n o n - c  
a s s o c i a t e d  a - ,  P -  a n d  y - s u b u n i t s .  T h e  a -  a n d  P - c h a i n s  a r e  i n v o l v e d  i n  
b i n d i n g ,  w h i l s t  t h e  P -  a n d  y - c h a i n s  f u n c t i o n  a s  s i g n a l  t r a n s d u c e r s .  B  
s u b u n i t s  a r e  m e m b e r s  o f  t h e  t y p e  I c y t o k i n e  r e c e p t o r  f a m i l y  ( r e v i e w e d  i n  
al., 2 0 0 0 ) .  W h e n  I L - 2  e n g a g e s  w i t h  i t s  r e c e p t o r  a  s e r i e s  o f  i n t r a c e l l u  
t r a n s d u c t i o n  p a t h w a y s  ( J A K / S T A T ,  p h o s p h a t i d y l i n o s i t o l - 3  k i n a s e  a n d  R a s  
p a t h w a y s )  i s  i n i t i a t e d  l e a d i n g  t o  a  r a p i d  i n t r a c e l l u l a r  r i s e  o f  c y c l i n  D 2  a n c  
p r o t e i n s .  T h e s e  p r o t e i n s  b i n d  a n d  a c t i v a t e  d i f f e r e n t  c y c l i n - d e p e n d a n t  k i i  
p h o s p h o r y l a t e  ( i . e .  a c t i v a t e )  s e v e r a l  p r o t e i n s  s u c h  a s  c y c l i n ,  t h a t  b r i n g  
t r a n s i t i o n  f r o m  t h e  G 1  t o  t h e  S  p h a s e  o f  t h e  c e l l  c y c l e .  I n  a d d i t i o n ,  I L - 2  a l s  
t h e  c y t o s o l i c  l e v e l s  o f  p 2 7 ,  a  p r o t e i n  i n h i b i t o r  o f  t h e  c y c l i n - k i n a s e  c o m p  
s u r v i v a l  i s  p r o m o t e d  b y  I L - 2 - i n d u c e d  p r o d u c t i o n  o f  t h e  a n t i - a p o p t o t i c  p r o t e i
T h e  p o t e n t  i m m u n e  s t i m u l a t i n g  a c t i v i t y  o f  I L - 2  h a s  a l l o w e d  i t  t o  b  
e f f e c t i v e  c a n c e r  t h e r a p y .  R o s e n b e r g  a n d  c o l l e a g u e s  ( 1 9 8 5 )  w e r e  th< 
d e m o n s t r a t e  t h e  a n t i - t u m o u r  c a p a b i l i t y  o f  I L - 2  w h e n  t h e y  t r e a t e d  p a d '  
s y s t e m i c  m e t a s t a s i s .  H o w e v e r  t h e  s y s t e m i c a l l y  h i g h  d o s e s  o f  I L - 2  
R o s e n b u r g  et al. ( 1 9 8 5 )  s h o w e d  s e v e r e  t o x i c  e f f e c t s  i n  a p p r o x i m a t e l y  2 0  ° 
p a t i e n t s .  I n  l i g h t  o f  t h i s ,  O t t e r  a n d  c o l l e a g u e s  ( 1 9 9 9 )  a d m i n i s t e r e d  r e p e a t e d  
I L - 2  i n j e c t i o n s  d i r e c t l y  o n l y  a t  t u m o u r  s i t e s  t o  s t i m u l a t e  t h e  a c t i v i t y  o f  tE 
i n f i l t r a t i n g  c e l l s  a n d  a v o i d  s y s t e m i c  t o x i c  e f f e c t s .  R e s u l t s  f r o m  t h i s  s t
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promising in a range of cancers and experimental animals, but still showed some 
toxicity. Nonetheless, later experiments with a single high-dose of IL-2 at the tumour 
site gave no observable toxic effects (Otter, 1999). Therefore this cytokine would 
have great significance for the cancer therapy aspects of this work.
Hie consequences of a deregulated expression of IL-2 have been studied in 
transgenic mice expressing the human IL-2 gene. Mice expressing IL-2 in the 
thymus, spleen, bone marrow, lungs, muscle and skin, show pronounced growth 
retardation and die prematurely. They have few Purkinje cells in the cerebellum and 
show a focal infiltration of lymphocytes, leading to pneumonia. In addition, their 
spleens show a massive increase o f lymphocytes. IL-2-deficient mice have also been 
analysed with respect to immune responses in vivo. Primary and secondary cytotoxic 
T-cell responses against the virus in these mice are normal, the T-helper cell 
responses are delayed but functional, and NK cell activities are markedly reduced but 
inducible. Collectively, these observations suggest that other factors may compensate 
for the IL-2 defects in vivo.
1.7.3 Tumour necrosis factor-alpha
TNF-a was originally identified as a factor present in animal serum after 
treatment with bacterial LPS that caused necrosis o f tumours (reviewed in Abbas et 
al., 2000). It is now known to kill transplanted and malignant tumours in vivo, and at 
picomolar concentrations in tumour cells in vitro. The anti-tumour effects of TNF-a 
are not based on tumour cytotoxic effects, but are actually largely due to the capacity 
o f TNF-a to stimulate endothelial cells of newly formed blood vessels to produce 
clotting factors resulting in their occlusion and necrosis (Joost and Feldmann, 2001).
Therefore, the principle physiologic function o f TNF-a (shown by recent 
transgenic mice studies) is to act as a key regulator of inflammation in host defence 
rather than a cytotoxic anti-tumour factor (reviewed in Tracey and Cerami, 1994). 
Depletion of TNF-a results in a failure to ward off infections, revealing its ability to 
stimulate the recruitment o f neutrophils and monocytes to sites o f infection and to 
activate these cells to eradicate microbes. TNF-a mediates these effects by evoking 
several effects on vascular endothelial cells and leukocytes. Firstly, TNF-a induces 
vascular endothelial cells to express leukocyte cell adhesion molecules, enabling 
them to bind circulating neutrophils, monocytes and lymphocytes respectively to
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recruit them at sites o f  infection. Furthermore, TN F-a also stimulates endothelial 
cells and macrophages to secrete chem okines that induce leukocytes by chemotaxis. 
It also acts on mononuclear phagocytes to secrete IL-1.
The major cellular sources o f  T N F-a are activated mononuclear phagocytes, 
neutrophils, T- and N K -cells respectively (reviewed in Tracey and Cerami, 1994). 
Stimulated peripheral neutrophilic granulocytes, inactive cells, transformed cell lines, 
astrocytes, smooth muscle cells, and fibroblasts can secrete smaller amounts. In 
mononuclear phagocytes, T N F -a is synthesised as a non-glycosylated type II 
membrane protein and is expressed as a homotrimer. The amino terminus o f  
membrane T N F-a is intracellular, whereas the carboxy terminus is large, extracellular 
and a ligand termed TNF-receptor 2 (TNF-R2). The secreted form o f  T N F -a is 
produced by the proteolytic cleavage o f  a 17,000 Da fragment o f  each subunit by 
m etalloproteinase from the m acrophage plasma membrane. Secreted T N F -a  
circulates in the body as a stable pyramidal-shaped homotrimer o f  51,000 Da. Each 
side o f  the pyramid is formed by one subunit, and the base o f  this structure provides a 
large surface area for binding multiple receptors.
Tw o distinct TNF receptors o f  molecular sizes o f  55,000 Da (TNF-R1) and 
75 ,000  Da (TN F-R 2) have been described on all somatic cells except mature 
erythrocytes. Both bind TNF-a with low  affinity. When TN F-a engages with these 
receptors, TNF receptor-associated proteins (TRAFs) attach to their cytoplasm ic 
domains, as the first step towards an intracellular signaling cascade that ultimately 
ends in the activation o f  the transcription factors; nuclear factor k B and activation 
protein-1 (AP-1). In addition, TNF-R1 induced signals have also been shown to 
trigger apoptosis in certain cell lines (reviewed in Abbas et al., 2000).
1.8 Aims of this thesis
From a drug delivery perspective, it is interesting to tie together the 
observations that som e b iologically  active polymers can modulate permeability, 
whilst others can stimulate the release o f  cytokines, as, at present there appear to be 
no studies on this area.
Before investigating whether alginate, HA, PAcAs or PAMAM generation 3.5 
dendrimers could be used to enhance drug delivery across rat intestinal tissue, it was
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first considered important to examine the cytotoxicity o f  these m olecules in vitro. 
This information was then used to ascertain polymer concentrations that were non­
toxic for further experiments. Each polymer was incubated with two model 
cancerous cell lines, at concentrations ranging from 1 -  0.001 mg/mL, and their effect 
on cell viability was measured using the MTT assay (Mossman, 1983). With this 
information, the effect o f  polymers on TN F-a, IFN-y or IL-2 release from either 
B16F10 or RAW 246.7 cells was measured by ELISA assay (Chapter 3). Cytokine 
release from polymer-incubated D U937 cells (used as a positive control for T N F -a  
release) was also investigated.
To test the hypothesis that cytokines can permeabilise biological barriers, the 
effects o f  rTN F-a, rlFN-y and rIL-2 on the transport o f  FITC-dextran across rat 
intestinal tissue with or without Peyer's patches was measured using the vertical 
diffusion system (Chapter 4).
The effects o f  polymers on FITC-dextran transport were also measured using 
the vertical diffusion system (Chapter 5), and to measure the effect o f  the polymers 
them selves on transport across rat intestinal tissue they were fluorescently labelled  
with Oregon green (OG). In parallel experiments the uptake o f  the OG-labelled  
polym ers by Caco-2eBc cells were also measured using flow  cytometry (Chapter 6 ).
Details o f  the materials and general methods that were used for these studies are 
described in the follow ing Chapter.
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2.1 Materials
All the materials and reagents used in these studies are given below, as are the 
suppliers. The general methods o f  the experiments used for this work are described 
in the following sections.
2.1.1 General chemicals
M ethanol, ethanol and sodium chloride were from Fisher Scientific, UK.
<§bPhosphate buffered saline (PBS) tablets were from Oxoid, UK. Klericide 5 was 
obtained from Shield Medicare, UK. Sigmaclean® water bath treatment was from  
Sigm a-A ldrich, UK. Pyruvate, nicotim anam ide adenine dinucleotide (N A D H ), 
hydrochloric acid (HC1), and tris(hydroxymethyl)aminomethane (Tris) were from  
Sigma-Aldrich, UK. Limulus amoebocyte lysate (LAL), control standard endotoxin, 
and endotoxin-free LAL reagent water were purchased from Charles R ivers 
Laboratories, UK. l-Ethyl-3-(-3dimethylaminopropyl)-carbodiimide (EDC), and N- 
hydroxysulfosuccinim ide (sulfo-NH S) were from Fluka, Germany. Oregon green- 
cadaverine (OGcad) was from Molecular Probes™, UK.
2.1.2 Polymers
PA cA  in a sodium salt form (SPACA30; molecular weight (MW) = 30,000 Da; 
40 % w /w  in FU0), and PAcAs o f  MW = 100,000 Da (PAcAioo; 35 % w /w  in FLO) 
and 450,000 Da (PACA450), PAMAM generation 3.5 dendrimers (MW = 12,931 Da; 
10 % w /w  in methanol), polyethylenimine (PEI; MW = 750,000 Da; 50 % w /v in 
H2O), dextran (M W  = 68,800 Da), and fluorescienisothiocyanate-dextran (FITC- 
dextran) o f  M W  = 4,000 Da, were obtained from Sigma-Aldrich, UK. Alginate (MW  
= 240,000 Da) and HA (MW = 50,000 - 8000,000 Da) were purchased from MP 
Biom edicals, USA. HA in a sodium salt form (sHA; MW = 3,000 - 58,000 Da), was 
obtained from Fluka, Germany. Pullulan standards (MW  = 738, 5,900, 11,800, 
22,800, 47 ,300  and 112,000 Da) for gel permeation chromatography (GPC) were 
from Polymer Laboratories, UK.
2.1.3 Animals and cell lines
Albino, male Sprauge Dawley (outbred) rats w eighing from 200 - 250 g were 
obtained from Harlan, UK. B16F10 adherent, murine melanoma cells, and U 937  
non-adherent, human histocytic lymphoma (m onocyte) cells, and Caco-2 BBe brush-
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border expressing, colon caricnoma cells were from ATCC, UK. The RAW 246.7  
semi-adherent, murine macrophage/monocyte, and ECV304 adherent, human bladder 
carcinoma, endothelial-like, epithelial cell lines were from ECACC, UK. The media 
used for all cells is given in Table 2.1.
2.1.4 Reagents fo r  tissue and cell culture
Media (Table 2.1) and supplements for cell and tissue culture included Rose 
Park Memorial Institute (RPMI) 1640, minimal essential media (MEM), Dulbecco’s
minimal essential media (DMEM), Hank's balanced salt solution (HBSS) and foetal
bovine serum (FBS) o f  both normal and low endotoxin grade were purchased from 
Invitrogen L ife T echnologies, UK, as was 0.05 % trypsin/0.53 mM sodium  
ethylenediaminetetraaceticacid (EDTA). Trypan blue solution, 0.4 % w /v, 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), analytical grade, 
98 % anhydrous, dimethyl sulphoxide (DM SO), and phorbol 12-myristate 13-acetate 
(PMA) were obtained from Sigma-Aldrich, UK. Medical grade carbogen (5 % CO2, 
95 % O2), nitrogen gas, and liquid nitrogen were supplied by BOC, UK.
2.1.5 Cytokines and Quantikine® sandwich-ELISA kits
Lyophilised, recombinant rat IFN-y (rlFN-y) was from MP Biomedicals, USA, 
whilst lyophilised, recombinant rat T N F-a (rTN F-a) and IL-2 (rIL-2), with bovine 
serum albumin (B SA ) as a carrier protein, were obtained from R&D Systems, UK. 
A ll sandwich-ELISA kits including murine T N F -a (m T N F -a), IL-2 (mIL-2) and 
IFN-y (mlFN-y) and human TN F-a (hTNF-a) and IL-2 (hIL-2), were also from R&D 
Systems, UK.
Each ELISA kit contained the follow ing materials and reagents; wash buffer 
concentrate (25 x concentrated buffered surfactant solution), colour reagents A and B 
(stabilised hydrogen peroxide and stabilised chrom ogen (tetramethylbenzidine)), 
adhesive plate covers, 96-w ell polystyrene microplates (12 strips o f  8 w ells coated 
with immunoglobulins (Igs) against the cytokine o f  interest), conjugate (polyclonal Ig 
against cytokine o f  interest, conjugated to horseradish peroxidase (HRP)), standard 
(lyophilised recombinant cytokine in a buffered protein base), assay and calibrator 
diluents (buffered protein bases), and an acid stop solution.
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T able 2.1 Tissue culture media and passage numbers o f  each cell line used.
C ell line C ulture m edia (with 10 % v/v  FBS) Cell passage num bers 
used
ECV304 DMEM 15 8 - 168
B16F10 RPMI with 25 mM HEPES, L-glutamine 
and phenol red
9 - 2 9
U 937 and RPMI with L-glutamine and phenol red 1 - 2 1
D U 937
RAW  246.7 DMEM with 1000 mg/L glucose,
TW
Glutimax , pyruvate and phenol red
9 - 2 9
C a c o -2 e B E DMEM with 4000 mg/L glucose, 
Glutimax™, pyruvate and phenol red 
HBSS (for flow  cytometry only)
6 0 - 8 0
Rat intestinal MEM with Earle’s salts, without -
epithelium glutamine or phenol red
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2.2 Equipment
2.2.1 General equipment
Disposable, black, flat-bottom 96-well plates, and transparent, sterile 96- and 
24-well plates for tissue culture, were from Coming Incorporated, UK. Vented-cap 
tissue culture flasks o f  25 cm 2, 75 cm2, and 150 cm2 volumes, and cell scrapers were 
obtained from Fisher Scientific, UK. Single and multichannel, variable volume, 
manual pipettes, and a caprex L2G Charles Austen aspirator, for the removal o f  cell 
supernatants, was from Jencons, UK. The sterile quills to attach to the aspirator were 
from Fisher Scientific, UK. Sterile pots and containers including 7 cm 3 bijous, 25 
cm 3 universal containers, 60 cm 3 containers, disposable plastic pipette tips, sterile 
plastic syringes and stripettes (for volumes o f  5 mL, 10 mL and 25 mL) were from 
Elkay, UK. The automatic pipetter for measuring these volum es was from Fisher 
Scientific, UK. Sterile needles (23 G) were from WLS, UK. Filters with 0.2 pM  
pores were from Sartorius Ltd, UK. A  Class II M icroflow Biological safety cabinate 
for tissue culture work was from Servicecare, UK. The 37 °C tissue culture incubator 
(supplemented with 95 %  O2, 5 % CO2 gas), was supplied by W olf Laboratories, UK.
A DM  IL Leica light microscope to view  cells between and during experiments 
was from Leica, Germany. Photographs o f  individual cell lines were taken with a 
Leica DM  IRB microscope and camera, using Improvision® Openlab™ software. A  
Varifuge 3.0 RS centrifuge was obtained from Heraeus Instruments, Germany, and 
the Toledo 320 pH meter from Mettler Toledo, Switzerland. The sonicator was 
supplied from Decon®, UK. The lyophiliser was from FTS Systems, Holland. 
Protein de-salting (PD )-10 columns were from Amersham Biosciences, UK. All 
endotoxin-free disposable pipette tips, 96-w ell plates and dilution tubes, were from 
Charles Rivers Laboratories, UK. The vertical diffusion chamber was obtained from 
Precision Instruments D esign, U SA. Thin layer chromatography (TLC) plates (0.2  
m m  silica 60 with fluorescent indicator UV254) were from Macherey-Nagel, 
Germany. D ialysis membrane was from Spectrum® Laboratories Inc, USA. Glass 
m icroscope slides (76 x 26 mm) and coverslips (22 x 40  mm) were from Menzel- 
Glaser®, Germany.
2.2.2 Analytical equipment
Ultraviolet (U V ) absorbance was measured using a sunrise UV-absorbance
plate reader from Tecan, Australia, and a Cary 1G U V -visible spectrophotometer
from Varian, Australia. A  hand-held U V  lamp was from UVP, UK. Fluorescence
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was measured using a Fluorostar Optimar plate reader from BMG Labtechnologies, 
Germany. Single detection GPC was performed using a Gilson 133 refractive index 
(RI) detector from Gilson Inc., U SA , a Jasco PU-980 intelligent high-performance 
liquid chromatography pump from Jacso UK Ltd, UK, and two GPC columns (TSK- 
gel G3000PWxi and TSK -gel G 4000PWxl), were from Supelco, UK. Polymer 
Laboratories, UK, provided Caliber software for GPC analysis. A kinetic, heated 
plate reader for Limulus am oebocyte lysate (LAL) assays was purchased from  
Charles Rivers Laboratories, UK.
2.3 General methods
All methods specified below describe the com m on procedures used in this 
thesis. In som e cases, a more detailed description o f  these methods, and more 
specific technical methods are given in each experimental chapter.
2.3.1 Cell culture
A ll cell lines utilised for this thesis were kept under aseptic conditions, without 
the addition o f  penicillin  or strepom ycin, and were m ycoplasm a-free. The 
manipulation o f  all cell lines was carried out in a Class II laminar flow  hood, pre­
sterilised by Klericide®, and 70 % v /v ethanol (in ddFUO) spray. Only sterile 
(autoclaved) PBS and double-distilled water (ddFLO), or tissue culture medium  
containing 10 % v /v  FBS were used. Any disposable tissue culture equipment that 
came into contact with the hood was first sprayed with 70 % v/v ethanol in ddFLO. 
In addition, all solutions that were added to cells were pre-warmed to 37 °C in the 
water bath (containing 5 L ddFhO and 1 mL Sigmaclean® water bath treatment). It is 
also important to note that all polymer solutions that were added to the cells were 
filter-sterilised first.
Thawing o f cryopreserved cells
Cryogenic vials o f  frozen cells were kept at -1 9 6  °C in liquid nitrogen until
required. Upon use, the frozen ampoules were removed from the liquid nitrogen and
were briefly defrosted in the water bath. Tepid cell suspensions were added to a
universal container with 20 mL o f  media, and were pelleted by centrifugation for 5
min at 1000 g. Supernatants were aspirated from the pelleted cells and were replaced
with 5 mL o f  fresh media. A syringe and needle was then used to gently break the
pellets and re-suspend cells before they were placed into 25 cm flasks. Cells were
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then grown for 48 h in the incubator before being viewed under the light microscope 
to check their growth. Their culture medium was then changed.
Routine maintenance o f cells
C ells were kept for 20 passages and were routinely view ed under a light 
microscope to check their growth. Media in the flasks was changed twice weekly to 
avoid depletion o f  essential nutrients. Only flasks that were > 70 % confluent were 
sub-cultured at a 1:10 ratio, into 75 cm2 flasks. For adherent cell lines, confluent 
flasks were aspirated o f  medium, washed once with PBS, and briefly incubated with 1 
mL trypsin-EDTA at 37 °C (to cause cell detachment). Trypsin-EDTA was then 
diluted with 10 mL o f  tissue culture media and cell suspensions were centrifuged for 
5 min (1000 g) at room temperature. Semi-adherent cell lines were removed with a 
cell scraper, whilst non-adherent cells were centrifuged in their medium. A 1 mL 
aliquot o f  cells re-suspended in fresh media was added to 9 mL o f  new media inside 
new 75 cm flasks.
Cell counting and assessment o f viability using trypan blue
Aliquots (100 pL) o f  suspended cells were mixed at a 1:1 v/v ratio with trypan 
blue solution (containing 50 % v/v PBS) in an eppendorf tube. Trypan blue is a blue 
dye that only penetrates the membranes o f  dead cells  and was thus used to 
approximate cell viability. A 20 pL volum e o f  the trypan blue-cell mixture was 
added to a Heamocytometer slide, with silver-stained Neubauer ruling, roofed with a 
glass cover slip (adhered by capillary force). The light microscope was used to count 
the number o f  cells in each o f  the 4-squared Neubaur grids (each divided into 16 
sections) surrounding the central square with 25 sections. N on-viable cells were 
stained blue and were not counted. The average number o f  cells per grid was found 
by dividing the total number o f  cells counted by 4. This number was then multiplied 
by 2 to account for trypan blue dilution. This gave the number o f  cells per mL o f  cell 
suspension, and was used to calculate the dilution factors for each experiment.
Freezing cells for cryopreservation
Batches o f  cells were routinely frozen to maintain stocks. Cells were grown to 
confluency in 150 cm 2 flasks, rem oved, centrifuged into a pellet, re-suspended, 
counted (as described above), and diluted to give 1 x 106 cells/m L suspension in
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sterile-filtered FBS containing 10 % v/v DMSO. One-mL aliquots o f  this suspension 
were placed into 1 mL cryogenic vials, wrapped in damp tissue paper and placed at -  
20 °C for 1 h, -  80 °C overnight, and at -  196 °C in liquid nitrogen the following  
morning.
2.3.2 Measurement of cell growth curves using the MTT assay
Before looking at the cytotoxicity o f  our polymers, growth curves for each cell 
line (B16F10, ECV304, RAW 246.7, Caco-2BBe and U937) were determined using 
the colourimetric MTT assay (Figure 2.1). This ensured all experiments were carried 
out during the exponential phase o f  cell growth (Figures 2.2a, b, c, d and e 
respectively).
The MTT assay was initially introduced by Mosmann (1983), and was later 
developed by Sgouras and Duncan (1990), for screening polymer biocompatibility. 
This assay is based upon the fact that MTT is a soluble, yellow  hydrogen acceptor 
that can only be reduced by the products (NADH and NADPH) o f  the mitochondrial 
enzyme succinate-dehydrogenase (Slater et al., 1963) in respiring cells. Metabolised 
MTT forms dark-blue formazan crystals that are readily dissolved in DMSO and can 
be read spectrophotomically (see below), where the optical density is proportional to 
the quantity o f  viable tissue.
For this assay, cells were first seeded into sterile, flat-bottomed, 96-w ell plates 
(100 p,L/well using a multi-channel pipette), by removing them from their flasks, 
centrifuging (1000  g), re-suspending, counting and diluting them in media to 1 x 104 
cells/mL. The w ells around the perimeter o f  the plates were always laced with 100 
pL/well o f  PBS (to prevent surrounding w ells from dehydration). Seeded plates were 
incubated for 24 h before the addition o f  MTT*.
Each day 20 p,L o f  MTT solution/well was added to a column o f  w ells in the 
96-well plates and the plates were returned to the incubator for 5 h. Following this 
media was carefully aspirated from the w ells and was replaced with DMSO (100  
pL/w ell) to solubilise blue formazan crystals. Plates were then incubated for a further 
30 min, until the crystals had dissolved. The optical density o f  the plates was then 
read in a UV plate reader set at 550 nm. The formazan-DMSO mixture was then 
removed from the wells (under local exhaust), and replaced with PBS (100 pL/well).
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Figure 2.1 Chemical structure o f  MTT before and after reduction by respiring cells
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Figure 2.2 (a & b) Cell growth curves. Panel (a) B16F10 cells, panel (b) ECV304 
cells. Cells were seeded at 1 x 103 cells/w ell in 96-well plates. Data represent mean ± 
SEM (n =  18).
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Figure 2.2 (c & d) Panel (c) RAW 246.7 cells, panel (d) Caco-2eBe cells. Cells were 
seeded at 1 x 103 cells/well in 96-well plates. Data represent mean ± SEM, n = 18.
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Figure 2.2 (e) U937 cells. Cells (1 x 104 cells/mL in 6-well plates) were counted on 
a daily basis. Data represent mean ± SEM, n = 3.
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Plates were returned to the incubator, and this process was continued for 7 days.
U937 cell growth curves were measured by counting cells (seeded into 6-well 
plates at 1 x 104 cells/mL per well) on a daily bases to give the number of cells per 
mL. Trypan blue was used to discount dead cells from the suspension.
tMTT solutions were prepared by dissolving 5 mg/mL of the compound in autoclaved 
PBS. As MTT is light sensitive it was always protected from light. Dissolved MTT 
solutions were squeezed through a syringe attached to a 0.2 juM filter, placed into 
sterile, foil-wrapped containers and were stored at 4 °C.
2.3.4 M easuring polymer cytotoxicity using the MTT assay
The MTT assay was also used to measure polymer cytotoxicity. Polymers were 
always added to cells during their logarithmic growth phase, as the metabolism of 
MTT is slower when cells reach confluence (Sgouras and Duncan, 1990). Sterile, 
flat-bottomed, 96-well plates were seeded as described above. Twenty-four hours 
post-seeding, polymers dissolved in media (2 mg/mL) were diluted with media to 
give concentrations ranging from 1.25 to 1000 pg/mL (Table 2.2). Polymer-laced 
plates were then incubated for 1 - 67 h (see Chapter 3, section 3.2.2) before MTT was 
added (20 pL/well). Plates were then returned to the incubator for a further 5 h, 
before supernatants were removed, DMSO was added, and the UV-absorbance of the 
plates was read (as described above).
Data from these experiments, were analysed using Microsoft Excel®, and were 
expressed as a percentage of the viability seen in the control (untreated) cells. The 
concentration-response curves generated from this data were then fit to the 
logarithmic function derived from the Hill equation (below) using Biograph vl.2c for 
Microsoft Windows 1995:
y =  (Rinin +  (Rmax ~  Rmin)/(1 +  (x /IC 5o)P)
Where Rmax was fixed at 100, and Rmin was fixed at 0 (Kean et al., 2005). The IC50 
value is the polymer concentration at which cell growth was inhibited by 50 %.
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Table 2.2 Dilutions made to establish polymer cytotoxicity.
Vol. of media 
added to plate 
(M-L)
Vol. of polymer solution (2 mg/mL) 
added to plate (jaL)
Polymer conc. in 
plate (pg/mL)
0 100 1000.0
20 80 800.0
40 60 600.0
80 20 200.0
90 10 100.0
0 *100 25.0
50 50 12.5
90 10 2.5
95 5 1.25
100 0 0
* Denotes from when dilutions were made using 0.05 mg/mL polymer solutions
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2.3.5 Measuring cytokine release with Quantikine® sandwich-ELISA kits
Sandwich-ELISA assays allow the quantitative detection o f  specific cytokines 
that are secreted into tissue culture medium. Details o f  individual ELISA  
experiments are given in Chapter 3 (section 3.2.3).
To collect samples for ELISA assays, cells were seeded into tissue culture 
plates and were left for 24 h, before the addition o f  polymers. Polymers were 
incubated with cells for 1 -  24 h, before the medium was collected, centrifuged and 
frozen. Frozen samples were thawed and were assayed according to directions in the 
R&D Systems kit-manuals (Tables 2.3 and 2.4).
A schematic showing how the ELISA assays were conducted is given in Figure 
2.3. In brief, before conducting ELISA work, all reagents were brought to room  
temperature (kits were kept at 4 °C), and the cytokine standard was reconstituted. 
Assay diluent was added to each well, and calibrator diluent was used to make a 
dilution series (calibration curve) with the cytokine standard. Dilutions or samples 
were then added to the microplate in duplicate. The plate was then sealed and left to 
allow cytokines to anneal, before it was washed using kit wash buffer. Next, 
immunoglobulin (Ig)-HRP conjugate was added, the plate was sealed, and was then 
left to allow  the Ig-HRP conjugates to anneal to cytokines bound (to Ig) in the plate. 
After several washing steps, substrate solutions were added and converted into a blue- 
coloured liquid by horseradish peroxidase. At 30 min the reaction was stopped with 
acid, and the optical density o f  the plate was read in the UV plate reader at 540 and 
450 nm. A ll data obtained were transformed using Microsoft Excel®.
To correct for optical imperfections in the plate, plate readings at 540 nm were 
subtracted from readings made at 450 nm. Next each duplicate reading was averaged. 
The zero standard optical density was then subtracted from these values. Plotting the 
log optical density against log cytokine concentration created a standard curve with 
the equation;
y = axb
Where a and b are constants, and b is the slope o f  the curve.
Standard curves were generated for each set o f  samples assayed (Figures 2.4a,
b for human kits, and Figures 2.5a, b and c for murine kits), and the following
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Table 2.3 Protocol for R&D Systems human ELISA kits.
A ssay Reagents Assay procedure Sample
hT N F -a TN F-a standard: Reconstitute with 1 mL ddH20  = 10,000 pg/mL, agitate for 15 min before use. 200 [xL/well
Calibrator diluent: 900pL to 1st o f  7 eppendorf tubes (labelled 1000, 500, 250, 125, 62, 31, 15 pg/mL), 500^L 
to remaining tubes. Add 100|iL TNF-a into 1st tube, mix, transfer 500|iL into next tube, 
mix and continue dilution.
Assay diluent: 50 p,L/well
Conjugate, substrate: 200 pL/well
Stop solution: 50 p,L/well
hIL-2 IL-2 standard: Reconstitute with 5 mL calibrator diluent = 2000 pg/mL, agitate for 15 min before use. 100 fxL/well
Calibrator diluent: 500jxL/tube to 6 ependorf tubes (labelled 1000, 500, 250, 125, 62, and 31 pg/mL). Add 
500pL IL-2 to 1st tube, mix, transfer 500|xL into the next tube, mix and continue dilution.
Assay diluent: 100 (iL/well
Conjugate, substrate: 200 pL/well
Stop solution: 50pJL/well
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Table 2.4 Protocol for R&D Systems murine ELISA kits.
Assay Reagents Assay procedure Sample
m TNF-a TNF-a standard: 
Calibrator diluent:
Assay diluent: 
Conjugate, substrate: 
Stop solution:
Reconstitute with 2 mL calibrator diluent = 1500 pg/mL, agitate for 5 min before use.
200 pL/tube to 6 eppendorf tubes labelled 750, 375, 187,93, 46 and 23 pg/mL. Add 200pL TNF-a in to 1st 
tube, mix and continue dilution.
50 pL/well 
100 pL/well 
50pL/well
100 pL/ 
well
mlFN^y IFN-y standard: 
Calibrator diluent:
Assay diluent: 
Conjugate, substrate: 
Stop solution:
Reconstitute with 2 mL calibrator diluent = 3000 pg/ml agitate for 5 min before use.
200pL/tube to 7 eppendorf tubes labelled 600, 300, 150, 75, 37, 18, and 9 pg/ml. Add lOOpL IFN-y in to 1st 
tube, mix and continue dilution.
50 pL/well 
100 pL/well 
lOOpL/well
50 pL/ 
well
mIL-2 IL-2 standard 
Calibrator diluent:
Assay diluent: 
Conjugate, substrate: 
Stop solution:
Reconstitute with 2 mL calibrator diluent = 1000 pg/ml agitate for 5 min before use.
200pL/tube to 6 eppendorf tubes labelled 500,250, 125, 62, 31 and 15 pg/ml. Add 200pL IL-2 in to 1st tube, 
mix and continue dilution.
50 pL/well 
100 pL/well 
100pL/well
50 pL/ 
well
00
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1. Prepare all reagents as directed
Add assay diluent to each well
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•  Cytokine
/ \  Immunoglobulin conjugate
Anti cytokine Ig bound to the surface of 
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Add dilution series, assay diluent (-ve control), or sample (thawed supernatant) to 
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t T T T t T f
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i
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8. Add stop solution to each well, read at 450 nm and 540 nm (within 30 min).
Figure 2.3 Schematic showing the protocol for ELISA assays
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equation was used in Microsoft Excel®, to quantify the amounts o f  cytokine in each 
sample.
= (O.D./a) A (1/b)
Where O.D. is the optical density o f  the corrected sample, a is a constant from the 
calibration curve, A is to the power of, and b is the slope o f  the curve.
2.3.6 Use of the vertical diffusion system to study transport across rat intestinal 
tissue
The vertical diffusion system (Figure 2.6) was used to measure the transport o f  
FITC-dextran across adult rat small intestinal tissue. Experiments were set up to 
measure transport in an apical to basal, or basal to apical direction (see Figure 2.6a). 
Intestinal tissue with or without Peyer’s patches was used. In some experiments 
cytokines (see Chapter 4) or polymers (see Chapter 5) were added into the system and 
their effect on FITC-dextran transport was measured. The transport o f the polymers 
themselves was also measured using this system after they had been fluorescently 
labelled (see Chapter 6 ). A  general outline o f  this method is given below, and the 
specific details o f  this work are given in each appropriate experimental chapter.
For each experiment, Sprauge Dawley rats were fasted overnight prior to 
sacrifice by cervical dislocation. Fasted animals were allowed free access to water. 
Post-sacrifice, the small intestine was quickly excised by cutting along the mesentery 
that supports it. The excised, extended intestine was then flushed through with a 50 
mL syringe o f  85 % w/v NaCl in ddFLO. The first 15 cm o f  the intestine, 
(corresponding to the duodenum and first half o f the jejunum) was always discarded 
(see Figure 1.6), leaving the distal jejunum and ileum, from which 1 cm segments 
(with or without Peyer’s patches) were cut and kept in MEM at 4 °C on ice. The 
tissue preparation method is shown in Figure 2.7.
Tissue was placed on an up-turned plastic weighing boat held on a tray o f  ice. 
It was cut along the mesenteric border, was pinned as a flat sheet to a plastic support, 
and the muscle layers and vasculature were removed with a scalpel. The remaining 
mucosal layer was carefully laid over the hole o f  one half o f  the diffusion
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Figure 2.4 (a & b) Calibration curves observed for human TN F-a and IL-2. Panel 
(a) hT N F-a and panel (b) hIL-2. In each curve, the data points represent a mean o f  
duplicate samples and the calibration curves observed in more than one experiment.
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Figure 2.5 (a & b) Calibration curves observed for murine TN F-a and IFN-y. Panel 
(a) m T N F-a and panel (b) mIFN-y. In each curve, the data points represent a mean 
o f  duplicate sam ples and the calibration curves observed in more than one 
experiment.
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Figure 2.5 (c) mIL-2. In each curve, the data points represent a mean o f  duplicate 
samples and the calibration curves observed in more than one experiment.
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Figure 2.6 (a & b) Schematic diagram o f a vertical diffusion cell (panel a), and a 
photograph showing the vertical diffusion system (panel b)
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(a) (b)
Figure 2.7 Preparation o f tissue for the vertical diffusion system 
See text (section 2.3.6) for details
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chamber and both chambers were tightly clamped together. Warmed MEM (37 °C in 
a water bath) was carefully placed in each half o f  the chamber simultaneously to 
avoid the effects o f  hydrostatic pressure. Two air-pipes were then attached to each 
side o f  the chamber to allow mixing and oxygenation to occur, and the system was 
kept at 37 °C via a heated block connected to a water bath.
After a few  minutes the medium was removed (to clear any debris not flushed 
from the lumen), and was carefully replaced with 1.5 mL o f  fresh medium/chamber. 
Immediately any treatment containing fluorescent probes (see Chapters 4, 5 and 6  for 
details) was applied to the donor chambers (on either mucosal or serosal sides o f  the 
tissue). Transport across the tissue was measured at 10 min intervals (from t = 0 -  60 
min) by the collection o f  25 pL samples from the recipient chamber. Fresh media (25 
pL) was quickly added to the chamber after each sample had been taken. At the end 
o f  each experiment, all acrylic diffusion cells were soaked in ethanol (70 % v/v in 
ddfLO), and were then sonicated and rinsed with ddFLO.
In most cases FITC-dextran was used as a fluorescent paracellular marker for 
this work (see Chapters 4 and 5). Samples containing this compound were collected  
into black 96-well plates, and were protected from light using silver foil. Plates were 
read in a fluorescent plate reader set at an excitation value o f  485 nm, and an 
em ission value o f  520 nm. The gain on the plate reader was always kept at 1000. All 
fluorescence data were then manipulated using Microsoft Excel®.
To account for dilutions made by collecting 25 pL samples, the following  
equation was formulated:
F -  (0.025/ 1.5 *L s)
Where, F equals the fluorescence value o f  the cell o f  interest, 0.025 equals the 
volume removed in mL, 1.5 equals the total volume in the chamber in mL, * denotes 
the multiplication symbol, and Ls equals the fluorescence o f  the sample(s) previously 
taken.
Permeability coefficients (Papp) for transported molecules were calculated as:
Papp = (dQ/dt)/ (Co* A)
6 6
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Where, Papp equals the apparent permeability coefficient (cm/s), dQ/dt is the amount 
o f  drug transported, A is the diffusion area o f  the mucosa (cm2), and Co is the initial 
concentration o f  the test compound in the donor compartment (pM ) (Lacombe et al,
2004).
2.3.7 Measurement of tissue viability using the lactate dehydrogenase assay
Lactate dehydrogenase (LDH) is a soluble, cytosolic, glycolytic enzyme found 
in most body tissues. It functions to catalyse the conversion o f  pyruvate (a 
respiratory product continually produced in tissues) into lactate, and is therefore 
important for energy production in cells. It is because LDH is such an abundant, 
cytosolic enzyme, that the presence o f  free LDH in the tissue culture media o f  cells is 
often measured to assess tissue (particularly membrane/plasma) damage. In these 
studies, LDH release from excised rat intestinal tissue (used in the vertical diffusion 
chamber) was measured, to gauge any cellular damage when cytokines were added.
First two stock solutions were prepared. A Tris/NaCl buffer was made using
81.3 mM Tris, and 203.3 mM NaCl dissolved in ddH20 to a total volume o f  500 mL. 
The pH o f  the solution was adjusted to 7.2 using 5 M HC1. This solution was then 
split into two flasks, to which either 0.244 mM o f NADH, or 9.70 mM pyruvate was 
added.
Using 2 mL plastic cuvettes, 1.5 mL o f  the Tris/NaCl/NADH solution was 
mixed with 50 pL incubation medium, and the cuvettes were then heated in the UV  
spectrophtometer to 30 °C for 5 min. The absorbance o f  the spectrophotometer was 
set to 339 nm using an enzyme kinetic programme. Once the programme had been 
set up, 300 pL o f Tris/NaCl/pyruvate was quickly added and the absorbance was 
quickly, and continuously monitored for 2 minutes. LDH activity was measured as 
the amount o f  pyruvate consumed due to oxidation o f  NADH, as shown below:
LDH
Pyruvate + NAD H  + H+ o  L (+) - lactate + N A D +
The amount o f  LDH activity within the samples (expressed as enzyme units 
mU/mL) was calculated using the follow ing formula;
LDH activity = [(d * absorption/ dt) * 1000 * V a s s a y ] /  (EC * d * V s a m p i e ) ,
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Where (d * absorption/ dt) equals the reduction rate o f  pyruvates absorption, V asS a y  
equals the volume o f  the assay, EC denotes the extinction coefficient for NADH at 
339 nm (63171/ mol/cm), d is the pathway length o f  the laser, and V s a m p ie  is the 
volume o f  the sample.
2.3.8 Gel permeation chromatography
Also known as size exclusion chromatography (SEC) and gel filtration 
chromatography, GPC is used to separate and characterise polymers according to 
their size. GPC can also be used to determine the polydispersity index (PDI) o f  
polymers that have a wide distribution o f  molecular weights. This is the ratio 
between MW and Mn averages o f  polymers, where;
MW = the weight average molecular weight 
Mn = the number average molecular weight
Theory:
During GPC the mobile phase moves through the stationary phase and it is 
temporarily retained. The retention is controlled by the stationary phase which is 
made o f  finely divided porous beads, whose size is chosen specifically for the 
polymer MW ranges o f  interest. Polymer m olecules dissolved in solvent are 
separated on the basis o f  their hydrodynamic volume. The smaller molecules pass 
through the pores and thus have a longer path and transit time than larger polymer 
molecules that continue following the solvent flow. Therefore, larger molecules elute 
earlier in the chromatogram. Polymer motion in and out o f  the pores is statistical, 
and is governed by Brownian motion. Usually a refractive index detector is used to 
monitor polymer samples as they are eluted from the column.
The solvent used in these studies was PBS pH 7.4 that was first filtered then 
sonicated to remove any air bubbles. Polymers for analysis were dissolved in this 
PBS at a concentration o f  5 mg/mL and were sterile-filtered. One mL o f each 
polymer solution was carefully drawn up into a glass syringe, and 60 pL o f  this 
solution was injected into the column to avoid any air bubbles. The flow  rate was 
kept at 1 mL/min, and the refractive index detector was calibrated to monitor samples 
as they eluted over 30 minutes. Pullulan polysaccharide standards o f  known
6 8
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molecular weight (738 - 112,000 Da) were used as molecular weight standards 
(Figure 2.8).
2.3.9 Determination of LPS contamination of polymer solutions
The Limulus amebocyte lysate (LAL) test was used to measure LPS. This assay 
was developed following the discovery that a clotting reaction occurs when the 
amoebocyte blood cells o f the horse-shoe crab, Limulus polyphemus, come into 
contact with LPS. This process was later found to be mediated by enzymes located in 
the amoebocyte granules i.e. LAL.
The particular LAL assay used in this thesis is kinetic. Serial dilutions o f  
control standard endotoxin reconstituted with endotoxin-free LAL reagent water 
(follow ing the lot specific certificate o f  analysis) was used to produce an endotoxin 
standard curve in endotoxin-free, sterile tubes. Polymers dissolved in LAL water at 1 
mg/mL were sterile filtered and assayed alone, or when spiked with 5 endotoxin units 
(EU)/mL o f  CSE. LAL water alone was used as a negative control. A template o f  
the plate was set on the kinetic plate reader, and 100 pL o f the negative controls, 
standards and samples were added, followed quickly by 100 pL o f  lysate that had just 
been reconstituted with LAL reagent water (amount at which was specified on the 
vial). The pipette tips for this work were all endotoxin-free. The plate without its lid 
was read in the plate reader over an hour.
2.4 Statistics
A ll data are expressed as an average ± S.E.M. When comparing a single 
sample against a control, two-tailed Students t-tests were used. The differences 
between multiple groups o f  data and the control were compared by one-way or two- 
way analysis o f  variance (ANOVA), depending on the experimental design. The p 
value for these studies was always set as 0.05.
If a significant difference between the control and groups o f  data was seen 
with A NO VA (p < 0.05), a post-hoc test was performed. Bonferroni post-hoc tests 
were used for most occasions.
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Figure 2.8 (a & b) GPC chromatogram for pullulan polysaccharide standards (panel 
a), calibration curve (panel b).
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CHAPTER 3: Cytotoxicity and cytokine release
3.1 INTRODUCTION
Before using the polymers in biological assays it was first necessary to establish 
their cytotoxicity, as this would enable non-toxic polymer concentrations to be 
identified for further experiments. Therefore during the first part of this study, the 
cytotoxicity of alginate, HA, PAcAs, and PAMAM 3.5 dendrimers, towards B16F10 
(murine melanoma) and ECV304 (human bladder carcinoma) cell lines was defined. 
Subsequent experiments then investigated whether these polymers would induce 
cytokine (TNF-a, IFN-y and IL-2) release from B16F10 or RAW 246.7 and DU937 
cells. The polymers and cytokines selected for these studies were chosen for the 
reasons explained earlier (Chapter 1, sections 1.6 and 1.7 respectively). The rationale 
for the cell lines and assays used for these studies are given below.
Rationale for the choice o f  cell lines used
Four cell lines were selected for these studies and the growth curves for each 
are shown in Chapter 2 (Figure 2.2). B16F10 murine melanoma and ECV304 human 
bladder carcinoma cells have commonly been used to study the biological activity of 
polymers (Wan et al., 2004) and polymer-anticancer drug conjugates (O'Hare et al., 
1993) as well as polymeric non-viral vectors for gene delivery (Richardson et al., 
1999; Fischer et al., 1999; Lavignac et al., 2004; Wan et al., 2004; Andersson et al.,
2005). ECV304 cells are endothelial-Tike’ and have been widely used as an 
endothelial model (Hughes, 1996). Both cell lines were used for initial cytotoxicity 
screening because (i) it was thought that B16F10 cells might be later used as an in 
vitro tumour model, and (ii) it was thought that ECV304 cells might be used as an 
endothelial monolayer model for permeability experiments (see section 1.9). In-fact 
they were not used for such experiments. Nevertheless both cell lines provide useful 
data on polymer toxicity that can be compared to literature values (Andersson et al, 
2005; Vicent et a l, 2004; Veronese et al., 2005; Tomlinson et al., 2003; Fischer et 
al., 2003). The RAW 246.7 and DU937 macrophage-like cell lines were chosen to 
provide a positive control for measurement of TNF-a release (Heming et a l, 2001; 
Boyce et a l, 1997).
Polymer cytotoxicity
Before assessing polymer cytotoxicity it was necessary to choose an
appropriate assay. Non-radioactive methods routinely used to assess cytotoxicity
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include; cell counting assays such as the Coulter Counter® (Pruden and W instea 
1964; Sgouras and Duncan 1990), assays that involve measurement o f  increases in 
membrane perm eability, such as trypan blue exclusion  (Cowan et a l, 1984), 
measurement o f  metabolic activity using dyes such as MTT (Mossman, 1983) or 
XTT (sodium 3 ,3 ’-[ 1 [(phenylam ino)carbonyl]-3,4-tetrazolim ]-6zs-(4-m ethoxy-6- 
nitro) benzene sulfonic acid hydrate), tetrazolium salt (Roehm et al., 1991), or the 
measurement o f  LDH release (Korovkin et al, 1963).
For these studies the MTT assay (described in Chapter 2, section 2.3.2) was 
preferred, as it is a rapid, quantitative screening method that can be easily adapted to 
measure a wide range o f  polymer concentrations using 96-w ell plates (Sgouras and 
Duncan 1990; Kean et a l, 2005; Peng et a l, 2005). The small well volume o f the 
plates means that minimal amounts o f  polymer are needed. Polymer cytotoxicty was 
initially assessed using a 72 h incubation time in accordance with Sgouras and 
Duncan (1990). However, as the cytokine release studies were conducted using an 
incubation time o f  1 or 24 h, it was also considered important to define polymer 
cytotoxicity over these incubation periods. High molecular weight PEI (MW =
750,000 Da) and dextran (MW = 68,800 Da) were used as positive and negative 
reference polymers for these studies, in accordance with the literature (Kean et al, 
2005; Fischer et a l, 2003).
High m olecular w eight PEI (Figure 3.1a) is a highly branched, synthetic, 
polycation that has a higher charge density than most linear polycations o f  the same 
size (Fischer et a l, 2003). The cytotoxicity o f  this polym er is molecular weight- 
dependent (Fischer et a l, 2003; Kunath et al, 2003), and as such, only low molecular 
weight PEI (M W  = 25,000 Da) is being studied as a gene delivery vector (Wagner,
2006). The flexible structure o f  PEI allows it to electrostatically interact with DNA, 
or in the case o f  cytotoxicity, with cell membranes (via the negatively charged 
phospholipid head groups). This induces curvature, which destroys membrane 
integrity (Fischer et a l, 2003; Moghimi et a l, 2005).
Dextran (Figure 3.1b) on the other hand is a h ighly w ater-soluble  
polysaccharide (P, 1-6 polyglucose produced by bacteria) that has a 50-year clinical 
history as a plasma expander (reviewed in Thoren, 1980). The chemical inertness 
and high number o f  hydroxyl groups o f  this polym er has also allow ed it to be
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Figure 3.1 (a & b) Chemical structures o f  (a) PEI and (b) dextran.
Note PEI essentially has no monomer. It is a branched chain polymer with 1:2:1 
primary:secondary:teriary amines with a branching site every 3 - 3 . 5  nitrogen atoms
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conjugated to a variety o f  pharmaceutical agents. Hence it has recently been  
investigated as a polymer-protein conjugate (to increase stability and decrease the 
immunogenicity o f  proteins), and as a polymeric drug carrier (reviewed in Mehvar, 
2000).
Cytokine release
The ability o f  polym ers to induce T N F -a , and IL-2 release from D U 937  
(human macrophage-like) cells, T N F-a, IFN-y and IL-2 release from B16F10 cells, 
and T N F-a, IFN-y and IL-2 from RAW 246.7 (murine macrophage/monocyte) cells 
was studied. For many years ELISA and bioassays have been most commonly used 
as methods to measure cytokine release (Whicher and Ingham, 1990). ELISA is 
more convenient and more sensitive than most bioassays (Whiteside, 2002) so it was 
used throughout the studies described here. Before using ELISA assays it was 
necessary to establish; (i) the reproducibility o f  the standard curve for each cytokine
(ii) the recovery o f  cytokine from tissue culture medium and (iii) the effect o f  the 
presence o f  polym ers on cytokine recovery from the tissue culture medium. In 
addition, to investigate whether PEI would interfere with ELISA kits, calibration 
curves were made with and without this polymer. As mentioned above, to establish a 
positive control cytokine-release experiments were conducted using DU937 cells, 
cultured with sodium hyaluronate (sHA) as this polymer had been shown previously 
to induce TN F-a (using L929 cells as a bioassay) when incubated with these cells for 
24 h (Boyce et a l, 1997). The profile o f  TNF-a release induced by LPS and HA was 
also measured over time.
The ability o f  HA, alginate, PAcA sodium salt (M W  = 30,000 Da; sPAcA30) 
and PAMAM 3.5 to induce release o f  TN F-a from D U 937 cells was examined after 
24 h and DU937 cells incubated with alginate and PAM AM  3.5 were also assayed for 
the release o f  IL-2 after 24 h. A time point o f  1 h was chosen to assess polymer- 
mediated T N F -a, IFN-y and IL-2 release from RAW  246.7 and B16F10 cells, PEI 
was used as a positive control in these assays, as it has been shown to induce TN F-a  
and IL-2 release from B16F10 cells after a 1 h incubation time (Puckey, 2002).
As the polymers used for this work were not of pharmaceutical grade, it was
considered possible that they could contain LPS. In humans, the tolerance levels of
LPS (defined by the Food and Drug Association (FDA)) depend on the route of
74
CHAPTER 3: Cytotoxicity and cytokine release
administration. For instance, the endotoxin tolerance for parentally delivered drugs 
and liquids is 5 EU/mL. Drugs and liquids in the circulation can have up to 0.5 
EU/mL, whilst for devices that contact the cerebralspinal fluid, the limit is much 
low er 0 .06 EU/mL. The way in w hich LPS induces cytokine release from  
macrophage cells has also been w ell characterised (Figure 3.2).
Circulating LPS binds LPS-binding protein (LBP) and is delivered to the CD 14 
receptor either in the circulation, or on the macrophage surface. When this occurs, 
LBP is released, and the CD 14 receptor triggers the T oll-like receptor to 
phosphorylate and activate several cytoplasmic MAP kinases. This activates several 
transcription factors, mainly AP-1 and NF-kB, and corresponding genes, that encode 
cytokines (such as TNF-a, IL-1, IL-6 and IL-8), and enzymes o f  the respiratory burst.
As LPS contamination might cause spurious results in ELISA assays, it was 
important to try to determine the concentration o f  LPS in all polymer stocks. This 
was investigated using the LAL assay (Jorgensen and Lee, 1978). However, it later 
proved difficult (and potentially unnecessary) to determine the LPS content.
The specific aims o f  these studies were to:
(i) Set up MTT assays to measure the cytotoxicity o f  alginate, HA, PAcAs and
PAMAM generation 3.5 dendrimers in different cell lines.
(ii) Establish ELISA assays to determine whether the polymers can induce TNF-a, 
IFN-y and IL-2 release from cells.
(iii) Devise a method in which LPS levels in polymers can be determined.
3.2 METHODS
The general methods used for this work have already been described in Chapter 
2 (sections 2.3.4, 2.3.5, and 2.3.9). U nless otherwise stated all experiments were 
carried out in triplicate, and all polymer and LPS solutions were prepared in serum- 
supplemented media, and were sterilised by filtration (through 0.2 \im Sartorious 
filters) before use.
The method used to grow U 937 cells is described in Chapter 2 (section 2.3.1). 
However, to mature this cell line into an adherent macrophage phenotype, cells were 
counted and diluted with media to give a 2 x 105 cells/mL suspension in 30 mL o f  
media containing 2.5 x 10'7 M PMA. After gently mixing the suspension with a
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manual pipette, 1 mL o f  the suspension was added/well to 24 well plates. Seeded  
plates were then incubated for 48 h to allow cell attachment and maturation to occur.
3.2.1 Setting up MTT assays
Firstly it was important to establish whether polymers being used would affect 
the pH o f  the tissue culture medium, as a change in pH could itself affect cell 
viability (M ackenzie et al., 1961). To conduct the MTT assays, polymers (1.25  
pg/mL to 1 mg/mL) were added to cells (seeded at 1 x 103 cells/w ell in 96-w ell 
plates) and were then incubated for 1, 24 or 72 h (in total). The experimental 
procedure is described in detail below, and in all cases the data are expressed as mean 
± SEM.
72 h MTT assay: B16F10 and ECV304 cells were incubated with polymers for 67 h, 
at which MTT (5 mg/mL in PBS) was added (20 p.L/well). After adding MTT, the 
plates were further incubated for 5 h. The tissue culture medium was then carefully 
removed before addition o f  spectrophotometric grade DMSO to dissolve the MTT 
crystals (100 p,L/well). Plates were then incubated at 37 °C for 30 min before being 
read in the plate reader (550 nm).
24 h MTT assay: DU937 cells were incubated with PEI or sHA for 19 h, before the 
addition o f  MTT. After adding MTT, plates were incubated for a further 5 h before 
they were processed as described above.
1 h MTT assay: B 16F 10 cells were incubated with polymers for 1 h before the cell 
culture medium containing polymer was removed using a multichannel pipette. The 
cells were then washed twice with warm media, and fresh media (without polymer) 
was then added to plates (100 p.L/well). The cells were further incubated for 66 h, 
and at 67 h MTT was added. After a further 5 h incubation (i.e. 72 h) the plates were 
processed as described above.
3.2.2 Use of ELISA assays to monitor cytokine release
The general procedures used for ELISA kits are given in section 2.3.5. First, to 
investigate the possibility that the polymers (alginate, HA, sHA, PEI, PAM AM 3.5, 
and PAcAs) might interfere with ELISA assays, polymer solutions (1 mg/mL) were
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prepared in tissue culture medium plus serum, and were spiked with m TNF-a (93.75 
pg/mL). Each polymer solution was then assayed for m T N F-a recovery using the 
calibration curve. Next, to investigate whether the polymers stimulated cytokine 
release from cells, each cell line was incubated with polymers for times between 10 
min -  5 h as detailed below.
Investigating cytokine release from DU937 cells
Twenty-four w ell plates seeded with DU937 cells (2 x 105 cells/m L) were 
viewed under the light microscope after 48 h (to check whether the cells had adhered 
and expanded). They were then washed twice with media to remove PM A (see pages 
17 and 77) and any dead cells. The polymer solutions (HA, sHA, alginate, SPACA30 
and PAMAM 3.5 at 0.1, 1, 10 and 100 pg/mL), and LPS (50 pg/mL) were then added 
to the plates (1 m L/well) and they were returned to the incubator. Medium was 
carefully collected from w ells using a 1 mL pipette at 0 - 5 or 24 h (in duplicate).
At each time point the medium samples were quickly transferred into labelled 
25 mL universal containers, and were then centrifuged at 1500 g (for 3 min) to pellet 
any dead cells. The supernatant was then gently (but quickly) removed from each 
container using a manual pipette, and was placed into a labelled bijous bottle and 
stored at -  20 °C until assayed (as described in Chapter 2, section 2.3.5).
Investigating cytokine release from B16F10 and RA W 246.7  cells
B16F10 and RAW  246.7 cells were seeded into 96-w ell plates (1 x 103 
cells/mL) and were left for 24 h to adhere. In this case, polymer solutions (2 mg/mL 
in medium) were added to each w ell to give a final content o f  1 mg/mL. In most 
experiments the plates were then returned to the incubator for 1 h. Following this h 
incubation period, the medium was collected from each well and quickly transferred 
into 1.5 mL eppendorf tubes, which were immediately frozen in liquid nitrogen, and 
then stored at -  80 °C until assayed. Before these samples were assayed by ELISA, 
eppendorf tubes were spun at 235 rpm (1500 g) in a bench-top centrifuge for 3 min, 
to pellet any cells.
In one experiment, the effect o f  HA (100 pg/mL) or LPS (50 pg/mL) on the 
time-dependent (10 min -  24 h) release o f  cytokines from RAW  246.7 or B16F10  
cells  was studied. In this case cells were seeded into 24-w ell plates (2 x 105 
cells/m L/well), and were left for 24 h before HA or LPS was added. At each time-
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point the medium was collected and processed as described above for D U937 cells.
The method used for the LAL assay is described in Chapter 2 (section 2.3.7).
3.3 RESULTS
When dissolved in RPMI and DMEM media (Table 3.1) the polysaccharides 
(alginate, HA, dextran) and low er molecular weight PAcA (SPACA30) produced little 
change in pH giving values around pH 7.0. Conversely, the higher molecular weight 
PAcAs (PAcAioo and PACA450 Da) caused a decrease in pH, whilst PAMAM 3.5 and 
PEI caused an increase in pH. For example, for PEI the pH increased to pH 8.68 in 
DMEM media, and pH 9.03 in RPMI media.
3.3.1 Evaluation of polymer cytotoxicity by MTT assay
O f the synthetic polymers tested, PEI displayed the highest cytotoxicity, and 
this increased with increasing polymer concentrations in D U 937 (Figure 3.3), 
B16F10 (Figure 3.4a), ECV304 cells (Figure 3.4b), and to increasing incubation 
times in B16F10 cells.
The polysaccharides (alginate, HA and dextran) had IC50 values o f  greater than 
1 mg/mL, regardless o f  the incubation time (figure 3.5a and 3.5b). Although HA 
caused a concentration-dependent cytotoxicity (from 0.12 mg/mL - 1 mg/mL) in 
ECV304 cells after a 72 h incubation, it displayed an IC50 value o f  > 1 mg/mL 
(Figure 3.5b).
sPA cA 30 showed som e toxicity in B16F10 cells from 0.1 mg/mL concentrations 
at 72 h, though the IC50 value o f  this polymer was still greater than 1 mg/mL (Figure 
3.6a). In ECV304 cells, it was less cytotoxic (Figure 3.6b). PAcAioo and PACA450 
also displayed concentration-dependant cytotoxicity in B16F10 cells (Figure 3.6a) 
and ECV304 cells (Figure 3.6b), and when the incubation time was decreased from 
72 h to 1 h, cytotoxicity was reduced in B16F10 cells. PAMAM 3.5 had an IC50 
value > 1 mg/mL in B16F10 cells after a 1 h and 72 h incubation (Figure 3.7a) and in 
EC V304 cells at 72 h (Figures 3.7b). A ll polymer IC50 values are shown in Table 
3.2. With hindsight, it would have been a good idea to match the control cells for 
these experiments with the polym ers being studied. Unfortunately however, this was 
not done at the time. N evertheless, no correlation between the pH o f  the polymer 
solutions added to the cells and polym er cytotoxicity was found, though caution has 
to be taken when making this assumption. It is difficult to truly estimate the extent o f  
polym er cytotoxicty without this important control.
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Table 3.1 Effect o f  polymers on the pH o f  medium (containing 10% FBS).
Polymer* pH in RPMI pH in DMEM
Medium only 7.49 7.56
PEI 9.03 8.68
Dextran 7.85 7.62
Alginate 7.13 7.20
HA 7.92 7.85
PAM AM  3.5 8.18 8.06
sPAcA 30 7.78 7.63
PAcA ioo 6.63 6.71
PACA450 6.54 6.70
* 1 mg/mL in media
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Figure 3.3 Effect of sHA on the viability of DU937 cells (24 h incubation). The 
cytotoxic reference control, PEI, is also shown. The data shown are mean ± SEM (n 
= 18).
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Figure 3.4 (a & b) Effect of PEI and dextran on cell viability (72 h incubation).
Panel (a) B16F10 cells and panel (b) ECV304 cells. The data shown are mean ±
SEM (n= 18).
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Figure 3.5 (a & b) Effect of polysaccharides on cell viability (72 h incubation).
Panel (a) B16F10 cells and panel (b) ECV304 cells. The data shown are mean ±
SEM (n= 18).
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Figure 3.6 (a & b) Effect of PAcAs on cell viability (72 h incubation). Panel (a)
B16F10 cells and panel (b) ECV304 cells. The data shown are mean ± SEM (n = 18).
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Figure 3.7 (a & b) Effect of PAMAM 3.5 on cell viability (72 h incubation). Panel
(a) B16F10 cells and panel (b) ECV304 cells. The data shown are mean ± SEM (n =
18).
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Table 3.2 Summary of the ICso  ^values observed.
Polymer Polymer
MW
(Daltons)
B16F10 
IC50 ± SEM (mg/mL)tf
ECV304 
IC50 ± SEM (mg/mL)+t
DU937 
IC50 ± SEM (mg/mL)ft
l h 72 h 72 h 24 h
Alginate 240,000 > 1 > 1 > 1 ND
Dextran 6 8 , 0 0 0 > 1 > 1 > 1 ND
HA 50 - 800,000 > 1 > 1 > 1 ND
sHA 3 - 58,000 ND ND ND > 1
sPAcA30 30,000 > 1 > 1 > 1 ND
PAcAioo 1 0 0 , 0 0 0 > 1 0.333 ± 0.04 0.958 ± 0.09 ND
PACA450 450,000 > 1 0.418 ±0.02 > 1 ND
PAMAM 3.5 12,931 > 1 > 1 > 1 ND
PEI 75,000 0.039 ± 0.00 0.004 ± 0.00 0.005 ± 4 x 0.00 0.008 ± 0 .0 0
* Inhibitory concentrations at which 50% cell death occurs 
^ Data show the mean (n = 18)
ND = not determined
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33.2 Establishing ELISA assays
When examining the recovery of cytokine from tissue culture medium in the 
presence and absence of polymers, medium alone gave a recovery of mTNF-a 
(97.4%) that was close to the spiked level of cytokine (93.4 pg/mL). In the presence 
of polymers recovery was apparently higher in almost all cases. Recovery of mTNF- 
a  from media containing PEI (82.4 %) was closest to the value recovered from the 
media (Figure 3.8). When calibration curves were made with and without PEI, the 
PEI appeared to reduce the levels of cytokine assayed (Figure 3.9).
3 3 3  Cytokine release from DU937 cells
TNF-aand IL-2 release at 24 h: LPS induced the highest amounts of hTNF-a 
from DU937 cells (see Figures 3.10, 3.11 3.12 and 3.13), but no hIL-2 (data not 
shown). A concentration-dependent increase in hTNF-a release was seen with 
increasing concentrations of sHA and HA, and 100 pg/mL of both polymers induced 
the highest TNF-a levels (Figures 3.10a and b and respectively). No hTNF-a or hlL- 
2 release was found when alginate (Figure 3.11), SPACA30 (Figure 3.12) or PAMAM 
generation 3.5 dendrimers (Figure 3.13), were introduced to the culture. In addition, 
no hIL-2 release was found when HA was added (data not shown).
Time-dependent TNF-a release: hTNF-a release was detectable at the earliest 
incubation time of 10 min, and increased quickly with time (Figure 3.10c). Highest 
levels of hTNF-a for both HA (175 ± 2 0  pg/mL) and LPS (1301 ± 127 pg/mL) were 
found at the final incubation time o f 5 h. These values are lower than those found 
after a 24 h incubation (Figure 3.10a).
33 .4  Cytokine release from B16F10 and RAW 246.7 cells
TNF-a, IFN-y and IL-2 at I h: PEI induced the highest levels of mTNF-a 
(Figure 3.14a and b), mIFN-y (Figure 3.15a and b) and mIL-2 (Figure 3.16a and b) in 
both B16F10 and ECV304 cells respectively. No other polymers induced cytokines.
Time-dependent TNF-a release: No mTNF-a release was detectable when 
B16F10 cells were incubated with HA or LPS at times up to 24 h (data not shown). 
In RAW 246.7 cells however, mTNF-a release from HA and LPS-incubated cells 
was detectable from 10 min (Figure 3.17). mTNF-a levels peaked at 12 h, before 
slightly decreasing at 24 h. LPS induced more mTNF-a release compared to HA.
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Polymer (1 mg/mL)
Figure 3.8 Effect o f  the addition o f  polymers (1 mg/mL) on the recovery o f mTNF-a 
from tissue culture medium. The data shown are mean ± SEM (n = 3), and were non­
significant (NS) according to analysis by one-way ANOVA.
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Figure 3.9 Effect of the addition of PEI to the calibration curve observed for mTNF- 
a . Data were assayed in duplicate (n = 2).
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Figure 3.10 (a & b) Effect o f  concentration and time o f  exposure on the ability o f  
HAs to induce hTNF-a release from DU937 cells (24 h incubation). RPMI media 
and LPS were used as positive and negative controls respectively. The data shown are 
mean ± SEM (n = 3), and were analysed by one-way ANO VA and Bonferroni post- 
hoc tests. * = p < 0.05
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Figure 3.10 (c) Effect o f  LPS and HA on the release o f  hTNF-a from DU937 over 
time. The data shown are the mean ± SEM (n = 3). One-way ANOVA and 
Bonferroni post-hoc test were carried out on HA data only, * = p < 0.05.
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Figure 3.11 Effect of LPS and alginate on release o f  hTNF-a from DU937 cells (24 h 
incubation). RPMI media and LPS were used as positive and negative controls 
respectively. The data shown are mean ± SEM (n = 3), and were analysed by one­
way ANOVA and Bonferroni post-hoc test, * = p < 0.05.
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Figure 3.12 Effect o f  LPS and SPACA30 on release o f  hTNF-a from DU937 cells (24 
h incubation). RPMI media and LPS were used as positive and negative controls 
respectively. The data shown are mean ± SEM (n = 3), and were analysed by one­
way ANOVA and Bonferroni post-hoc test, * = p < 0.05.
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Figure 3.13 Effect o f  LPS and PAMAM 3.5 on the release o f  hTNF-a from DU937 
cells (24 h incubation). RPMI media and LPS were used as positive and negative 
controls respectively. The data shown are mean ± SEM (n = 3), and were analysed 
by one-way ANOVA and Bonferroni post-hoc test, * = p < 0.05.
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Figure 3.14 (a & b) Effect of polymers on mTNF-a release at 1 h from B16F10 cells
(a) and RAW 246.7 cells (b). Data shown are mean ± SEM (n = 3), and NS
according analysis by to one-way ANOVA.
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Figure 3.15 (a & b) Effect of polymers on release of mlFN-y at 1 h from B16F10
cells (a) and RAW 246.7 cells (b). Medium alone is shown as a control. Data shown
are mean ± SEM (n = 3), and NS according analysis by to one-way ANOVA.
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Figure 3.16 (a & b) Effect of polymers on release of mIL-2 at 1 h from B16F10 cells
(a) and RAW 246.7 cells (b). Medium alone is shown as a control. Data shown are
mean ± SEM (n = 3), and NS according analysis by to one-way ANOVA.
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Figure 3.17 Effect o f  LPS and HA on the release o f  m TNF-a from RAW  246.7 cells 
over time. The data shown are the mean ± SEM (n =  3). One-way ANO VA and 
Bonferroni post-hoc test were carried out on HA data only, * = p <  0.05.
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3.4 DISCUSSION
The purpose o f these studies was to evaluate the cytotoxicity o f the chosen 
polymers using the MTT assay in B16F10, ECV304 and DU937 cell lines, and thus 
to enable the subsequent use o f  non-toxic polymer concentrations. ELISA assays 
were then set up and used to determine the ability o f the polymers to induce the 
release o f the cytokines hTNF-a and hIL-2 from DU937 cells, and mTNF-a, mIL-2 
and mlFN-y from B16F10, and RAW 246.7 cells.
Before conducting cytotoxicity experiments, it was important to have 
documented the growth rate o f each cell line, as polymers should only be added to the 
cells during their logarithmic growth phase. The metabolism o f MTT is slower when 
cells reach confluence (Finlay e t  a l. , 1986), thus cells should be used pre-confluence 
to ensure reproducibility. Moreover, the pH o f the tissue culture media containing 
dissolved polymers was also measured (see Table 3.1), as cell growth is known to 
decline suddenly on the alkaline side, and more steadily on the acid side o f the pH 
range 7.38 - 7.87 (Mackenzie e t  a l. , 1961). Optimum cell growth occurs at pH 7.4. It 
was therefore important to measure the pH o f the polymer solutions used for these 
studies. Unfortunately however, during cytotoxicity experiments the pH o f the 
control cells were not matched with those incubated with the polymer solutions. This 
was important, as it would have allowed the cytotoxicity o f only the polymers to be 
assessed, and the effect o f pH to be discounted from the MTT assay results.
As expected the high charge density o f PEI caused an increase in the pH o f the 
culture medium (pH 8 - 9 )  (Table 3.1). PAMAM generation 3.5 dendrimers also 
increased the pH o f the culture media (pH 8 ), despite their 64 anionic (-COOH) 
terminal end groups. This increase in pH is likely to be due to the exposure o f the 
NH2 groups within the dendrimer's inner structure (Chen e t  a l ,  2000; Rietveld e t  a l.,
2001). The polysaccharides dextran, alginate and HA had little effect on the pH of  
the culture media. PAcAioo and PACA450 were the most acidic polymers, and reduced 
the pH o f the media (pH 6 ). SPACA30 was less acidic in media, as the Na+ groups on 
this polymer would neutralise some o f its negative charges.
P o l y m e r  c y t o t o x i c i t y
Since the MTT assay was first used to look at the cytotoxicity o f polymers in
the early 1990’s (Sgouras and Duncan, 1990), several general trends with regard to
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polymer cytotoxicity have been identified. It is now widely accepted that polymer 
cytotoxicity increases with polymer molecular weight (Malik e t  a l. , 2000; El-Sayed e t  
a l. , 2003b; Fischer e t  a l. , 2003) and that polycations are more destructive to cell 
membranes than polymers that display negative charges (El-Sayed e t  a l . ,  2003b; 
Fischer e t  a l . ,  2003; Chen e t  a l . ,  2004). It is for these reasons that the highly 
branched, high molecular weight, cationic polymer, PEI, was used as a positive 
control for cytotoxicity experiments.
A s expected PEI was more cytotoxic towards B16F10 and ECV304 cells, than 
the acidic polymers: PAcAs, alginate and HA, or the negative reference control 
polymer dextran (Table 3.2). It was also more cytotoxic than sHA in DU937 cells 
(Table 3.2), and thus provided a good positive control. Dextran also provided a good  
negative control polymer for cytotoxicity studies, as in accordance with literature, 
both B16F10 and ECV304 cells remained 100 % viable when incubated with it (up to 
1 mg/mL) over 72 h (Figure 3.4a and b respectively). A summary o f  IC50 values 
reported for the polymers used in this study is given in Table 3.3, however, caution 
should to be taken when comparing experiments conducted in different laboratories. 
The phenotype and characteristics o f  cells (i.e. i f  a suspension or an adherent line), as 
w ell as the incubation times with polymers are both important, as these factors affect 
the IC50 values observed (Sgouras and Duncan, 1990; Fischer e t  a l. , 2003).
PAcAioo, PAcA jso and PEI for example showed time-dependent cytotoxicity  
toward B16F10 cells. They were less cytotoxic at 24 h than at 72 h (Table 3.2). In 
addition, the B16F10 cells were more sensitive to polymer-induced cell damage than 
EC V304 cells (Table 3.2), and this effect is likely to be due to a difference in cell 
metabolism. B16F10 cells have a faster growth rate (doubling time = 1 day) than 
ECV304 cells (doubling time = 4 days), though it could also be due to a difference in 
extracellular cell-membrane composition. Furthermore, the culture conditions o f  the 
cells used can also affect results obtained in cytotoxicity experiments. For example, 
unlike Sgouras and Duncan (1990) who investigated polymer cytotoxicity in 
heptacellular carcinoma and lymphoblastic leukemia cells, the polymers used in this 
study were always dissolved in media containing 10 % FBS. This was because 
B 16F10 cells have shown arrested growth at low  serum concentrations (Rodriguez- 
Ayerbe and Smith-Zubiaga, 2000).
1 0 0
Table 3.3 Summary of IC50 values from literature.
Polymer Cell line Polymer
MW
(Daltons)
Assay method Total polymer 
incubation (h)
IC 50 value (pg/mL) Reference
PEI L929 750,000 MTT 1 31.0 (Fischer e t  a l ,  2003)
24 9.0
Eyrthrocytes 25,000 RBCLf - Complete lysis ^ 1000 (Fischer e t  a l , 2003)
B16F10 MTT 72 (Malik e t  a l ,  2000)
COS-7 MTT 24 < 2 0 (Kean e t  a l ,  2005)
PAMAM 3.5 Caco2 12,931 MTT 3 > 1000 (Jevprasesphant e t  a l ,  2003)
B16F10 MTT 72 > 2000 (Malik e t  a l ,  2000)
Dextran CCRF* 40,200 MTT 72 98.0 ± 11.9 (Sgouras and Duncan 1990)
B16F10 70,000 MTT 72 > 2000 (Malik e t  a l ,  2000)
* cells grown in the absence o f  serum proteins.
* Red blood cell lysis
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Cytotoxicity o f the polymer library
Alginate and HA had IC50 values o f  greater than 1 mg/mL in ECV304, B16F10  
(72 h incubation), and DU937 cells (24 h incubation) (Table 3.2). This was expected, 
as both polymers are routinely used in a variety o f  applications (see Chapter 1, 
sections 1.6.1 and 1.6.2 respectively), and have been adopted by the European 
Pharmacopoeia.
PAcAs (introduced in Chapter 1, section 1.6.3) are also regarded as non-toxic 
and non-irritant polymers, and are included in the FDA inactive ingredients guide. 
They are commonly used in non-parental medicines. The lethal dose 50 values 
(LD50; chemical dose that is lethal to 50 % o f  a test population) for the PAcAs used 
for these studies according to the supplier (www.sigmaaldrich.com) are: 2000 mg/kg 
for PAcAioo, 2500 mg/kg for PACA450, and > 40,000 mg/kg for SPACA30 when orally 
administered to rats. The rank order for PAcA cytotoxicity in both B16F10 and 
ECV304 cells at 72 h also showed this trend, where PAcAioo > PACA450 > SPACA30 
(Figure 3.6, Table 3.2). The IC50 value o f  SPACA30 was greater than 1 mg/mL.
Due to increasing interest in the possibility o f  using PAMAM dendrimers for 
drug and gene delivery, the cytotoxicity o f  these m olecules has been w idely  
investigated. The toxicity o f  these m olecules is dependent upon their generation, and 
terminal end groups. Lower generation PAM AM  dendrimers are som etim es 
cytotoxic due to their open molecular structure (as their core is more accessible to 
cells (Malik et al., 2000)), whilst full generation, cationic, PAMAM dendrimers 
(displaying -N H 2 termini) show  generation-dependent cytotoxicity (Malik et al., 
2000; El-Sayed et al., 2003b). Quatemised (-OH) and half (-COOH) generation 
PAM AM  dendrimers have a lower level o f  cytotoxicity thought to be due to the 
shielding o f  their internal cationic charges (Lee et al., 2005).
In accordance with the literature (Table 3.3), in these studies PAM AM  
generation 3.5 dendrimers did not have an effect on B16F10 or ECV304 cell viability 
at concentrations up to 1 mg/mL over 72 h.
Cytokine release caused by the polymer library
Before conducting ELISA experiments, it was important to determine whether
the polymers would interfere with the assays. Addition o f  cytokine standard (mTNF-
a )  to tissue culture media did not affect recovery (Figure 3.8). This was expected as
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the supplier information states that the kits can be used for this purpose 
(www.rndsystems.com). PEI appeared to interact with the assay, as the m TNF-a  
standard calibration curve spiked with this polymer gave a lower recovery (Figure 
3.9). This is likely to be due to the electrostatic interaction o f PEI with the cytokine 
or the Ig bound in the ELISA plates.
One draw back o f  using ELISA kits to assay for cytokines is that samples have 
to be measured in duplicate, and they are costly (approximately £250 - £500  
depending on the kit). This limits the number o f  experiments that can be conducted. 
As a result, the calibration curves spiked with PEI were only conducted once.
Using a well-known cell line and standard it was important to verify that the 
assays used were working. D U937 macrophage-like cells and LPS provided good  
positive controls for h T N F -a  ELISA assays. In accordance with Boyce and 
colleagues (1997) (who used L929 cells as a bioassay), sHA stimulated the release o f  
hT N F-a from these cells in a concentration-dependent (0.1 -  100 pg/mL) manner, 
after 24 h incubation (Figure 3.10a). Likewise, HA also had the same effect (Figure 
3.10b), suggesting that the salt form o f  HA is not important for hTNF-a release. The 
release o f  hTNF-a from DU937 cells also increased with incubation time from 0 - 5 h 
(Figure 3.10c).
The ability o f  (s)HA to induce hTNF-a release from DU937 macrophage cells 
(Boyce et al., 1997), is probably due to a receptor mediated reaction. HA has been 
shown to interact with several cell surface receptors including CD44, ICAM, and 
RHAMM, and to activate cells accordingly (as reviewed in Chapter 1, section 1.6.2).
Similarly, the positive response o f  D U 937 cells to LPS was also expected (see  
section 5.1), as macrophage cells express CD 14, and thus react to picogram (pg) 
quantities o f  this molecule (Ulevitch, 1993; Wright et al., 1990).
However, when D U937 cells were incubated with alginate (Figure 3.11), 
sPAcA30 (Figure 3.12) and PAMAM 3.5 (Figure 3.13) for 24 h, no hTNF-a release 
was seen. In the case o f  alginate, this result was surprising. As mentioned in Chapter 
1 (section 1.6.1), many reports have shown that high M alginates induce TN F-a from 
macrophage (Thomas et al., 2000; Son et al., 2001) and monocyte (Otterlei et al., 
1991; Otterlei et al., 1993; Espevik et al., 1993; Jahr et al., 1997; Berntzen et al., 
1998; Jahr et al., 1997) cells via interaction with CD 14, and this response is not due
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to LPS contamination. Though attempts were made in this study to measure the LPS 
content o f  polymer stocks, the polymers appeared to interfere with the assay. 
However, as no cytokine release was seen from polymer-incubated cells, the assay 
was considered unnecessary.
Possible reasons for the negative response o f alginate in ELISA assays
Alginates have been found to bind not only to CD 14, but also to bind LBP and 
the bactericidal/permeability-increasing protein (Jahr et al., 1997). It induces TNF-a  
release in a similar way to LPS.
As membrane-bound CD 14 lacks a cytoplasmic tail, it is thought to aggregate 
LPS or alginate at the cell surface, to interact with TLRs (possibly TLR 4 or TLR 2) 
for signal transduction (Flo et al., 2000). Both receptors are present on PMA- 
differentiated U937 cells (Greene et al., 2004), thus it is not clear why no hTNF-a 
release was seen from this cell line. It was considered that the sterile-filtration 
(through 0.2 pM pore filters) o f  alginate-containing tissue culture media could have 
reduced the quantity o f  alginate added to the cells, i f  the polymer had stuck to the 
filter, yet in the literature, alginates o f  up to 550,000 Da have also been sterilised via 
this method (Otterlei et al., 1991; Otterlei et al., 1993).
As polymer-incubation time is also important for cytokine production (Figure 
3.10c), it was also considered that simply investigating hTN F-a release after 24 h 
might not have been useful. In the literature reports have demonstrated hTNF-a  
release from alginate-incubated monocytes after 6 - 24 h incubations (Otterlei et al., 
1991; Otterlei et al., 1993; Espevik et al., 1993; Jahr et al., 1997; Bemtzen et al., 
1998; Flo et al., 2000). As previously mentioned, the M-content o f  the alginate is 
important, and although a high M alginate was selected for this work, the exact M 
content is not known. Alginates in the literature were mainly from bacteria, and were 
85-99 % M. It would be interesting to determine the M content o f  the alginate used 
for these studies, perhaps by using *H nuclear magnetic resonance spectroscopy.
In comparison to D U937 cells, a different TN F-a release profile was seen in 
RAW  246.7 cells incubated with HA and LPS, where release o f  the cytokine 
remained low until 5 h (Figure 3.14). As with cytotoxicity, this is likely to be due to 
a difference in cell metabolism and cell surface composition. What's more, a recent 
report in the literature has shown that CD44, TLR 4 and RHAMM receptors are
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Table 3.4 Phenotype, origin, common experimental applications, and cytokines produced by the cell lines chosen for this work.
C ell line Species and 
Phenotype
Cell origin Cytokines
secreted
Experim ental applications References
B16F10 Murine, dendritic From B16 murine melanoma cells after IL-2 Tumour model in mice. Their (Garcia de
pigmented isolation o f  metastases and serial passages in IL-18 pigment allows them to be Galeano et
macrophages culture. visualised when metastasised al, 1996)
ECV304 Human, Spontaneously transformed human umbilical VEGF Endothelial model for angiogenesis, (Huges et
endothelial-like vein cell line, taken from a newborn Japanese TGF-pl cell migration, glucose transport, al, 1996
cells female. and blood-brain barrier studies
RAW Murine, monocyte Established from tumour ascites o f  a male IL-lra Widely used as a model (Heming,
246.7 and macrophage­ mouse, induced by an i.p. injection o f TNF-a marcophage cell line 1996)
like cells Abselon Leukaemia Virus. IL-6
VEGF
DU937 Human, DU937 cells are a mature from o f IL-1 ra Served as a model for monocyte- (Boyce et
macrophage-like promonocytic, U937 cells that were TNF-a macrophage differentiation. al, 1997)
cells established from a human diffuse histiocytic TGF-p
lymphoma patient. M-CSF
o
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responsible for mTNF-a release from HA-incubated cells in this cell line (Wang et 
al, 2006). N o cytokine release was seen in B16F10 cells when incubated with the 
above over 24 h. There appear to be no reports in the literature that have detected the 
release o f  m TNF-a from this cell line (Table 3.4), and they do not express TLR 2 or 
TLR 4 (Manjili et al., 2006), but do express high levels o f  CD44 (Zawadzki et al., 
1998).
Only PEI induced m T N F-a, m lF N -y and mIL-2 release from B16F10 and 
RAW 246.7 cells at 1 h. This data is in accordance with Puckey 2002, who reported 
high levels o f  m T N F-a release from B16F10 cells incubated with this polymer (3 
mg/mL). A s B16F10 cells were unresponsive to LPS, PEI was used as a positive 
control for ELISA experiments with these and the RAW 246.7 cells.
The exact mechanism o f  cytokine release caused by PEI is not known, though it 
can be speculated that disruption o f  the cell membrane and release o f  cytosolic  
proteins into the culture media from cells killed by this polymer, may have interfered 
with the ELISA assay. Additionally, PEI could have caused membrane proteins to 
gather into two-dimensional clusters (Godbey et al., 1999), and the gaps between the 
aggregated proteins could then play the part o f  pores allowing potassium ions to rush 
out from the cell, and Ca2+ to rush in along a concentration gradient (reviewed by 
Kabanov, 2004). To compensate for this difference, the cell would then increase its 
consumption o f  ATP, resulting in the activation o f  molecular pumps that would give 
start-up signals to other intracellular systems that could lead to cytokine release. PEI 
has already been shown to enhance the immune system towards transplanted tumour 
cells in test animals (Moroson, 1971), and to activate macrophage cells in vitro 
(Bogwald et al., 1984).
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CHAPTER 4: Effect of cytokines on FITC-dextran transport
4.1 INTRODUCTION
Although most o f  the polymers studied in the previous chapter did not show  
cytokine release from the cell lines used, it was decided to move forward and 
examine the ability o f  cytokines (rTNF-a, rlFN-y or rIL-2) to stimulate the transport 
o f  FITC-dextran across rat intestinal tissue. This physiological tissue was used as a 
model epithelial barrier as it was thought to provide the best opportunity to explore 
the effects o f  rTNF-a, rlFN-y or rIL-2 on a ‘mixed cell population’, and thus to 
provide maximum opportunity to stimulate transport.
Progression to these studies was important as a growing number o f  papers were 
suggesting that the polymeric excipients such as PAcA (Kast and Bemkop-Schnurch,
2002), chitosan (Borchard et al, 1996; Kotze et al., 1997; Kotze et al., 1999; Thanou 
et al., 2000) and PAMAM dendrimers (El-Sayed et al., 2003; El-Sayed et al., 2003; 
as w ell as cytokines (m ost notably T N F -a and IFN-y), could increase cellular 
permeability. However it is also known that both cytokines are also involved in 
hyper-permeable inflammatory bowel diseases (IBD).
Elevated levels o f  T N F -a are associated with the pathogenesis o f  Crohn’s 
disease (CD) (review ed in V anD eventer, 1997; Yamamoto et al., 2004) and 
ulcerative colitis (UC) (Murch et al., 1993; Masuda et al., 1995; Scarpa et al., 2004). 
T N F -a  is thought to play a key role in these diseases by damaging the integrity o f  
epithelial (Chakravortty and Kumar, 1999; Schmitz et al., 1999; Gitter et al., 2000a; 
Gitter et al., 2000b; Bruewer et al., 2005; Poritz et al., 2004) and endothelial 
membranes and increasing inflammatory cell recruitment (reviewed in VanDeventer, 
1997). High concentrations o f  this cytokine have been identified in the inflamed 
mucosa, serum and stools (Breagger, 1992) o f  these patients, and inhibitors for TNF- 
a  (see Chapter 1, section 1.3.1) are known to alleviate their symptoms.
IFN-y is also known to be involved in the pathogenesis o f Crohn’s disease, and 
has been identified in the inflamed intestine o f  these patients, where it is produced by 
large numbers o f  active lym phocytes (Fais et al., 1991; Agnholt et al., 2001; 
Olaussen et al., 2002).
To study the effect o f  cytokines on transport across the rat intestine, FITC- 
dextran (Figure 4.1) was chosen as a marker for paracelluar integrity and the vertical 
diffusion system was used as a model. The rationale for this selection is discussed in 
the following sections.
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Figure 4.1 Chemical structure o f  FITC-dextran
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Rationale for the choice o f paracellular marker
FITC-dextran (MW = 4,000 Da; a hydrophilic, fluorescently labelled dextran 
polymer; see Figure 4.1) was chosen as a model paracellular probe for these studies, 
as it has been widely used by others to study TJ integrity in Caco-2 cells (Sakai et al., 
1997; Lindmark et al., 1997), porcine and human buccal mucosa (Hoogstraate et al., 
1994; Junginger et al., 1999 and Van der Bijl et al., 1998 respectively) and the rat 
intestine (Horie et al., 2001; Nakamura et al., 2003). Like most hydrophilic drugs 
e.g. bisphosphonates (review ed by Lin, 1996), and macromolecular therapeutics 
including proteins (e.g. monoclonal antibodies) peptides (e.g. insulin), and many 
polymers, FITC-dextran is normally excluded from the paracellular pathway (see 
Figure 1.4) due to the restriction o f  TJ.
Rationale for the choice o f transport model used
A number o f  in vitro m odels have been developed to study the intestinal 
permeability o f  drugs and polymers (reviewed in Barthe et al., 1999). The simplest 
involve the use o f  epithelial cell monolayers, namely human colon carcinoma cells 
such as T84 (Madara et al., 1987) and HT29 (Zweibaum et al., 1985), or Caco-2 
human primary colon carcinoma cells (Fogh et al., 1977; Hidalgo et al., 1989; 
Hilgers et al., 1990). The cells are grown on filters until they reach a confluent 
monolayer (often monitored by reading the TEER) and they are then used to measure 
intestinal permeability. O f them, Caco-2 cell monolayers are the most commonly 
used model, and have been w idely adopted by the pharmaceutical industry, for 
screening the potential oral bioavailability o f  new drugs. Caco-2 monolayers have 
advantages over other intestinal cell lines, as they differentiate (spontaneously) into 
polarised cells that possess the greatest number o f  adult entrocyte features, including 
a brush-border (Pinto et al., 1982) with ectoenzym es (Zweibaum et al., 1983; 
Zweibaum et al., 1984; Hauri et al., 1985). However, they require culture for up-to 
20 days in order to develop an intact monolayer (Pinto et al., 1983), and as a 
consequence are usually grown in media containing antibiotics. Moreover, mature 
Caco-2 cells are devoid o f  a mucus layer (Wikman-Larhed et al., 1995; Hilgendork et 
al., 2000), as expressed by goblet cells in vivo, over-express P-gp (Hosoya et al, 
1996; Goto et al., 2003; Anderle et al., 2003), and possess tighter TJ compared to 
other epithelial models. This is thought be due to them having smaller paracellular 
pores (Artursson et al., 1993; Collett et al., 1997).
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Consequently, more physiological models that use segments or explants o f  
intestinal tissue are sometimes preferred. These methods offer some benefit over 
monolayer models as they are more physiological, and they possess mucus. They can 
also be used to investigate permeability differences across different regions o f  the GI 
tract, and can be selected to contain Peyer’s patch regions.
The closest example to the intestine in vivo, is the single pass perfusion model 
(reviewed by Roig and Vinardell, 1991; reviewed by Barthe et al, 1999), which uses 
segments o f  the intestine from anesthetised animals that are cannulated, flushed, and 
perfused with a drug-containing solution. In this case the blood supply and clearance 
capabilities o f  the animal remain intact, and the amount o f  drug absorbed from the 
perfusate can be calculated from blood samples taken from the mesenteric vein. 
However, no information about drug permeation at the cellular level is gained with 
this method, and some evidence has shown that the anaesthesia and surgical 
manipulation o f  the animals can have pronounced effects on absorption (Uhing and 
Kimura, 1995). Moreover, the flow  rate o f  the perfused intestine is often higher than 
that in vivo, resulting in increased luminal hydrostatic pressure that may also affect 
permeability (Chiou, 1994).
In contrast, the everted gut sac method first described by W ilson and Wisemann 
in 1954, and developed as a screening tool by Barthe and colleges (1998), is a 
relatively quick and simple model that can be used to gain an insight into the 
mechanism o f  drug absorption. Excised intestine from fasted rats, is flushed with 
saline, placed into oxygenated (TC 199) medium, and everted over a glass rod (3 mm 
in diameter). The resultant intestinal tube is filled with fresh oxygenated medium, 
and divided into (2-4 cm) sacs using silk suture. Each sac is then incubated with test 
compounds for up to 2 h, with shaking to ensure mixing (that would occur naturally 
as a result o f  peristalsis), and at the end o f  each experiment test compounds are 
analysed in the sac tissue and the serosal fluid (Diamanti, 2004). Compounds that are 
metabolised by cell surface enzym es in the intestine are detectable in the medium  
follow ing incubation, whilst drugs that are absorbed by cells may be susceptible to 
first-pass metabolism. These drugs may be transported into the serosal space, or 
confined to the cell interior. If compounds are transported via the paracellular route, 
they w ill only be found in the serosal space. This form o f  transport would also be
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concentration-dependent. Finally, to normalise each sac to per unit protein, each sac 
is also dissolved in acid (NaOH), so that tissue protein content can be measured.
The only disadvantage o f  using this model are that the serosal compartment o f  
each sac is a closed system, which could misrepresent the absorption kinetics o f  drugs 
during long incubations, or if  a drug is very rapidly absorbed (reviewed in Barthe et 
al, 1999).
The U ssing chamber is an electrophysiological technique that has proved a 
popular alternative for studying transport. This method was originally developed by 
Ussing, who used it to prove the active transport pathway, when he measured Na+ 
transport across frog skin (Ussing and Zehran, 1951). To-date, virtually all types o f  
epithelial tissue has been studied using this model. The Ussing chamber essentially 
consists o f  two functional halves: one is the chamber itself, whilst the other is the 
electric circuitry. To measure transport across the intestine using this method, small 
sections o f  tissue are clamped between two chambers (containing medium), so that 
the transport o f  detectable compounds between the chambers can only occur across 
the tissue. Electrodes positioned in each chamber accompany measurement o f  
transport, by measuring the electrical potential, which indicates the rate o f  ion flow  
across the tissue.
The vertical diffusion system (Grass and Sweetana, 1988) as used for these 
studies is a relatively quick and simple adaptation o f  the Ussing chamber model. It 
contains six transparent acrylic chambers (though only four were used for these 
studies) that are kept at 37 °C via a heated block, and are supplied with gas (95 % O2, 
5 % CO2) to circulate the buffer, and to keep the tissue viable (see Figure 2.8). The 
benefits o f  using this model are that (i) several experiments can be carried out 
simultaneously using all the chambers, (ii) using physiological tissues provides a 
mixed cell population (unlike many o f  the traditional monolayer models), in which 
Peyer’s patches can be included, and (iii) transport can be measured in both an apical 
to basal (Ap—>Bas) direction, corresponding to transport from the intestinal lumen to 
the blood/lymph, or a basal to apical (Bas-»A p) direction, corresponding to transport 
from the blood/lymph to the intestinal lumen (see Figure 2.6a). As cytokine receptors 
are known to be largely present on the basal side o f  intestinal epithelial cells (Adams 
et al., 1993), transport was measured in both directions.
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Finally, to reflect the permeation o f  FITC-dextran across only the intestinal 
mucosa, the rat tissues used for these studies were stripped o f  muscle layers by blunt 
dissection (Dickens and Weil-Malherbe, 1941). Therefore, the main disadvantage o f  
this method is that the stripping o f  the muscle and serosal layers can compromise the 
integrity o f  the mucosal layer. The toxicity o f test compounds during this work can 
also be easily assessed, by measuring LDH release (see Chapter 2, section 2.2.7).
The specific aims o f  the experiments conducted here were to:
(i) Set up a model that could be used to measure FITC-dextran transport.
(ii) Establish tissue viability using the LDH assay.
(iii) Study the effects o f  rTNF-a, rlFN-y or rIL-2 on transport across tissue with or 
without visible Peyer’s patches.
However, before work could begin, it was important to carefully consider 
which concentration o f  cytokines would be used for the experiments. It was initially 
decided to use physiological concentrations (pg/mL) o f  cytokines, though in the 
literature, studies using epithelial cell line models have used higher (ng/mL) levels o f  
TN F-a and/or IFN-y to decrease TJ integrity (Madara and Stafford, 1989; Rodriguez 
et al, 1995; Mahraoui et a l, 1997; Marano et al, 1998; Fish et a l, 1999; Schmitz et 
a l,  1999; Gitter et a l, 2000a; Bruewer et al, 2003; Ma et a l, 2004; Poritz et al, 
2004; Kawaguche et a l, 2005; Utech et a l, 2005; Wang et a l, 2005). To enable 
comparisons with this data, the later experiments used similar levels o f  these 
cytokines. In some experiments, the synergistic effects o f  rTNF-a and rlFN-y on 
FITC-dextran transport across the intestinal tissue were also measured.
4.2 METHODS
The general methods (i.e. the vertical diffusion chamber, LDH assay and GPC) 
applied to this study have previously been described in Chapter 2 (sections 2.3.6, 
2.3.7 and 2.3.8 respectively). Throughout FITC-dextran was dissolved in MEM (with 
Earles salts, without L-glutamine or phenol red; see Table 2.1), at a concentration o f  
0.1 mg/mL. To prevent photo bleaching, all FITC-dextran solutions were protected 
from light, and the fluorescence o f  this polymer was read using the fluorescence plate 
reader (see Chapter 2, section 2.3.6).
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4.2.1 Characterisation of FITC-dextran
A s different batches o f  FITC-dextran were used for these studies, it was 
considered important to define the molecular weight characteristics and fluorescence 
o f  the batches used, and also to investigate the effect o f storage on molecular weight.
The molecular weight and polydispersity o f FITC-dextran was measured using 
GPC (for general method see Chapter 2, section 2.3.8). PBS at pH 7.4 was used as a 
solvent for this work, and was filter-sterilised, and sonicated to remove contaminants 
and air bubbles respectively. FITC-dextran (5 mg/mL) in PBS was sterilised by 
filtration (through 0.2 pm filters). To conduct GPC, 80 pL o f FITC-dextran solution 
was carefully drawn up into a glass syringe (to avoid air bubbles), and 60 pL o f  this 
was injected onto the first column. A  TSK G3000PWxl - TSK G4000PW xl column 
set run in series was used (as described in section 2.3.8). In brief, the flow  rate 
through the column was 1 mL/min, and a refractive index detector was used to 
monitor samples as they eluted over 30 min. A calibration curve was made using six 
pullulan polysaccharide standards (5 mg/mL in PBS) o f  known molecular weights 
(738 -  112,000 Da) and this was used to determine the molecular weight o f  each 
sample (see Chapter 2, Figure 2.8).
Using this system, the molecular weight characteristics o f  two different batches 
o f  FITC-dextran were compared, as was the effect o f  FITC-dextran (5 mg/mL in 
PBS) storage at room temperature, - 20 °C and 4 °C, for 24 h.
To determine the fluorescence yield o f  different batches o f  FITC-dextran, and 
also the effect o f  storage on fluorescence output, solutions were made up in MEM (1- 
0.03 mg/mL), by serially diluting a 1 mg/mL FITC-dextran stock solution in MEM  
(at a 1:2 ratio) into eppendorf tubes containing 500 pL o f MEM only. The 
fluorescence o f  these solutions (200 pL/w ell in a black 96-well plate) was read in the 
fluorescence plate reader. To measure the effect o f  freezing (- 20 °C) on the 
fluorescence output o f  FITC-dextran, serial dilutions o f  the polymer in M EM  were 
made (1 - 0.03 mg/mL as above), and were immediately read in the fluorescence plate 
reader (as above). Remaining dilutions were frozen (- 20 °C) for 24 h, and the 
fluorescence output o f  these samples were also read the using the fluorescence plate 
reader, once they had thawed. Each o f  these experiments was carried out on three 
separate occasions, and the data were expressed as an average ± standard deviation 
(S.D ).
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4.2.2 Evaluation o f FITC-dextran transport in the presence o f cytokines u sin g  
the vertical diffusion system
The intestinal epithelial tissue used for this work, was prepared by stripping the 
muscle layers (as shown in Chapter 2, section 2.3.6). To look for any tissue damage 
caused during preparation, stripped and un-stripped tissues were viewed under the 
light microscope (Leicia, Germany). Tissues were placed on a glass microscope slide 
(76 x 26 mm) and were covered with a glass cover slip (22 x 40 mm). Each slide was 
immediately viewed under the x 40 and x 63 oil emersion objectives, and 
photographs o f  the tissue were taken using the Leica camera. These photographs 
were processed using Improvision® Openlab™ software.
In addition, in some experiments tissue viability was also assessed by 
measuring LDH release as described in section 4.2.4.
The effect o f  cytokines on FITC-dextran transport from both the A p-*B as or 
Bas—*Ap directions were studied, and comparisons were made using tissue with or 
without visible Peyer’s patches. Cytokines were always reconstituted with 
autoclaved PBS (1 mL) containing 0.1 % BSA, that had been sterilised by filtration 
(through 0.2 pm Sartorious filters). The stock concentrations o f  each cytokine were 
10 pg/mL for rTNF-a and rIL-2, and 100 pg/mL for rlFN-y, and each reconstituted 
cytokine was serially diluted with PBS and 0.1 % BSA, into autoclaved, labelled 
eppendorf tubes. Aliquoted tubes (1000 ng/mL) were then bagged and stored at - 70 
°C until use. A ll aliquoted cytokines were used within 6 months o f  reconstitution, as 
the activity o f  these proteins is known to decrease after this time (R&D systems 
product data sheets: www.mdsystems.com).
Before each transport experiment, thawed cytokine solutions were serially 
diluted with M EM  containing FITC-dextran (1 mg/mL) to reach the cytokine 
concentration required. An aliquot (150 pL) o f  each stock solution was then added to 
the vertical diffusion chamber on either the mucosal or serosal sides o f  the tissue, 
thereby adjusting the total volume o f  this compartment to 1.5 mL (i.e. 1.35 mL o f  
MEM plus 150 pL o f  cytokine and FITC-dextran). The recipient chamber also 
contained 1.5 mL o f  MEM only. Samples (25 pL) were collected from the recipient 
chamber at 10 min intervals (at t = 0 - 60 min), and were placed into black 96-well
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plates (covered in foil). All samples were stored at room temperature until they were 
read in the fluorescence plate reader as described in Chapter 2 (section 2.3.6).
There were many ways in which the data from these experiments could be 
expressed. For example, the effect o f  cytokines on FITC-dextran transport could be 
expressed as a % o f  the control (FITC-dextran only). Alternatively, the flux rate and 
the apparent permeation coefficients (Papp values), o f each sample transported across 
the tissue could also be calculated as previously described (Chapter 2, section 2.3.6). 
This would enable comparisons in the permeability o f  FITC-dextran across the rat 
intestinal tissue to be made with the literature.
4.2.3 FITC-dextran stability during incubation in the vertical diffusion system
The stability o f  FITC-dextran during transport experiments was measured using
TW
a Sephadex G-25, PD-10 column. This commercially available disposable 
chromatography column, separates samples o f  1000 - 5000 Da in molecular weight, 
by gravity flow. For these experiments, samples o f  FITC-dextran in MEM (0.5 mL) 
were collected from the vertical diffusion system before and at the end o f  the 60 min 
incubation period, and were stored frozen (- 20 °C) until assay. The columns were 
equilibrated with 10 mL o f  PBS before use. Samples (0.5 mL) were added to the 
column when thawed, and were eluted with PBS (80 x 0.5 mL). The fractions (0.5 
mL) were collected into eppendorf tubes, and 200 pL o f  each was then transferred 
into a black 96-well plate, to be read in the fluorescent plate reader. Free FITC (5 
pg/mL in MEM) was used as a control for this experiment. The data were plotted as 
eluted fraction number against fluorescence.
4.2.4 Use of the LDH assay to measure tissue viability
The LDH assay was carried out as described in Chapter 2, section 2.3.7. In  
brief, samples o f  medium (50 pL) were collected from each diffusion cell at t = 0 and 
at t = 60 min. Each sample was always taken from the recipient chamber, to 
minimise any possible interference with the assay that may be caused by FITC- 
dextran, and/or added cytokines. These samples were then immediately frozen at -  
20 °C until they were assayed. The data from these experiments are expressed as 
enzyme activity in units (U)/mL.
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4.3 RESULTS
4.3.1. Properties of FITC-dextran batches and their stability
GPC analysis o f  two different batches o f FITC-dextran, showed no difference 
between the molecular weight o f  each sample (Figure 4.2a). Furthermore, the 
molecular weight o f  FITC-dextran was not affected by storage in MEM at room  
temperature, -  20 °C, or at 4 °C for 24 h (Figure 4.2b). Serial dilutions o f  different 
FITC-dextran batches in MEM (1 - 0.03 mg/mL) showed no differences in 
fluorescent output (Figure 4.3a). A  linear relationship between fluorescence and 
concentration was seen for the FITC-dextran concentration range (0.1 mg/mL) used 
for transport work (Figure 4.3b). Freezing (- 20 °C) FITC-dextran for 24 h also had 
no effect on its fluorescence (Figure 4.4).
N.B. It should be noted that FITC fluorescence output is strongly dependent on 
pH (see Chapter 5).
4.3.2. Establishment of the vertical diffusion system
Although stripping the intestinal tissue o f  muscle layers (by scalpel) is quite 
harsh, no visible holes in Peyer’s patch or non-Peyer’s patch tissues, could be seen 
after tissue preparation, when view ed under a light microscope at x 40 magnification 
(Figure 4.5). During transport experiments the levels o f  LDH released into the 
culture media, over the 1 h incubation, increased by 72 % (a 4.5-fold  increase) from t 
= 0 min, even in the absence o f  FITC-dextran (Figure 4.6a). When FITC-dextran (0.1 
mg/mL) was introduced into the system, the LDH levels released into the culture 
media increased by 85 % (a 6.8-fold increase) from t = 0 min (Figure 4.6b). 
Therefore it was possible to progress onto the transport studies.
4.3.3 Transport of FITC-dextran across rat intestinal tissue in the vertical 
diffusion system
Ap-^Bas and Bas-*Ap FITC-dextran transport across non-Peyer ’s patch tissue
The transport o f  FITC-dextran across non-Peyer’s patch tissue increased 
linearly with time in both the A p—>Bas and Bas-»Ap directions (Figure 4.7a). 
A p—>Bas FITC-dextran transport was greater than B as-*A p transport, and highest 
amounts o f  transported FITC-dextran were seen at t = 60 min. The apparent 
permeability coefficient for A p-»B as FITC-dextran transport was 2.69 x 10"6 cm/s. 
In the Bas—»Ap direction the apparent permeability coefficient was 1.85 x 10*6 cm/s.
116
CHAPTER 4: Effect of cytokines on FITC-dextran transport
151
Batch 073
1 0 -IZJ
Batch 809
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-10  -
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FITC-dextran M n M W Polydispersity
batch number (g/m ole) (g/mole) M W /M n
073 4078 4892 1.2
809 4027 4848 1.2
Figure 4.2 (a) Molecular weight and polydispersity o f  different FITC-dextran batches 
(5 mg/mL in PBS).
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Room temp (20 °C) 4133 5060 1.2
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Figure 4.2 (b) Molecular weight and polydispersity of FITC-dextran (5 mg/mL in 
PBS) after storage at different temperatures for 24 h.
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Figure 4.3 (a & b) Fluorescence output o f  different FITC-dextran batches diluted in 
MEM. Panel (a) dilutions in MEM 0.03 mg/mL - 1 mg/mL, panel (b) 0.03 mg/mL - 
0.125 mg/mL, showing a linear relationship between fluorescence and concentration. 
The data shown are mean ± SD (n = 3).
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Figure 4.4 Fluorescence output o f  FITC-dextran (batch 073) after storage in MEM at 
different temperature for 24 h. The data shown are mean ± SD (n = 3).
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(a) Non-Peyer’s patch tissue
Unstripped
(c) Peyer’s patch tissue
(b)
---------------- ► Stripped
(d)
Unstripped --------------------------------------- ► Stripped
Figure 4.5 Photographs o f rat intestinal tissue at x 40 magnification. Panel (a) 
unstripped non-Peyer’s patch tissue, panel (b) stripped non-Peyer’s patch tissue, panel 
(c) unstripped Peyer’s patch tissue, and panel (d) stripped Peyer’s patch tissue.
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Figure 4.6 (a & b) LDH release from rat intestinal tissue during 60 min incubation 
in the vertical diffusion system. Panel (a) MEM only, panel (b) MEM and FITC- 
dextran (0.1 mg/mL). Data were analysed by paired t-test, * = p > 0.05.
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(a) Non-Peyer’s patch tissue
40-
600 10 20 30 40 50
Ap-»Bas
Bas-*Ap
Time (min)
Figure 4.7 (a) Ap->Bas and B as-*A p transport o f  FITC-dextran across non-Peyer's 
patch tissue. The data shown are mean ± SEM (n > 15). The Papp values for 
A p-*B as transport = 2.69 x 10*6 cm/sec; Bas—>Ap transport = 1.85 x 10*6.
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Whilst setting up this assay it became apparent that there was considerable 
daily variation in the rate o f  FITC-dextran transport across the tissue in both Ap—>Bas 
(Figure 4.7b) and Bas-^Ap (Figure 4.7c) directions. Although sometimes this could  
be attributable to equipment malfunction (e.g. difficulties in controlling adequate 
oxygenation into all chambers, or sample leakage across the tissue), on other 
occasions it could not. The rates o f  transport did get more consistent with practice at 
tissue preparation, but there was still considerable variability. Nevertheless a large 
number o f  replicate experiments were always needed to reduce the size o f  the error 
bars (the standard error o f  the mean (SEM)). Note for Ap->Bas transport, n was 40 
(Figure 4.7b), and for Bas—»Ap transport n was 20 (Figure 4.7c).
Ap-*Bas and Bas-+Ap FITC-dextran transport across Peyer's patch tissue
The transport o f  FITC-dextran across Peyer’s patch tissue was lower than that 
seen for tissue without Peyer’s patches. Transport increased in a time-dependent 
manner over the 1 h incubation period and was linear with time. A 5 min lag phase in 
FITC-dextran transport was seen in both A p-*B as and Bas-»Ap directions across this 
tissue (Figure 4.8). Once again, A p-*B as (Papp = 1.24 x 10'6 cm/s) FITC-dextran 
transport was greater than Bas-»A p (Papp = 0.78 x 10'6 cm/s). Highest amounts o f  
FITC-dextran transport were seen at t = 60 min.
4.3.4 Stability of FITC-dextran during incubation
FITC-dextran eluted first, in fractions 3 - 79, during PD -10 colum n  
chromatography, whilst free FITC eluted later in fractions 8 - 1 2 3  (Figure 4.9). Free 
FITC seemed to adsorb to the column, and when the column was viewed under a UV- 
lamp, there were traces o f  fluorescence until 125 (0.5 mL PBS) fractions had been 
collected (Figure 4.9). When samples taken from either the donor or recipient 
chambers after the 60 min incubation were analysed by PD-10 chromatography, there 
was no increase in free FITC compared to the FITC-dextran standard (Figure 4.9).
Furthermore, only a small amount o f  FITC-dextran was transported across the 
tissue into the recipient chamber at t = 60 min (Figure 4.9). The fluorescence units 
detected in the fractions from these samples was very low compared to the donor 
chamber samples. These studies showed FITC-dextran was not degraded during the 
transport studies.
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Figure 4.7 (b & c) A p-> B as (panel b) and B as-*A p  (panel c) transport o f  FITC- 
dextran across non-Peyer's patch tissue. The data shown were collected in individual 
experiments. Although these data were variable, only experiments in which the 
fluorescence at t = 0 min was below a value o f  15 were used.
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Figure 4.8 Apical-»Bas and Bas—»Ap transport o f  FITC-dextran across tissue with 
Peyer's patches. The data shown are mean ± SEM (n > 5). The Papp values for 
A p-*Bas transport = 1.24 x 10*6 cm/sec; Bas—>Ap transport = 0.78 x 10'6.
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Key:
FITC-dextran in M EM  (0.1 m g/m L ) stock solution at t =  0 min 
FITC-dextran in M EM  from donor chamber (Ap side o f  tissue) at t = 60 min 
" FITC-dextran in M EM  from recipient chamber (Bas side o f  tissue) at t =  60 min 
FITC only
Figure 4.9 Elution profile of FITC-dextran fractions from a PD-10 column.
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4.3.5 Effect of cytokines on FITC-dextran transport across rat intestinal tissue 
with or without Peyer’s patches
Physiological concentrations o f rTNF-a (pg/mL)
As above, in tissue without Peyer’s patches the A p-*B as transport o f  FITC- 
dextran was linear with time (Figure 4.10a). No increase in Ap-»Bas FITC-dextran 
transport occurred in the presence o f  rTNF-a over the concentration range 30 - 100 
pg/mL. Similarly, Bas—»Ap transport o f  FITC-dextran was linear over time in both 
the presence and absence o f  rTNF-a. Again, rTNF-a caused no increase in transport 
at all concentrations tested (Figure 4.10b).
As mentioned above, (section 4 .3.2) when using Peyer’s patch tissue the 
transport o f  FITC-dextran was slower (in both directions) than seen in non-Peyer's 
patch tissue. However, again in these studies, there was no significant change in 
Ap-*Bas or Bas-»A p transport when rTNF-a was added (Figure 4.10c and d).
Physiological concentrations o f rIFN-y (pg/mL)
In non-Peyer’s patch tissues, the A p-*Bas transport o f  FITC-dextran was linear 
up to 50 min, then plateaued at 60 min (Figure 4.1 la). The reason for the differences 
in the controls was not clear, but the inherent variability o f  these experiments is 
mentioned above. Again, B as-*A p transport was linear over the 60 min incubation. 
Once more, the transport o f  FITC-dextran in the B as-»A p direction was lower than 
seen for A p—>Bas transport. N o increases in either A p—>Bas (Figure 4.11a) or 
B as-»A p  (Figure 4.11b) FITC-dextran transport were seen when rIFN-y (10 - 60 
pg/mL) was added to the donor chamber.
When tissue containing Peyer’s patches was used in these experiments, the 
Bas-*Ap (Figure 4.1 Id) transport o f  FITC-dextran was greater than Ap-*Bas (Figure 
4.11c). Nevertheless, once again, no significant changes were observed in FITC- 
dextran transport in the A p-»B as (Figure 4.11c) or the Bas->A p (Figure 4.10d) 
directions when rIFN-y ( 1 0 -6 0  pg/mL) was added.
Effect o f rTNF-a and rIFN-y on LDH release
For experiments in which rTNF-a was used, the control tissue incubated with 
this cytokine showed an LDH increase in the recipient compartment that increased by 
43 % over the 60 min (Figure 4.12a). This compared to a control value 76 % LDH
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Figure 4.10 (a, b, c & d) Effect of rTNF-a on the transport of FITC-dextran across
rat intestinal tissue. The data shown are mean ± SEM (n > 6), and NS at t = 60 min
according to one-way ANOVA.
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Figure 4.11 (a, b, c & d) Effect of rIFN-y on the transport of FITC-dextran across rat
intestinal tissue. The data shown are mean ± SEM (n > 6), and NS at t = 60 min
according to one-way ANOVA.
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release in the rIFN-y experiments (Figure 4.12b).
Throughout all experiments in which rTNF-a or rIFN-y was added, there was 
no correlation between the concentration o f  cytokine and LDH release, and the results 
obtained were often quite variable (Figure 4.12). The levels o f  LDH (expressed as 
enzyme activity mU/mL) released into the culture media from tissues incubated with  
rTNF-a (Figure 4.12a) and rIFN-y (Figure 4.12b), did not change significantly from  
the control (FITC-dextran only). It can therefore be concluded that the cytokines had 
no detrimental effect on tissue viability over 60 min.
Physiological concentrations o f  IL-2 (pg/mL)
As above in tissue without Peyer’s patches no increases in FITC-dextran 
transport were seen when rIL-2 was added to the apical (Figure 4.13a) or basal 
(Figure 4.13b) compartments with FITC-dextran.
Similarly, no significant changes in transport were observed with tissues 
containing Peyer’s patches where A p-»B as (Figure 4.13c) and B as-*A p (Figure 
4.13d) transport o f  FITC-dextran was unaltered by rIL-2 at all concentrations used 
(30 - 60 pg/mL).
4.3.6 Effect of high concentrations (ng/mL) of rTN F-a and rIFN-y on FITC- 
dextran transport
As before in all control experiments, the transport o f  FITC-dextran with and 
without the addition o f  cytokines was greater in tissue without Peyer’s patches 
(Figures 4.14a and b; 4 .15a  and b; 4.16a and b). A s before, Bas—»Ap FITC-dextran 
transport occurred at a low er rate than rate in the Ap—»Bas direction.
The higher concentration o f  rTNF-a (10 ng/mL) did not affect either the 
A p—3►Bas (Figure 4 .14a) or Bas—>Ap (Figure 4 .14b) transport o f  FITC-dextran in both 
Peyer’s patch and non-Peyer’s patch tissue respectively. However, addition o f  a 
higher concentration o f  rIFN-y (10 ng/mL) to non-Peyer’s patch tissue appeared to 
enhance the transport o f  FITC-dextran in both the A p—♦Bas (Figure 4.15a) and 
Bas—*Ap (Figure 4.15b) directions, though this was not significant. This was in 
contrast to the results seen in tissue containing Peyer’s patches where no effect on the 
A p-*B as (Figure 4.15a) or B as->A p (Figure 4.15b) transport was found.
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Figure 4.13 (a, b, c & d) Effect of rIL-2 on the transport of FITC-dextran across rat
intestinal tissue. The data shown are mean ± SEM (n > 6), and NS at t = 60 min
according to one-way ANOVA.
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Figure 4.14 (a & b) Effect of rTNF-a (10 ng/mL) on the transport of FITC-dextran 
across rat intestinal tissue. Panel (a) Ap-*Bas, panel (b) Bas->Ap. The data shown 
are mean ± SEM (n> 6), and NS at t = 60 min according to one-way ANOVA.
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Figure 4.15 (a & b) Effect of rIFN-y (10 ng/mL) on the transport of FITC-dextran
across rat intestinal tissue. Panel (a) Ap-*Bas, panel (b) Bas->Ap. The data shown
are mean ± SEM (n> 6), and NS at t = 60 min according to one-way ANOVA.
135
CHAPTER 4: Effect o f cytokines on FITC-dextran transport
O
GO
oo■'T
go
o
E
(a) Ap-*Bas 
NS
(b) Bas-*Ap 
NS
—| — FITC-dextran 
— •— FITC-dextran & rTNF + rIFN 
-  -  -4-  - - FITC-dextran (PP)
- - - A - --FITC-dextran & rTNF + rIFN (PP)
Key:
—0—FITC-dextran 
0 FITC-dextran & rTNF + rIFN 
— 0— FITC-dextran (PP)
—A—FITC-dextran & rTNF + rIFN (PP)
2 0  3 0  4 0
Time (min)
Figure 4.16 (a & b) Effect of rTNF-a (2.5 ng/mL) and rIFN-y (10 ng/mL) on the 
transport of FITC-dextran across rat intestinal tissue. Panel (a) Ap—*Bas, panel (b) 
Bas-*Ap. The data shown are mean ± SEM (n> 6), and NS at t = 60 min according 
to one-way ANOVA.
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To investigate a potential synergistic effect between TNF-a (2.5 ng/mL) and 
IFN-y (10 ng/mL) they were added together as a mixture. Interestingly, there 
appeared to be no change in FITC-dextran transport across Peyer’s patch, or non- 
Peyer’s patch tissues in either Ap-^Bas (Figure 4.16a) or Bas-^Ap (Figure 4.16b) 
directions.
4.4 DISCUSSION
These experiments indicated that the addition of rTNF-a, rIFN-y or rIL-2 at the 
lower, more physiological (pg/mL), concentrations did not influence FITC-dextran 
transport in either direction across rat intestinal tissue (with or without Peyer’s 
patches), using the vertical diffusion model (Figures 4.10, 4.11 and 4.13 
respectively). At higher (ng/mL) concentrations, only rIFN-y showed an effect on 
FITC-dextran transport in both directions, across non-Peyer’s patch tissues (Figure 
4.13a and b), though this data was not significant. A concentration of 10 ng/mL was 
chosen in accordance with Ma et a l, (2004), who showed a maximum drop in TEER 
across Caco-2 cells at 10 ng/mL of TNF-a. IFN-y was also used at the same 
concentration for comparison. For synergistic experiments, the concentration of both 
TNF-a and IFN-y were chosen in accordance with Wang et al, (2005). The 
observations at higher concentrations of rTNF-a, rIFN-y, or at higher concentrations 
of both rTNF-a and rIFN-y, were not in agreement with the literature.
High (ng/mL) concentrations of TNF-a or IFN-y (as found in IBD diseases) can 
decrease the barrier function of cell monolayers within a matter of h (as measured by 
TEER and the transport of paracellular markers), and this occurs in a concentration- 
and/or time-dependent manner (Adams et a l, 1993; Madara and Stafford, 1996; 
Marano et al, 1998; Youakim and Adieh, 1999; Schmitz et al, 1999; Ma et al, 2004; 
Poritz etal., 2004). The ability of these cytokines to permeabilise monolayers differs 
between cell lines: IFN-y has been studied in T84 cell monolayers, though TNF-a has 
been studied in T84, HT-29 (and its variants), and Caco-2 cell monolayers. It has no 
effect on T84 cells (Madara and Stafford, 1989; McKay et al, 1996). Nevertheless, 
the permeabilising effects seen with these cytokines are reversible (Mullin and Snock, 
1990; Adams et al, 1993).
Some studies have suggested that the decrease in barrier properties induced by 
TNF-a or IFN-y are due to them causing apoptosis (Gitter et al, 2000b), however
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several recent publications have shown that this is not the case. Neither TNF-a 
(Marano et al., 1998; Smitz et al., 1999; Ma et al., 2004) nor IFN-y (Youakim and 
Adieh, 1999; Madara and Stafford, 1996; Bruewer et al., 2005) is cytotoxic to these 
cell lines at high concentrations. Both cytokines also work synergistically, as IFN-y 
up-regulates the receptors for TNF-a (Fish et al., 1999), further enhancing 
permeability (Bruewer et al., 2005; Wang et al., 2005).
Currently, the exact molecular mechanism(s) of TNF-a and/ or IFN-y-induced 
TJ permeability have not been defined, though they appear to involve the 
redistribution of TJ proteins within the cell (see Figure 1.5). TNF-a appears to 
activate the cytosolic transcription factor NF-kB (Ma et al., 2004), which ultimately 
causes the re-distribution o f TJ proteins, particularly ZO-1, away from the TJ (Poritz 
et al., 2004; Ma et al., 2004). IFN-y also decreases ZO-1 levels from the TJ, and 
alters the distribution of ZO-2 and occludin (Youakim and Ahdieh 1999). More 
recently, it has also been found to cause endocytosis of the TJ proteins: occludin, 
JAM-A and claudin-1 (Bruewer et al., 2005; Utech et a l, 2005).
Though the results seen for FITC-dextran transport in the presence of cytokines 
were not as expected, it is important to note that the interpretation of the results 
obtained in the vertical diffusion system were difficult, due to the variability seen for 
the transport of the control FITC-dextran.
Several groups have used the Ussing chamber model, and its variants such as 
the vertical diffusion system, to study the GI transport of drugs (Berggren et al., 
2004; Wantanabee et al., 2005), particularly for those that are P-gp substrates (e.g. 
digoxin: Ungell et al., 1998; Sababi et a l, 2001), or the transport of paracellular 
markers (Pantzar et al., 1994; Ghandehari et al., 1997). Each has claimed 
reproducibility of these models. However, in these studies, a high number of 
experiments were needed in order to reduce the SEM error bars, due to the high 
degree of variability between the experiments.
Nevertheless, the rank order for FITC-dextran transport across the rat intestinal 
tissue at 60 min was: Ap—►Bas > Bas—*►Ap > Ap—*Bas in Peyer’s patch tissue > 
Bas-*Ap in Peyer’s patch tissue (Figure 4.17). Furthermore, transport in the 
Ap-*Bas direction at 60 min, across non-Peyer's patch tissue, was significantly 
higher than all other transport (Figure 4.17). The data in the literature regarding
138
Fl
uo
re
sc
en
ce
 
(e
xc
ita
tio
n 
48
5,
 e
m
iss
io
n 
52 
52
0 
nm
)
CHAPTER 4: Effect o f cytokines on FITC-dextran transport
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Direction o f  transport and tissue type
Figure 4.17 FITC-dextran transport at t = 60 min. The data shown are mean ± SEM 
(n > 20), and were analysed by one-way ANOVA, and Bonfeerroni post-hoc test, * = 
p < 0.05.
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directional paracellular transport however are conflicting. Pantzar and colleagues 
(1994) have also shown the Ap->Bas transport o f  various paracellular markers across 
the intestine, including FITC-dextran (MW  = 3,000 Da), is greater than Bas—>Ap 
transport, though Nakamura and colleagues (2003) have shown increased FITC- 
dextran transport in the B as-»A p  direction across stripped rat colonic mucosa. A 
table comparing the Papp values o f  FITC-dextran according to the literature is given 
in Table 4.1. However, care should be taken when trying to make quantitative 
comparisons o f  these values, as differences in rats used (i.e. weight and species), 
length o f  fasting ( if  any), and method used to assay transport may affect the results 
obtained. Even individual com ponents in the medium such as glucose or Ca2+ 
concentration can affect results, by altering TJ permeability. MEM tissue culture 
medium was used for this work in accordance with Diamanti (2004).
The studies conducted by Diamanti (2004) and those carried out in this study 
were essentially the same, though the Papp values for FITC-dextran transport are 
marginally different (see Table 4.1). This is likely to de due to a difference in rat 
intestinal region used (see below), different batches o f  animals, and the FITC-dextran 
used by Diamanti was also slightly larger (M W  = 4,400 Da), and may have had a 
different fluorescent loading. N evertheless, the Papp values observed for FITC- 
dextran transport observed in these studies were in-keeping with the literature which 
have shown transport across non-Peyer's patch tissue to be at values o f  0.5 - 10 x 10’6 
cm /s (Table 4.1). What's more, in accordance with the literature, the ileal-jejunal 
A p—*Bas Papp values described in these studies are greater than those reported for 
A p—»Bas transport across the stripped colon mucosal tissue (see Table 4.1).
It is also important to note that FITC-dextran is likely to be transported across 
the tissue via transcellular transcytosis m echanism s as w ell as paracellularly 
(Diamanti, 2004). Higher m olecular w eight FITC-dextran (MW = 10,000 Da) is 
commonly used as a fluid-phase marker for endocytosis (Bacic et al., 2006). I f time 
had permitted, it would have been interesting to investigate the specific mechanism o f  
FITC-dextran transport across this tissue, perhaps with the aid o f  metabolic inhibitors 
to cease active transport m echanism s. Inhibitors o f  microtubule assem bly (e.g. 
colchicines) could also be used to stop endocytosis. Knocking out these mechanisms, 
would have allowed their contribution towards FITC-dextran transport to be assessed.
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Table 4.1 Papp values for the paracellular transport of paracellular markers across the rat intestine.
Marker Cone" Method Rat Fasted Region Direction Papp (cm/s) Reference
FITC-dextran (4400 Da) 1 mg/mL Perfusion (3 h) Male Wister Ileum Ap-*Bas 1.0 x lO'6 (Nakamura et
Ussing chamber (2 h) (180-220 g) Colon
Colon stripped
Bas-*Ap
0.6 x 10'6 
1.3 x 10'6 
1.6 xlO '6
a l,  2002)
FITC-dextran (4400 Da) 0.1 Vertical diffusion Male 24 h Rat Ileum Ap-*Bas 7 x 10'6 (Diamanti,
mg/mL system (1 h) Sprauge 
Dawley 
(200-250 g)
stripped 2004)
Mannitol (182 Da) 100 pM Rat everted gut sacs Jejunum Ap-»Bas 4.6 x 10'5 (Lacombe et al.,
Lucifer yellow (457 Da) o h ) 3.9 x 10'5 2005)
Rantidine (351 Da) 3.9 x 10'5
Mannitol (182 Da) 40 |xM Ussing chamber (2 h) Male Wister 48 h Jejunum stripped Ap-*Bas 9.4 x 10'5 (Wu-Pong et a l, 
1999)
Mannitol (182 Da) Male 
Sprauge 
Dawley 
(200-300 g)
no Ileum stripped Ap-*Bas 5.1 x 10‘6 (Tsutsumi et a l,  
2002)
(-) donotes where data is not available.
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Viability in the vertical diffusion model
The d ifferences in the transport o f  FITC-dextran betw een individual 
experiments (Figure 4.7b and c) was not due to FITC-dextran batch variation (Figure 
4.2a and 4.3), nor was it due to the transport o f  free FITC across the tissue (Figure 
4.9). FITC-dextran is a robust m olecule, as its molecular weight (Figure 4.2b) and 
fluorescence (Figure 4.4) were not affected by storage at different temperatures. The 
probe was also not degraded during incubation, with rat intestinal tissue (Figure 4.8), 
thus only the intact polym er m olecule would be available for transport across this 
barrier. Several factors could influence FITC-dextran transport (as described below), 
though great care was taken in order to control each variable.
(1) Extrinsic factors such as food and environmental stress are known to 
influence absorption from the small intestine. Eating produces some physiological 
modifications such as a decrease in gastric emptying or the stimulation o f  biliary 
secretion, which among other things affects the pH o f  the small intestine, and thus the 
results obtained. Therefore the fasting times o f  the animals were very important. In 
these studies, Sprauge D aw ley rats were fasted for 23 h before each experiment, to 
minimise the effect o f  food on tissue behaviour. The animals were also kept in a 
comfortable environment, and were housed for one week after delivery to allow them 
to acclimatise before experiments. Som e reports have shown that stressed rats have a 
morphologically different m esenteric microvasculature (W ilson and Baldwin 1998), 
and intestinal m ucosa (W ilson  and B aldw in, 1999; B aldw in et al., 2006). 
Furthermore, for consistency, each animal used for these studies weighed between 
200 -  250 g.
However, the food and environment subjected to the animals by the supplier 
were outside our control. A  change in animal chow could have played a role in 
affecting the data seen in these studies. For example, exposure to different dietary 
antigens early in life could have important implications on the effect on the mucosal 
immune system o f  the adult rats (Yelda et al., 1996).
(2) Several studies have show n that drug efflux (Sababi et al., 2001) 
m etabolism  (Zhang et al., 1997) and absorption (P lusquelle et al., 1987; 
Schaiquevich et al., 2002) vary betw een different regions o f  the rat intestine. 
Nejdfors et al., (2000) have show n that mannitol permeability is higher in the rat
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ileum than jejunum and colon. Nakamura and colleges (2002) have shown that 
FITC-dextran (MW = 4,400 Da) transport was greater across the rat ileum compared 
to the colon (see Table 4.1). Therefore to limit regional variation in the intestinal 
segments used for these studies, the first 15 cm of the each rat intestine (extending 
out from the stomach), was always discarded. Tissue segments (with or without 
Peyer’s patches) were then taken from the remaining distal jejunum and ileum.
However, Peyer's patches are distributed at random throughout the ileum, and 
were of different size. It is important to note that these animals are outbred, and 
different batches of them would have had exposure to different anitgens. Of the 0.9 
cm tissue surface area between each donor and recipient chamber, the patches 
usually occupied 10 - 40 % of surface area.
(3) Differences in the viability of the tissue could also play a key role on the 
transport of FITC-dextran across the rat intestine. It was important to preserve the 
integrity of the rat intestinal tissue during preparation for the vertical diffusion 
chamber, by keeping it in MEM on ice. As electrical equipment supplied with the 
vertical diffusion system was not functioning, the LDH assay was chosen as a means 
to measure tissue integrity, in accordance with Diamanti (2004). Though the release 
of LDH seen with this assay was highly variable, and the levels of LDH released into 
the culture media after t = 60 min were significantly different from t = 0 min, it was 
considered an unnecessary experiment. Firstly there appeared to be no correlation on 
the rate of transport and LDH levels. Secondly, though once the animal has been 
sacrificed, the tissue begins to die anyway, previous reports (Grass and Sweetana, 
1998; Soderholm et al., 1998) have consistently shown that intestinal tissue can 
remain viable for 2 h, and quite often transport studies using intestinal tissue are 
conducted over a 1 - 2 h time-frame. Although this assay is widely used to measure 
viability, it is perhaps not the best for this work.
Scraping the muscle layers from the mucosal epithelium would of course result 
in large amounts of LDH being released into culture media from lysed cells, though 
in an attempt to combat this, the media was always changed from the chambers 
before the start of each experiment. Furthermore, as mentioned previously, the 
experiments in which leakage had occurred, perhaps on rare occasions from tissue 
laceration, or perhaps from dying tissue segments, were discarded.
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Albeit rather crude, the photomicrographs taken of longtitudal sections of 
stripped and unstripped tissues used for these studies at x 40 magnification showed 
no visible lacerations in the stripped mucosal segments (Figure 4.5). This was 
expected as this method is routinely used for studying transport (Dickens and Weil- 
Malherbe in 1941; Grass and Sweetana, 1988; Wu-Pong et al., 1999; Diamanti, 2004; 
Watanabe et al., 2005). Photomicrographs (x 107 magnification) of transverse 
sections of stripped intestinal tissue have shown that only the mucosa (i.e. epithelia, 
lamina propria and mucuslaris mucosae) remains (Field et al., 1971). Lastly 
difficulties in oxygenation of the chambers could mean that the viability of the tissue 
was also compromised, as this would effect the mixing of the solution in the chamber, 
as well.
Effect o f cytokines on FITC-dextran transport, why didn’t it work?
The effects rTNF-a, rIFN-y and rIL-2 on tissue permeability were varied 
possibly due to the reasons described above. One limitation of the vertical diffusion 
model is that the duration of the study can only be conducted over an hour due to 
tissue viability. Permeability studies involving immortalised cell lines however can 
be continued for h - d. It is possible that the cytokines did have an effect on the 
tissue, though a 60 min incubation was not enough time in which to see an effect on 
TJ permeability. For example, Ma et al., (2004), have shown that though NF-kB is 
activated in minutes in TNF-a incubated Caco-2 cells, a delay of ~ 24 h was found 
between this and a functional increase in TJ permeability. It is also possible, that the 
half-life of the cytokine was too short to have an effect. Another disadvantage of 
these experiments is the number of animals required, compared with rapid in vitro 
models, however, as previously mentioned this model is more physiological.
Despite the variability in FITC-dextran transport, as the vertical diffusion 
system had been established as a model to measure transport across rat intestinal 
tissue, it was decided to move forward and use this model for further studies in 
which the effects of polymers on transport were measured. This was mainly due 
to the physiology of the intestinal tissue used, which is more appropriate for these 
studies than would be intestinal cell monolayers. The next chapter investigates 
the effects of polymers on FITC-dextran transport across rat intestinal tissue.
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5.1 INTRODUCTION
As rTNF-a, rIFN-y and rIL-2 did not significantly increase the transport of 
FITC-dextran across rat intestinal epithelial tissue, it was decided to examine whether 
the polymers themselves would modify the transport rates of this paracellular marker.
As mentioned in Chapter 4 (section 4.2), recent work has demonstrated that the 
anionic, mucoadhesive polymer, PAcA, can permeabilise the intestine, and as a result 
enhance the transport of the paracellular marker sodium-fluorescein across this tissue 
(Kast and Bernkop-Schniirch, 2002). It has also been shown that dendrimers, 
particularly PAMAM dendrimers, display rapid transport rates across everted rat 
intestinal tissue (Wiwattanapatapee et al., 2000) as well as monolayer models (El- 
Sayed et al., 2003). Their mechanism of transport across this barrier is still unclear, 
and it could be by either transcellular (probably endocytosis) or paracellular pathways 
(if the TJ are opened).
Consequently, PAcAs and PAMAM generation 3.5 dendrimers were chosen 
along with alginate, HA and sHA, to study the effect of polymers on FITC-dextran 
transport across intestinal tissue. The vertical diffusion system was once again used 
as a transport model for these studies, and the rationale for the choice of polymers 
used for these particular experiments is given in the following paragraphs (for a 
review of these macromolecules see Chapter 1 sections 1.6.1 - 1.6.4).
Rationale for the choice ofpolymers used for transport studies 
PAcA
PAcA was originally thought to enhance permeability across the intestine by 
chelating extracellular Ca2+ (Charmen et al., 1990), as it acts like a weak ion 
exchanger and binds Ca2+ at neutral pH (Kriwet and Kissel, 1996). However, when 
polymerised into microparticles (1-10 pm in diameter), this polymer (MW = 300,000 
Da) has also shown the ability to adhere to, and physically widen paracellular gaps 
between Caco-2 cells in monolayers (Kriwet and Kissel, 1996). As a result these 
microparticles increase the paracellular transport of sulforhodamine, and this effect is 
not due to swelling of the microparticles, nor due to cell damage (Kriwet and Kissel, 
1996). Most of the polymer remains swollen in the particles, and cannot cross the 
monolayer due to its large size (Kriwet and Kissel, 1996). Furthermore, because
145
CHAPTER 5: Effects of polymers on FITC-dextran transport
Caco-2 cells do not possess a mucus layer, the increase in permeability caused by this 
polymer is not due to its mucoadhesive properties. The transport of sulforhodamine 
across Caco-2 cells is also dependent on the side to which the microparticles are 
administered. Basal to apical transport of sulforhodamine was 30 times greater than 
that seen in the apical to basal direction (Kriwet and Kissel, 1996).
Water-soluble PAcAs (MW = 30,000 100,000 and 450,000 Da) were chosen for 
these studies. Besides the reported ability of PAcA to induce IFN-y (see section 
1.6.3), the specific PAcAs chosen for this work have been shown to enhance the 
transport of Na-Flu across guinea pig small intestinal tissue, mounted in Ussing type 
chambers. The increases in permeability caused by these polymers are molecular 
weight-dependant, with the rank order for enhancement being PACA450 > PAcAioo > 
PACA30 (Kast and Bernkop-Schniirch, 2002). Thiolated, thus more mucoadhesive, 
forms of these polymers have also shown greater transport rates in this mucus- 
containing tissue, though the rank order for permeability was repeated (Kast and 
Bernkop-Schniirch, 2002).
PAMAM dendrimers
The potential of PAMAM dendrimers to be used for drug delivery has been 
demonstrated in several cell lines including Caco-2 (El-Sayed et al., 2003a; El-Sayed 
et al., 2003b; Jevprasesphant et al., 2003a; Jevprasesphant et al., 2003b) and Madin- 
Darby canine kidney (epithelial) cell monolayers (Tajarobi et al., 2001), as well as in 
hamster microvascular endothelium (El-Sayed et al., 2001).
Wiwatanapatepee and colleagues (2000) were the first to appreciate the 
possibility of using PAMAM dendrimers for enhancing oral drug delivery. They 
radioiodinated ( 125I-labelled) anionic (generations 2.5, 3.5, 5.5) and cationic PAMAM 
dendrimers (generations 3 and 4), and measured their uptake and transport across the 
everted rat intestine. Compared to other macromolecules including PVP, HPMA, 
BSA and tomato lectin, PAMAM dendrimers had high serosal transfer rates 
(Ap-*Bas) of transport into the serosal sac fluid. Although high levels of PAMAM 
generation 5.5, and the cationic PAMAM dendrimers, generations 3 and 4, were 
detected in the sac-tissue at the end of the experiment, the anionic PAMAMs were 
not, indicating very high transport across the tissue. The high endocytic index (El) 
values (an endocytic index has been defined as the volume-equivalent of substrate 
cleared (pi) from the medium/mg tissue protein/h; Williams et al., 1975) measured
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for these molecules suggested uptake by absorptive endocytosis. This would 
certainly seem probable for the cationic PAMAM dendrimers, as they would bind to 
the cell surface non-specifically due to charge interaction.
El-Sayed et al, (2003a) found further evidence for the rapid transcytosis of 
PAMAM dendrimers. This came from the observation that cationic dendrimers were 
rapidly transported across Caco-2 cells. Transport was reduced at 4 °C so they 
concluded that it occurred via an energy-dependent mechanism. In addition 
Jevprasesphant and colleagues (2004) observed gold-labelled PAMAM generation 3 
dendrimers inside Caco-2 cells, confirming uptake by endocytosis. Also supporting 
the hypothesis that transport is at least in part by endocytosis was the fact that the 
endocytosis inhibitor colchicine significantly reduced the absorption of PAMAM 
generation 2 dendrimers in Caco-2 cells (El-Sayed et a l, 2002). Interestingly 
PAMAM dendrimers avoid efflux by the membrane efflux pump P-gp. El-Sayed et 
a l, (2003a) showed this by adding the P-gp substrate, paclitaxel, to Caco-2 
monolayers, and monitoring the transport of PAMAM generation 2 dendrimers. In 
both Ap-*Bas or Bas—*Ap directions, the permeability of generation 2 dendrimers 
did not change.
However, it has also been shown that PAMAM dendrimers have the ability to 
permeabilise Caco-2 cell monolayers by opening TJ and increasing paracellular 
transport. PAMAM generations 1, 2, 3 and 4 decreased the TEER of Caco-2 
monolayers, and increased the transport of the paracellular marker [14C]mannitol (El- 
Sayed et al, 2003a; El-Sayed et al, 2003b; Jevprasesphant et al, 2003a). Although 
it could be useful that cationic PAMAM dendrimers can allow transport via the 
paracellular route, it is also a potential cause for concern if the physiological barrier is 
destroyed, albeit transiently.
In addition, the general cytotoxicity of some dendrimers may be a concern if 
they were to be used to prepare oral formulations (reviewed in Duncan and Izzo, 
2005). As previously mentioned (section 3.4) the cytotoxicity of cationic PAMAM 
dendrimers has been shown to increase in a generation-dependent manner (Malik et 
al, 2000; El-Sayed et a l, 2003b) so they may not be the best option for enhancing 
oral drug delivery. Conversely, anionic PAMAM dendrimers were not cytotoxic 
towards B16F10 cells in vitro (Malik et al, 2000) and were less cytotoxic towards
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Caco-2 monolayers than cationic PAMAMs (El-Sayed et al, 2003b). Interestingly, 
El-Sayed et al., (2003b) showed that unlike other anionic PAMAM dendrimers, 
PAMAM 2.5 and 3.5 dendrimers caused an incubation-time dependent decline in the 
TEER values of Caco-2 monolayers. In addition, there was up to a 6-fold increase in 
mannitol permeability at non-toxic concentrations. These results can be correlated 
with the studies of Wiwatanapatepee et al., (2000), who using the everted rat 
intestine, showed that the El values of I25I-labelled PAMAM generation 2.5 and 3.5 
dendrimers were very low (0.6 - 0.7 pl/mg protein/h), and suggested rapid 
transcytosis via a fluid-phase mechanism. For these studies, it was therefore thought 
that PAMAM generation 3.5 dendrimers might be the most interesting, to explore the 
effects of polymers on permeability.
Alginates
As mentioned in Chapter 1 (section 1.6.1), alginates are widely used in drug 
delivery systems (i.e. in capsule coatings (as a vegetarian substitute for gelatin) and as 
a component of microcapsules (Gonzalez Ferreiro et al., 2002; Robitaille et al., 
2005)). Alginate has also been used as a protein (an antigenic VP2 peptide) and drug 
(5-aminosalicyclic acid) carrier (Morgan et al., 1995), and is well tolerated and 
poorly immunogenic when systemically administered to rats (Al-Shamkhani and 
Duncan 1995b). The fate of 125I-labelled alginate when administered intravenously, 
subcutaneously, intraperitoneally and orally, to rats has also been examined. It was 
found that its distribution throughout the body was molecular weight-dependant (Al- 
Shamkhani and Duncan 1995b). Lower molecular weight fractions of 125I-labelled 
alginate (MW < 48,000 Da) were excreted in the urine, whilst larger polymer 
fractions remained in the circulation and did not accumulate in any organs. Orally 
administered alginate appeared mainly in intestinal tissue washings, thought to be due 
to the entanglement of the macromolecules with the glycocaylx (Al-Shamkhani, 
1993). It also appeared to be degraded, as free [125I]iodine was found in the urine and 
thyroid gland of test animals.
Early studies were interested in alginates as potential oral bioadhesive polymers 
to delay GI transit time, although it did not seem to fulfil its potential in this role (Al- 
Shamkhani, 1993). Although alginates have been developed as polymer-drug 
conjugates for delivery of peptides and anticancer drugs, from a drug delivery 
perspective, the effect alginate on transport across the small intestine has not been
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well examined. It was therefore considered important to investigate this polymer in 
these studies.
HA
As mentioned in Chapter 1 (section 1.6.2), HA is a large hydrophilic, water- 
retaining polymer that is present in a variety of tissues, though it is not present in 
intestinal epithelial cells (Fraser, 1989). It is located in the loose connective tissue of 
the lamina propria, where it is synthesised by mesenchymal cells, from where it is 
easily mobilised (Fraser, 1989). Like alginate, HA is also being developed as a drug 
carrier. When conjugated to the anticancer drug Taxol®, it has been shown to be 
taken up into cancer cell lines (HB1-100 breast and SK-OV-3 ovarian, human) via the 
CD44-receptor (Luo et al., 2000).
HA was specifically chosen for these studies due to its known potential to act as 
a mucoadhesive polymer and to promote penetration enhancement. The GI 
mucoadhesive properties of HA have been investigated in the rat, where it has been 
found to be a better bonding agent than Carbomer® (Pritchard et al., 1996). 
Furthermore, in ophthalmology, the mucoadhesive properties of this polymer have 
been used to improve the residence time of drug formulations on the eye (Saettone et 
al., 1994).
The penetration enhancement properties of HA have been demonstrated in nasal 
epithelial mucosa, where HA enhanced the delivery of insulin (Ryden and Edman, 
1992) and vasopressin (Morimoto et al., 1991). More recently, the HA has been 
shown to increase the absorption of the antiviral drug, acyclovir in porcine buccal and 
vaginal tissue, Caco-2 cell monolayers and the rat jejunum. (Sandri et al., 2004). It 
was found that as HA molecular weight decreased, its mucoadhesive properties 
increased. The lowest molecular weight fraction of HA (MW = 202,000 Da), showed 
the best penetration enhancement properties (Sandri et al., 2004).
HA is also known to play a role in the pathophysiology of disease. It has been 
detected in jejunal fluid, and in the inflamed colon of IBD patients (De la Motte et al., 
2003), as well as throughout the epithelium in patients with celiac disease 
(Kemppainen et al., 2005). In celiac disease, it is thought that defects in the epithelial
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permeability (known to be an early sign o f  the disease), increase the leakage o f  
mobile, stromal, HA into the jejunal lumen. This depletes the HA levels in the villi 
connective tissue. A s H A is such an abundant molecule in the villous stroma, and has 
a high capacity to bind water and expand the tissue, its loss may contribute to villous 
destruction and the flattening o f  the epithelium in this syndrome. It is also speculated 
that the presence o f  C D44-bound H A in the intestine delays and prevents the TJ 
formation and, thus enhances the diffusion o f  molecules through the intestinal 
epithelium in this condition (Kemppainen et al., 2005). Thus, the interest in 
assessing its effect on FITC-dextran transport across rat intestinal tissue.
Therefore, the overall objectives o f  this study can be summarised as follows:
(i) First it was important to investigate the effect o f  the polymers on medium pH - the 
polymers tested have quite different pKa values.
(ii) A s fluorophores often show  pH - and concentration-dependence, it was important 
to determine the effect o f  both on the fluorescence output o f  FITC-dextran.
(iii) The effect o f  alginate, H A , sH A , PA cA s (SPACA30, PAcAioo and PACA450) and 
PAMAM generation 3.5, on the transport o f  FITC-dextran across the intestinal 
tissue, in the vertical d iffusion chamber from both the Ap—»Bas and the Bas-^Ap  
directions was then studied.
(iv) Finally, it was considered important to investigate whether the presence o f  
Peyer’s patches would influence transport.
5.2 METHODS
The preparation o f  rat intestinal tissue for transport experiments, along with the 
use o f  the vertical diffusion system  has previously been described in Chapter 2 
(section 2.3.6). Only specific details relating to the experiments earned out in this 
Chapter will be described below . During all experiments FITC-dextran solutions 
were protected from light to prevent photo-bleaching. Unless otherwise stated, all 
experiments were carried out in replicates o f  three.
5.2.1 Effect of polymers on the pH  of tissue culture media
Before polymers were introduced into the vertical diffusion system, it was 
considered important to investigate their effect on the pH o f  the tissue culture
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medium (MEM). This was key, not only because pH plays a basic role in 
cytotoxicity (Mackenzie et a l, 1961), but also because FITC is a pH-sensitive 
fluorophore (supplier information: www.sigmaaldrich.com, accessed 12/03/2002). 
The pH o f  MEM containing dissolved polymers (1 mg/mL) was therefore measured.
5.2.2 Effect of pH on FITC-dextran fluorescence
The effect o f  pH on the fluorescence-output o f  FITC-dextran was investigated 
using citric acid-sodium citrate buffers at pH 5.5, or 6.5, and phosphate buffer at pH 
7.4. Each buffer was prepared according to recipes from Dawson et a l (2002) (as 
described below), and was used to make calibration curves (1 -  0.001 mg/mL) from a 
FITC-dextran stock solution (1 mg/mL in appropriate buffer). All dilutions were 
prepared in eppendorf tubes and then the solutions were pipetted into black 96-well 
plates (50 pL/well) and read in the fluorescence plate reader as previously described 
(section 2.3.6). The data obtained were plotted as concentration (mg/mL) against 
fluorescence.
To make citric acid-sodium citrate buffers, a 0.1 M citric acid monohydrate 
(C6H8O7) solution (21 mg/mL in 10 mL ddH2 0 ), and a 0.1 M trisodium citrate 
dihydrate (CbHsCbNas) solution (29 mg/mL in 20 mL ddH2 0 ) were prepared. Each 
solution was mixed to give a pH 5.4 and pH 6.2 buffer (see Table 5.1). The pH o f  
these solutions was read using the pH-meter, and the solutions were adjusted to pH
5.5 and pH 6.5 using NaOH (0.1 M).
Phosphate buffer (Na2HPC>4 - NaH2P0 4 ) was prepared in a similar fashion, 
using a 0.2 M solution o f N a2H P 0 4 (2H20 : 35.61 mg/mL in 5 mL o f ddH20 ) , and a 
0.2M solution o f  N a^PC L  (71.64 mg/mL in 2 mL in ddH20). Both Na2HP04  and 
NaH2P04  solutions were mixed (4.05 mL and 0.95 mL respectively) to give a pH 7.4 
buffer. The pH o f this solution was checked using the pH meter.
Table 5.1 Recipe for citric acid-sodium citrate buffer
PH 0.1 M citric acid (mL) 0.1 M trisodium citrate (mL)
5.4 2.55 7.45
6.2 0.80 9.20
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5.2.3 Effect of polymers on FITC-dextran transport across rat intestinal tissue 
using the vertical diffusion system
To exam ine the effect o f  polym ers on FITC-dextran transport, a 1 mg/mL 
solution o f  each polym er was made with M EM  containing FITC-dextran (0.1 
mg/mL). In som e cases solutions were made 12 h in advance o f  an experiment and 
were kept in the fridge (4 °C) overnight, to allow  polymers (HA, sHA, P A C A 450 and 
alginate) to dissolve in the tissue culture medium.
Prior to each experiment, the tissue w as prepared, and the vertical diffusion  
system was set up as previously described (Chapter 2, section 2.3.6). To start the 
experiment, MEM was removed from each chamber, and the apical and basal 
compartments were immediately replenished w ith either fresh MEM, or polymer - 
containing MEM (depending on whether A p—*Bas or Bas—>Ap transport was being 
investigated).
All solutions were pre-warmed (37 °C) before they were added to the tissue. 
Samples (25 pL) were then collected from the recipient chambers at 5 - 10 min 
intervals from t =  0 - 60 min, and were treated as previously described in Chapter 2 
(section 2.3.6). It is important to note that the total volum e was maintained by the 
addition o f  an equal volum e o f  fresh M EM  at each sample time.
5.3 RESULTS
5.3.1 Effect of polymers on MEM pH
Addition o f  FITC-dextran, alginate, HA, SPACA30 and PAM AM  generation 3.5 
dendrimers to MEM caused little change in the pH (all 1 mg/mL). A  range o f  pH 7.0 - 
8.0 was observed (Table 5.2) with alginate causing the greatest decrease (pH 7.04) 
and PAM AM  3.5 causing the greatest increase (pH 7.97). The higher molecular 
weight PAcA polym ers (P A c A 100 and PACA450) were more acidic in the culture 
media, and reduced the pH to 6.43 and 6 .36 respectively.
5.3.2 Effect of pH on FITC-dextran fluorescence
A  linear concentration-dependent increase in FITC-dextran fluorescence was 
seen at all pHs (Figure 5.1). However, fluorescence output was highly dependent on 
pH. It was greatest at pH 7.4, and decreased at low er pHs. For example at 1 mg/mL, 
fluorescence output was reduced by 47 % at pH 6.5, and by 86 % at pH5.5, compared 
to pH 7.4.
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Table 5.2 Effect of polymers on tissue culture media pH.
Polymer dissolved in MEM 
(1 mg/mL)
pH
MEM only 7.42
FITC-dextran 7.55
Alginate 7.04
HA 7.70
s P A c A 3o 7.55
P A c A ioo 6.42
PAcA 450 6.36
PAMAM 3.5 7.97
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F igure 5.1 Fluorescence output o f  FITC-dextran (MW = 4,000 Da) in different pH  
buffers.
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5.3.3 Effect of polymers on FITC-dextran transport across rat intestinal tissue
Ap—>Bas transport and Bas—>Ap transport across non-Peyer ’spatch tissue
In control experim ents FITC-dextran transport with or without polymers (1 
mg/mL) was linear over time (t = 0 - 60 min), and in this set o f  experiments the rate 
o f  FITC-dextran transport across the rat intestinal tissue was lower than that seen 
previously in Chapter 4 (Figure 4.7a). A  5 min lag phase in FITC-dextran transport 
was seen for A p—*Bas and B as—*Ap transfer across tissue with or without Peyer's 
patches (Figure 5.2). The Papp values o f  transport across non-Peyer's tissue were 0.5 
x KT6 for transport in the A p -» B a s  direction, and 1.0 x 10‘6 for transfer in the 
Bas-*A p direction.
A lginate (Figure 5.3a), H A  (Figure 5.3b) and sHA (Figure 5.3c) did not 
enhance FITC-dextran transport in the A p -»B as direction across tissue without 
Peyer’s patches. Instead, these polym ers appeared to reduce it. When PAcA was 
used, the A p—»Bas transport o f  FITC-dextran appeared to be dependent on PAcA  
molecular weight. The highest m olecular weight PAcA (PACA450) had no effect on 
FITC-dextran transport (Figure 5.3d), whilst PAcAioo reduced it (Figure 5.3e). At t = 
60 min a 62 % decrease in fluorescence was seen for FITC-dextran transport in the 
presence o f  PAcA 100, com pared to the control FITC-dextran (Figure 5.3e). In 
contrast, the sm aller m olecular w eigh t PA cA  in sodium salt form (SPACA30) 
increased FITC-dextran transport in the A p—»Bas direction as an increase (o f 16 % at 
60 min) in fluorescence w as seen  (Figure 5.3f). This data however was not 
significant. When the effect o f  PA M AM  generation 3.5 dendrimers on FITC-dextran 
transport was measured, like other polymers, it appeared to reduce Ap—»-Bas transport 
(Figure 5.3g).
As sPAcA 30 appeared to enhance A p-»B as transport across non-Peyer’s patch 
tissue, it was decided to also measure the effect o f  this polymer on FITC-dextran 
transport in the Bas—»Ap direction. For comparison, alginate and HA were also 
chosen for this work. A lginate (Figure 5.4a) and HA (Figure 5.4b) caused a 
significant reduction in FITC-dextran transport across non-Peyer’s patch tissue in the 
B as—>Ap direction. Interestingly, P A cA 30 also reduced transport in this direction 
(Figure 5.4c).
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Figure 5.2 Ap—►Bas and B as—»>Ap FITC-dextran transport across rat intestinal tissue 
with or without Peyer’s patches. The data shown are mean ± SEM (n > 11), and NS at t 
= 60 min according to one-w ay A NO VA.
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Ap—t’Bas transport and Bas—*Ap transport across tissue with Peyer’s patches
The control transport of FITC-dextran across Peyer’s patch tissue was lower 
than that seen for transport across tissue without Peyer’s patches (see Figure 5.2). 
The Papp value for Ap—»Bas transport across tissue without Peyer’s patches was 0.5 
x 10 6. For Bas—»Ap transport across this tissue, the Papp value was 1.0 x 10'6. The 
transport of FITC-dextran in the presence of all polymers increased linearly over 
time. Addition of SPACA30 (Figure 5.5a), HA (Figure 5.5b) and alginate (Figure 5.5c) 
all reduced FITC-dextran transport. Ap—>Bas FITC-dextran transport with SPACA30 
was 33 % less than that of the control (FITC-dextran only) at t = 60 min, and this is in 
contrast with the observations made in non-Peyer’s patch tissue where this polymer 
appeared to enhance FITC-dextran transport. For HA and alginate, Ap—>Bas 
transport was 25 % and 41 % lower than the control respectively at 60 min.
Bas—>Ap transport of FITC-dextran across Peyer’s patch tissue with SPACA30 
(Figure 5.6a), HA (Figure 5.6b) and alginate (Figure 5.6c) was also significantly 
reduced.
5.4 DISCUSSION
It would seem that no one has previously examined the effect of polymers, on 
the transport of FITC-dextran in any intestinal model. As mentioned in the 
introduction, previous studies investigating the effect of polymers on GI permeability 
have used Na-Flu (Kast and Bernkop-Schnurch, 2002), mannitol (El-Sayed et a l, 
2003a; El-Sayed et a l, 2003b; Jevprasesphant et a l, 2003a; Wu-Pong et a l, 1999; 
Tsutsumi et a l, 2002; Lacombe et a l, 2004), rhodamine (Kriwet and Kissel, 1996), 
lucifer yellow (Lacombe et a l, 2004) and in some cases PEG (Artursson et a l, 1993; 
Ghandehari et a l, 1997) as substrates.
As previously mentioned, FITC-dextran might cross the intestinal epithelial 
barrier by paracellular or transcellular mechanisms (Figure 5.7), and thus polymer 
enhancement of FITC-dextran transport could theoretically occur by (1) polymers 
stimulating endocytosis, (2) polymers opening TJ, via cytokine release, or through 
interactions with the apical cell membrane (Figure 5.7). However the addition of 
polymers might also inhibit FITC-dextran transport if they bind to either the cell 
membrane, or FITC-dextran itself, and block its transport across the tissue. They 
could also act as a competitive inhibitor for FITC-dextran endocytosis, or could alter
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the diffusion kinetics of FITC-dextran across the tissue by increasing the viscosity of 
the medium in the donor chambers of the vertical diffusion system.
Interestingly, the control transport (Papp) rates for FITC-dextran without the 
addition of polymer observed in these experiments were lower than those seen 
previously in Chapter 4. This is likely to be due to the fact that different animal 
batches were used. It is also probable that an improvement in the method used to 
remove the muscle layers from the mucosa, resulted in a more intact tissue, as with 
practice the time taken to prepare the tissue for the diffusion chamber was reduced.
Also in contrast to Chapter 4, the Ap—>Bas transport of FITC-dextran across the 
tissue was not greater than the rate o f Bas-*Ap transport (Figure 5.2). Similarly 
however, the transport of FITC-dextran across Peyer’s patch tissue was lower than 
across tissue without Peyer’s patches.
When polymers were added to the vertical diffusion system, their effect on 
FITC-dextran transport was first investigated only in the Ap-»Bas direction, and only 
in non-Peyer's patch tissue. The results obtained from these studies are summarised 
in Table 5.2. With the exception of HA (Figure 5.3b) and SPACA30 (Figure 5.3d) the 
other polymers (alginate, sHA, PAcAioo, PACA450, and PAMAM generation 3.5 
dendrimers) appeared to decrease the transport of FITC-dextran (Figure 5.3a, c, e, f 
and g). As SPACA30 and HA were the only polymers that increased transport, they 
were selected for further studies to investigate their effect on FITC-dextran transport 
in both the Bas-*Ap direction across non-Peyer’s patch tissue, as well as in both 
(A p—*Bas and Bas-*Ap) directions across tissue containing Peyer’s patches. 
Although alginate did not enhance Ap—*Bas FITC-dextran transfer, it was decided to 
use this polymer as a negative reference control.
Disappointingly however, in the further studies none of the polymers tested 
(sPAcA30, HA, or alginate) enhanced the transport of FITC-dextran in any direction 
or tissue model (Figure 5.4, 5.5 and 5.6). Even though HA and SPACA30 did enhance 
transport in the Ap-»Bas direction in non-Peyer's patch tissue, inhibition was seen in 
the Bas—»Ap direction (see Table 5.2).
Possible mechanisms o f polymer-induced effects
As described above, there are a number of factors to consider when interpreting
165
CHAPTER 5: Effects of polymers on FITC-dextran transport
Table 5.2 Summary of the effect of polymers on FITC-dextran transport across 
rat intestinal tissue.
Polymer Non-Peyer’s patch tissue Peyer’s patch tissue
Ap—*Bas Bas-*Ap Ap-*Bas Bas-*Ap
Alginate 4 4 4 4
HA t 4 4 4
sHA 4 ND ND ND
PACA30 t 4 4 4
PAcA 100 4 ND ND ND
PACA450 unchanged ND ND ND
PAMAM 3.5 l ND ND ND
ND -not determined
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these results (see Figure 5.7). It was shown that several o f  the polymers caused 
changes in medium pH at the concentrations used (Table 5.2), and this could 
potentially influence the fluorescence output o f  FITC-dextran, as well as cell viability 
and TJ integrity. In respect o f  the potential mechanisms o f  action o f  the polymers 
(shown in Figure 5.7) it is interesting to compare these data with the literature.
Polymer-induced pH  effects
Although, the MEM tissue culture medium used for this work contains Earle’s 
salts and a high sodium bicarbonate buffer (2.2 g/L) to minimise pH fluctuations 
(Eagle, 1959), as seen previously in RPMI and DMEM culture media (containing 10 
% FBS; see Table 3.2), PAcAioo, PACA450 and PAMAM generation 3.5 dendrimers 
were still able to alter the medium pH; in the range pH 6 - 8  (Table 5.2). As FITC is 
a pH-sensitive fluorophore, in theory this could affect the interpretation o f  the results 
observed. FITC-dextran exhibits a maximal fluorescence at pH 8 (supplier 
information; w ww .sigm aaldrich.com , accessed 12/03/2002), and as shown earlier 
(Figure 5.1), as the pH becom es more acidic fluorescence output decreases. This 
raises the question, could the apparent inhibitory affects seen for PAcAioo PACA450 
and PAMAM generation 3.5 in som e experiments be an artefact?
Compared to FITC-dextran, w hich exhibits properties o f  an expandable coil in 
solution (Granath 1958), and is small enough to pass through TJ o f  the rat intestine, 
the large molecular mass o f  PAcAioo and PACA450, means that they are unlikely to be 
transported across the tissue via the TJ pathway. However, the pH changes in the 
MEM tissue culture m edia caused by these and other dissolved polymers may have 
had an affect on the fluorescence output o f  FITC-dextran in the recipient chamber. In 
order to determine the extent o f  this effect, the pH o f  the MEM in the recipient 
chambers should have been measured at the end o f  each experiment. Unfortunately 
however, this important control was not measured at the time making it difficult to 
determine the effects o f  polym ers on FITC-dextran transport.
However, as discussed previously (in section 5.1), PAM AM  generation 3.5 
dendrimers have been reported to decrease the TJ permeability in Caco-2 monolayers 
at non-toxic concentrations (El-Sayed et a l, 2003b), and to transverse rat everted 
intestinal sacs via an extremely efficient pathway; the El value o f  which suggests that
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polymer in the tissue culture medium would have had an effect in the recipient 
chamber. As the pH of PAMAM 3.5 in MEM was approximately pH 8  (Table 5.3), 
then the transport of FITC-dextran measured across the tissue could have been over­
estimated.
Polymer cytotoxicity
It is also possible that the polymer effects observed for FITC-dextran transport 
could also be due to polymer-induced cytotoxicity. The transport of FITC-dextran 
across the rat intestinal tissue by endocytic pathways would be decreased if the 
energy supply were compromised. Conversely, a decrease in viability that leads to TJ 
opening/breakdown, would allow more FITC-dextran to pass the epithelial barrier. 
As it was previously shown that the IC50 values of these polymers were greater than 1 
mg/mL during the 1 h incubation with B16F10 cells (see Chapter 3), it can be 
assumed that the polymers would not be cytotoxic in the system. Again, an important 
control here would have been to measure the pH of the medium in the recipient 
chambers.
TEER is usually used to measure the changes in the permeability of epithelial 
barriers, in conjunction with/or the transport of paracellular markers. However, as 
mentioned above TEER is reduced as tissue viability decreases. The permeation- 
enhancing effects o f PAcAs described by Kast and Bemkop-Schnurch, (2002) and 
Kriwet and Kissel (1996) have solely been measured using the above methods. The 
cytotoxic effects of PAcA were not measured in these papers.
Possible transport mechanisms fo r  sPAcA 30 and HA
It is interesting to consider why SPACA30 and HA had and effect on FITC- 
dextran transport only in the Ap—>Bas direction across non-Peyer’s patch tissue, 
particularly as P-gp is largely located on the apical membrane. The variability in 
transport observed when using this model has been previously described (in Chapter 
4 ), though the experiments conducted here were more reproducible (possibly due to 
the reasons described above). The data shown are n = 6  ± SEM. Nevertheless, the 
transport of the control, FITC-dextran, did not show the same trend as seen in 
Chapter 4 (Figure 4.16). It is possible that the increases in the transport observed with 
sPAcA3o and HA are an artefact, as the data are non-significantly different to the 
control.
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It is also possible that enhanced transport seen with SPACA30 could be due to 
activation of the sodium-glucose transporter on the apical membrane of intestinal 
epithelial cells, caused by the presence of extra sodium ions in the tissue culture 
medium compared to the control (sodium enhances polymer solubility). When active, 
this transporter has been shown to increase TJ permeability due to the 
phosphorylation of myosin light chain kinase, and contraction of the perijunctional 
actinomycin ring (reviewed in Nusrat et al, 2000). However, sHA did not have an 
effect on the TJ permeability. Therefore, the effect of sPAcA on FITC-dextran 
transport across rat intestinal tissue could be due to some other physiochemical 
properties.
The molecular weight, geometry and surface charge or pKa of polymer 
molecules are also features that govern whether they can physically permeabilise TJ. 
Clearly the effect of polymer molecular weight on FITC-dextran transport has been 
demonstrated in these studies with PAcA, though the results observed were in 
contrast with Kast and Burnkop-Schnurch, (2002), and the results observed with 
PAcA microparticles (MW = 300,000 Da) Krewet and Kissel (1996).
As it is not clear what effect the polymers are having on FITC-dextran transport 
from this work, and that none of the polymers significantly enhanced transport across 
the rat intestinal tissue, it was decided to move forward and to measure the transport 
of polymers themselves across the tissue.
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6.1 INTRODUCTION
The studies in Chapter 5 showed some evidence of increased Ap—>Bas transport 
of FITC-dextran across rat intestinal tissue in the presence of HA and SPACA30, but 
unexpectedly, not in the presence of PAMAM generation 3.5 dendrimers. In fact in 
many experiments the polymers tested inhibited transport. It was therefore 
considered important to try and monitor the transport of the polymers themselves 
across the rat intestinal tissue, instead of simply looking at their effect on a 
paracellular marker. Though to do this, it was first necessary to label SPACA30 and 
PAMAM generation 3.5 dendrimers with a fluorescent dye, and Oregon green (OG) 
was chosen as the fluorophore. The rationale for methods used to synthesise, purify 
and characterise polymer-OG conjugates are given below.
Rationale for the choice o f  fluorescent dye
Many fluorescent dyes are available for conjugation (a list can be seen on the 
Molecular Probes website: http://probes.invitrogen.com/handbook/tables/0726.html 
(accessed 23/6/2006)), but few have the functionality to react with the carboxylic acid 
groups on the chosen polymers, to form amide bonds. These dyes typically have 
amine groups and include BODIPY FL, the dialkylamino-, hydroxyl- and methoxy- 
coumarins, fluoresein, Oregon green-cadaverine (OGcad) and rhodamine. The OG 
fluorophore was preferred for this work, as it has previously been used to label 
polymers such as PEI (MW = 25,000 Da), and PAMAM generation 2, 3 and 4 
dendrimers (Seib et al., 2006), PEG-dendrons (Xyloyiannis et al., 2003; Bema et al., 
2006), polymethacrylates (Dubruel et al., 2004), and HPMA copolymers (Jensen et 
al., 2001). Conjugation to this fluorophore has then enabled the intracellular 
trafficking of these polymers to be studied, using both confocal scanning laser 
microscopy and flow cytometry techniques. Moreover, OG was considered a better 
fluorophore than fluorescein, as fluorescein is pH-sensitive (see Chapter 5, Figure 
5.1), and has a high rate of photobleaching (Haugland, 2002). Being a fluorinated 
analogue of fluorescein, OG (developed by Molecular Probes), has matching 
absorption (494 nm) and emission (520 nm) spectra, but it is more pH- and photo­
stable (Haugland, 2002). Though many forms of OG are commercially available, 
OGcad was chosen for these studies, as cadaverine posseses the primary reactive 
amine group.
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Rationale fo r the choice o f  conjugation chemistry
In order to label the polymers with OGcad, the carbodiimide coupling reagent, 1- 
ethyl-3(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was used. EDC 
mediates the formation of stable amide bonds between the polymer carboxylate 
groups and the amine group on OGcad, by modifying the carboxylic acid groups into 
active ester groups. The reactive esters then bind OGcad by aminolysis (reviewed in 
Hermanson, 1996).
Several carbodiimides such as DIC; Woodward’s reagent K; N,N’- 
carbonyldiimidazole; dicyclohexy carodiimide (DCC); cyclohexyl -3-(2- 
morpholinoethyl) carbodiimide (CMC); and EDC, and are commercially available, 
for conjugation, though few are soluble in water. Fortunately, CMC, DCC and EDC, 
are water soluble, and can therefore be directly added to a reaction without prior 
dissolution in organic solvent. Each of these reagents works in a similar fashion, 
though the reactive complexes formed by these molecules can be subject to 
hydrolysis (Hoare and Koshland, 1967; reviewed in Hermanson, 1996). 
Consequently, if the target amine does not find the active carboxylate before it 
hydrolyses, the desired coupling cannot occur.
To increase the stability o f the active intermediate 7V-hydroxysulphosuccinimide 
(sulpho-NHS) can be used. Sulpho-NHS esters are soluble in water and in the 
presence of amine nucleophiles, which can attack at the carbonyl group of the ester, 
the N-hydroxysulfo-succinimide group rapidly leaves, creating a stable amide linkage 
with the amine (reviewed in Hermanson, 1996). The concentration of sulfo-NHS 
used in a reaction is normally much greater than the concentration of the target 
molecule, so the reaction preferentially can proceed through a longer-lived 
intermediate.
The EDC/sulfo-NHS reaction was preferred for this study, as the use of these
reagents for polymer-OGcad conjugation has been well characterised (Jenson et al.,
2001; Bema et a l, 2006; Izzo, 2005). A schematic representation of this reaction is
given in Figure 6.1. Unlike EDC, DCC is normally used as a coupling agent for
organic (particularly peptide) synthesis in organic solvent (Delmonte et al., 1999),
and not to perform biomolecular conjugations. It also has the disadvantage of being a
waxy solid that is difficult to remove from a bottle (reviewed in Hermanson, 1996).
CMC is not normally used for polymer conjugation purposes, and has been shown to
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Figure 6.1 Reaction scheme for polymer (R) conjugation to O G c a d  using EDC and 
Sulfo-NHS coupling reagents
Reaction scheme adaptedfrom  Hermanson, (1996)
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react with phenols, alcohols, and other nucleophils to quench coupling reactions 
(reviewed in Hermanson, 1996).
Optimising the reaction conditions and characterisation
It was important to optimise OGcad-polymer conjugation, and silica-based thin 
layer chromatography (TLC) was used to monitor the reaction over time. Although 
many protocols seem to assume that all the probe will be bound, it is essential to 
purify the product well, and to calculate the bound and free OGcad. Dialysis was first 
used for purification, and then a commercially available PD-10 desalting column was 
used to characterise the product. The large polymer-OGcad molecules elute first from 
the column (in the void volume), and the smaller OGcad molecules elute later (for the 
theory of GPC see Chapter 2, section 2.3.8). The eluted fractions can then be 
analysed using fluorescence.
Though conjugates could be purified using PD-10 chromatography, dialysis 
was preferred, as it can be used more easily to purify larger volumes of conjugate 
from reaction mixtures. Moreover, as the reagents and the isourea by-products from 
the conjugation reaction were all water-soluble, they could be easily removed by this 
method.
Once purified all products were finally lyophilised (a process also known as 
freeze-drying). This method is useful for drying materials that are sensitive to heat, 
or have unstable structures (reviewed in Tang et al., 2004). The primary mechanism 
for lyophilisation is sublimination, whereby ice is directly converted into water 
vapour, without passing through the intermediary stage of a liquid (reviewed by 
Franks, 1997). This is achieved via a vacuum, which lowers pressure to around 1 
milibar (as opposed to atmospheric pressure, of 1017 milibars), causing water 
molecules to be drawn out of the sample into a condenser that converts the moisture 
into liquid and drains it away.
Ultraviolet-visible (UV-Vis) spectroscopy was used to determine the total OG 
content in each product, using the Beer-Lambert law equation (see equation 1, section 
6.2.4), to find the molar absorption coefficient (e) of OG^d. This value is the 
absorbance of a molar concentration of OGcad with a 1 cm path-length, at a 494 nm 
(the excitation wavelength of OGcad). PD-10 column chromatography was then used
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to calculate the free OG content in each sample, and fluorescence spectroscopy was 
used to determine the concentration-dependence of the fluorescence yield.
Assessing polymer transport and polymer uptake
To monitor the transport o f OG-labelled polymers across the rat intestinal tissue 
(with or without Peyer’s patches), the vertical diffusion chamber was used (Chapters 
4 and 5).
In parallel, the uptake o f the polymers into cells (thus to give an idea if they 
were being taken up by endocytosis), was determined using flow cytometry and 
Caco-2eBe cells were chosen as a model. Caco-2BBe cells differ from standard Caco-2 
cells, as they are a brush-border expressing (sBe) phenotype (Peterson and Mooseker, 
1992). However, it takes several weeks in culture for these cells to fully differentiate, 
and in order to polarise, they need to be grown as a monolayer on filters. For flow 
cytometry experiments however, Caco-2eBe cells were grown in 6 -well plates for 2 d, 
and thus would not be a fully mature Caco-2 BBe phenotype.
In summary the specific aims o f this chapter were to:
(i) Synthesise and characterise PACA30-OG and PAMAM 3.5-OG conjugates.
(ii) Study the transport of the conjugated polymers across intestinal tissue in the 
vertical diffusion chamber.
(iii) Study the uptake of the polymers by the Caco-2BBe cells to see if there was any 
evidence of endoytic capture.
6.2 METHODS
6.2.1 Conjugation of Oregon green-cadaverine to polymers
Synthesis o f  sPAcAjo-OGCad
sPAcA30 (supplied as 40 % weight in H20 ) was weighed (439 mg) into a foil- 
wrapped, round-bottomed glass flask containing a magnetic flea, and ddH20  (2 mL) 
was added. The flask stoppered, and the solution was stirred to mix the polymer. 
EDC (366.5 mg) and sulfo-NHS (415.0 mg) were added as a solid to a give 1 molar 
equivalent of each reagent. The reaction was stirred for a few moments (~ 10 sec), 
before 1.91 x 10*5 moles o f OGcad were added. This was estimated to label 1 % of the 
polymer. The solution was left to stir for 3 h at room temperature, and the reaction
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was monitored on an hourly basis using TLC as described below (section 6.2.2).
Synthesis o f  PAMAM 3.5-OG
PAMAM generation 3.5 dendrimers (supplied as 10 % weight in methanol) 
were weighed (2.2 g) into a glass flask (covered with foil), and a stream of nitrogen 
was used to evaporate the methanol from the polymer. Double distilled water (3 mL) 
was then added and the solution was stirred using a magnetic flea. PAMAM 
generation 3.5 dendrimers have 64 terminal -COOH groups, so enough EDC (6.7 mg) 
and sulfo-NHS (7.6 mg) was added to activate each group. The amount of OGca<j 
added (1 pL of 5 mg/mL OGcad in ddH2 0 ) was calculated to give a ratio of 1 OGcad 
per dendrimer. Once EDC, sulfo-NHS and OGcad had been added, the reaction was 
left to stir for 22 h at room temperature, and TLC was again used to monitor OG- 
conjugation (see section 6.2.2)
6.2.2 TLC method
Silica-covered TLC plates (with fluorescent indicator: UV254) approximately 4 
x 6 cm in size were used, and samples were applied at the origin using a capillary 
tube. Free OGcad (5 mg/mL in ddH2 0 ) was used as a control, and samples of reaction 
mixture were spotted onto the plate and dried using a hair drier on a cool setting. The 
plates were placed into a small 250 mL glass beaker, containing ~15 mL of methanol, 
used as the running phase. The beaker was then covered and the TLC ran for 
approximately 5 min, or until the solvent had travelled 3/4 the way up the plate. The 
plates were then removed, and the solvent front marked. Again a hair dryer was used 
to dry the plates, before they were viewed under a UV-lamp. The fluorescent spots 
(i.e. free and bound OG) were noted. Polymer-bound OG begins to appear at the 
origin and the reaction times were optimised to give minimum free OGcad. At the end 
of each reaction, polymers were purified by dialysis as described below.
6.2.3 Purification and lyophilisation of polymer-OG conjugates
Dialysis
The polymer-OG reaction mixture was placed into a dialysis tube (membrane 
molecular weight cut-off = 2,000 Da), which was sealed at both ends using dialysis 
clips. This was then placed into a 5 L conical flask containing of ddH20 (5 L), and 
was protected from light with a bin liner. The flask was placed on a magnetic stirrer,
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and a magnetic bead was used to stir the water and slowly rotate the bag. The water 
was changed from the flask a total of seven times over two days.
PD-10 column chromatography
Each column was equilibrated with 10 mLs of PBS before use. Samples (0.5 
mL containing 25 p,L of reaction mixture in PBS) were then added to the columns, 
and were eluted with 0.5 mL fractions of PBS. Each eluted fraction (0.5 mL) was 
collected into eppendorf tubes, and 200 p,L of each was pipetted into black 96-well 
plates. All plates were then read in the fluorescence plate reader as previously 
described (Chapter 2, section 2.3.6).
Lyophilisation
The dialysed polymer conjugates were placed into foil-wrapped plastic tubes, 
and were snap-frozen using liquid nitrogen (-196 °C) at atmospheric pressure. This is 
important to prevent shrinkage o f the sample during the lyophilisation process. 
Tongs were used to remove samples from the liquid nitrogen, and the lids of the tubes 
were quickly removed and replaced with tin foil (secured with tape), that was pierced 
several times with a needle. Samples were then placed into the lyophilisor, and were 
dehydrated for 48 h.
Once lyophilised, the OG-labelled polymers were then placed into labelled, 
foil-wrapped plastic containers, sealed with parafilm, and kept in the freezer until use.
6.2.4 Characterisation of polymer-OG conjugates
Using UV/Vis spectroscopy to determine total OG content
First, to check the molar extinction coefficient of OGcad, 1 mg was weighed into 
plastic bijous (covered with foil), and was dissolved in 1 mL PBS (pH 7.4). This 
solution was then diluted with PBS to a concentration of 2.0 x 10'7 moles/L. It was 
then pipetted (1 mL) into 1 cm3 quartz cuvette, and read spectrophotometrically at 
494 nm, against a reference cuvette containing only PBS (1 mL).
To estimate the OG content of each polymer-OG conjugate, the lyophilised 
conjugates were first weighed (1 mg) into plastic bijous (covered with foil), and were 
dissolved in 1 mL with PBS (pH 7.4). These solutions were also read 
spectrophotometrically at 494 nm against PBS. Assuming that the extinction of
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OGcad is the same as polymer bound-OG, the total OG content was calculated as 
follows:
(1) [OG] = A/e
Where [OG] is the concentration of OG in moles/L, A is the absorbance of the sample 
at 494 nm, and e is molar absorption coefficient of OG in moles/L.
The weight % of OG in each polymer-OG conjugate was calculated by first 
converting [OG] into an mg/mL value ([OG] x OGcad MW (496.47 Da)). The 
following equation was then used:
(2) OG/P x 100 = total polymer-bound OG (weight %)
Where OG is the concentration of OG in mg/mL, and P is the mg/mL concentration 
of the polymer dissolved in PBS.
6.2.5 Analysis of polymer-OGc«d transport across ra t intestinal tissue using the 
vertical diffusion system
Rat intestinal tissue was prepared, and the vertical diffusion system was set up 
as described in Chapter 2, section 2.3.6. MEM was removed from both the donor and 
recipient chambers of each diffusion cell, and was immediately refilled with fresh, 
pre-warmed (37 °C) MEM (1.5 mL), or MEM containing polymer (PACA30-OG or 
PAMAM 3.5-OG) conjugates (1 mg/mL). Samples of media (25 \iL) were collected 
from the recipient chambers at 1 0  min intervals, from t = 0  - 60 min, and were placed 
into black 96-well plates (covered with foil). All plates were read in the fluorescence 
plate reader as previously described (chapter 2, section 2.3.6).
6.2.6 Flow cytometry analysis of polymer-OG uptake by Caco-2BBe cells
For flow cytometry experiments, Caco-2eBe cells were incubated with PACA30- 
OG or PAMAM 3.5-OG (1 mg/mL in HBSS), for 10 min intervals (from 0 - 6 0  min), 
at either 37- or 4 °C.
In experiments conducted at 37 °C, Caco-2BBe cells were seeded into 24-well 
plates (2.5 x 105 cells/500 ^L/well), with DMEM containing 4500 mg/L glucose and
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phenol red (see table 2.1). All experiments were carried out in duplicate (two 
wells/time point). Seeded plates were placed into the incubator, and were allowed to 
grow for 48 h. Following this, the plates were removed from the incubator, and the 
media was quickly aspirated from the t = 60 min wells. The wells were washed once 
with pre-warmed (37 °C) PBS (pH 7.4), to remove dead cells and DMEM media. 
HBSS media (0.5 mL) containing either PAMAM 3.5-OG, or PACA30-OG conjugates 
(1 mg/mL) was then added, and the plates were returned to the incubator. At 10 min 
intervals the process was repeated for t = 50 min, 40 min etc, until the end of the 
incubation at t = 0  min.
For experiments carried out at 4 °C, the procedure was essentially the same. 
Each plate (seeded with two wells/time point) was placed on ice 30 min prior to the 
addition of HBSS (0.5 mL) containing polymer-OG conjugates (1 mg/mL). Plates 
were kept on ice in the cold room (4 °C) throughout the experiment.
Samples of cells were treated the same irrespective of incubation temperature 
(37 °C and 4 °C). The plates containing cells were immediately placed on ice, and 
transferred to the cold room (37 °C). The incubation medium was removed from the 
cells, and they were washed 3 times using ice-cold PBS (1 mL/well). Caco-2BBe cells 
were then removed from the wells, using a rubber cell scraper, and were pipetted into 
labelled, foil-wrapped, 25 mL centrifudge tubes. All tubes were kept on ice until they 
were transferred to the chilled (4 °C) centrifuge. They were spun at 1000 g for 5 min, 
and the pellets were resuspended in 200 pL of ice-cold PBS. To break up aggregates 
of cells, a 1 mL syringe with a 23 G needle was used. Then the cell suspensions were 
placed into labelled Falcon tubes, kept on ice and protected from light until assay by 
flow cytometry.
During flow cytometry, the cell-associated fluorescence of each sample was 
measured for a minimum number of counts (40,000 cells) and the data were 
expressed as the geometric mean of each sample compared to the gated control cells 
(Caco-2BBe in HBSS only). The experiments were carried out in triplicate, and the 
data are plotted as incubation time (min) against fluorescence.
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6.3 RESULTS
6.3.1 Synthesis and characterisation of polymer-OG conjugates
For PACA30, TLC showed that the majority o f  OGcad had bound to the polymer 
after 3 h (Figure 6.2). However, for PAM AM  3.5, OG conjugation was much slower, 
and the optimised conjugation tim e was 22 h (Figure 6.4). In both cases, PD-10 
analysis confirmed that P A cA 30- (Figure 6.3) and PAMAM 3.5- (Figure 6.5) OG 
conjugates had been fluorescently labelled as florescence was seen with the polymer 
in the void volume. The free OGcad still present in the reaction mixture was eluted 
later (Figure 6.3a and Figure 6.5a). PD -10 analysis performed after dialysis showed 
that all free OGcad had been rem oved from the PA cA 3o-OG (Figure 6.3b) and 
PAMAM 3.5-OG (Figure 6.5b) conjugates.
Using the molar extinction coefficient estimated for OG^d (41,500 moles/L), 
the total OG content o f  the P A cA 3o-OG and PAM AM  35-OG conjugates was 
calculated using the U V /V is spectra o f  each polym er (Figure 6 .6 a and 6 .6b 
respectively). The molar OG content o f  each conjugate, as w ell as the % free OG 
present, were calculated and the results are shown in Table 6.1.
The fluorescence spectrum o f  PAcAo-OG (Figure 6.7a) and PAMAM 3.5- 
OG (Figure 6.7b) (1 m g/m L), show ed the difference in the fluorescence-loading o f  
each polymer. At 494 nm, the fluorescence intensity o f  PA cA 3o-OG was 0.30 
arbitrary units, compared to 0 .17 arbitrary units for PAMAM 3.5-OG.
Using the data shown in Table 6 .1 , the mg/mL concentration o f  PAM AM  3.5-OG  
required, to give an equivalent amount o f  OG as in 1 mg/mL o f  PA cA 3o-OG. 
Therefore, for every 1.00 m g/m L o f  PA cA 3o-OG used, a concentration o f  2.06  
mg/mL o f  PAM AM  3.5-O G  w as required to g ive a comparable amount o f  
fluorescence. These concentrations were used for vertical diffusion work.
6.3.2 Polymer-OG transport across ra t intestinal tissue in the vertical diffusion 
system
PAcAso-OG transport across tissue without Peyer’spatches
When P A c A 3o- O G  transport w as measured across rat intestinal tissue without 
Peycr’s patches, a 5 min lag phase in both A p-»B as and Bas—>Ap transfer was seen 
(Figure 6 .8a), followed by a linear increase with time. Interestingly, the transport o f
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Figure 6.3 (a & b) PD-10 column chromatography elution profile of PAcA3o-OG 
before (panel a) and after (panel b) purification by dialysis.
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Figure 6.5 PD-10 column chromatography elution profile of PAMAM 3.5-OG before 
(panel a) and after (panel b) purification by dialysis.
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Figure 6 . 6  (a & b) UV/Vis spectrum for PACA30-OG (0.5 mg/mL; panel a) and 
PAMAM 3.5-OG (1 mg/mL; panel b). The absorbance of unconjugated SPACA30 and 
PAMAM 3.5 were also measured for comparison. The data shown are n = 1.
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Table 6.1 Characteristics of polymer-OG conjugates.
Conjugate Polymer MW (g/mol) Batch name Batch size (mg) Total OG (wt %) Molar Ratio
PACA30-OG 30,000 kpog9 1 0 2 . 0 0.16 1 0 .2
PAMAM 3.5-OG 12,931 kppam5 60.0 0 . 0 2 0.007
CHAPTER 6: Uptake and transport of polymer-OG conjugates
0.35-,
IS 0.25-
0 . 2 -
r  0.15-
^  0.05-
480 500 520 540 560 580 600
Wavelength (nm)
0.71
C/5•*->*s
bIlo
cd'w '
0.6
0.5
& 0.4-
U)c<u
-  0.3-ooC3<L>
§  0 .2 -UiOJ3
E
600480 500 520 540 560 580
Wavelength (nm)
Figure 6.7 (a & b) Fluorescence spectrums of PACA30-OG (panel a) and PAMAM- 
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Figure 6 . 8  (a & b) Transport of PACA30-OG conjugates (1.00 mg/mL) across rat 
intestinal tissue (panel a), or rat intestinal tissue containing Peyer’s patches (panel b). 
The data shown are n = 4 ± SEM.
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the polymer in both directions was then over-lapping until t = 2 0  min, at which a 
greater rate of Bas-^Ap transport was seen. At t = 60 min, the Bas-> Ap transport of 
PACA30-OG was 63 % greater than transported in the Ap->Bas direction.
PAcA30-OG transport across Peyer ’s patch tissue
The Ap-»Bas and Bas—>Ap transport of PAcA3o-OGcad across rat intestinal 
tissue with Peyer’s patches (Figure 6 .8 b) was lower than that seen across non-Peyer’s 
patch tissue (Figure 6 .8 a). A 20 min lag phase in PAcA3o-OGcad transport was seen 
for transport in both directions across this tissue, and the rate of transport remained 
parallel until t = 30 min. From t = 30 -  60 min, PACA30-OG transport was greater in 
the Bas-*Ap direction.
PAMAM 3.5-OG transport across tissue without Peyer’spatches
Although the concentration of PAMAM 3.5-OG (mg/mL) required to give an 
equivalent amount OG as in 1 mg/mL of the PACA30-OG conjugate was calculated, 
the fluorescence output of PAMAM 3.5-OG seen in the vertical diffusion system was 
relatively lower. Nevertheless, the transport of the polymer across tissue without 
Peyer’s patches increased with time, but to a lesser extent than PACA30-OG. 
Transport was also greater in the Bas-»Ap direction (Figure 6.9a). A ten min lag- 
phase in transport was seen for Ap—>Bas transfer, whilst Bas->Ap transport occurred 
in a stepwise fashion.
PAMAM 3.5-OG transport across Peyer’s patch tissue
No difference in the Ap->Bas or Bas—*Ap transport of PAMAM 3.5-OG was 
seen across tissue containing Peyer’s patches (Figure 6.9b). Instead, transport in both 
directions was overlapping. At t = 60 min Bas—*Ap transport was marginally greater 
than Ap-*Bas.
Stability o f OG-conjugates during incubation in the vertical diffusion chamber
Small amounts of free OG ( 6  %) were found in the PACA30-OG stock solution 
(1 mg/mL) at t = 0 min (Figure 6.10a). Only a 1 % increase in the level of free OG, 
compared to the stock solution, was found in the donor chamber of the vertical 
diffusion system at the end of the incubation (t = 60 min) (Figure 6.10b). Highest
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recipient chamber (panel c) at t = 60 min.
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amounts of free OG (26 %) were seen in the recipient chamber at t = 60 min (Figure 
6.10c).
For PAMAM 3.5-OG conjugates, the fluorescence-output of the stock solution 
was lower than seen for PAcA30-OG (Figure 6.1 la). A small amount of free OG was 
found in the stock solution at t = 0 min (7 %), as well as in the donor chamber at 60 
min (8 %) (Figure 6.1 lb). Over half the fluorescence found in the donor chamber at t 
= 60 min was due to free OG (56 %) (Figure 6.1 lc).
It is important to note, that during storage, the PAMAM 3.5-OG conjugates 
appeared to take up water, and adhered to the plastic container in which they were 
held. They were therefore not used for flow cytometry studies.
6.3.3 PAcA3o-OGCad uptake by Caco-2BBe cells
The up-take of PAcA3o-OG (1 mg/mL in HBSS) into Caco-2BBe cells increased 
with time (t = 0 - 60 min), though the increase in cell-associated fluorescence was not 
linear (Figure 6.12a). Only marginally lower levels of cell-associated fluorescence 
were seen for cells incubated with PAcA3o-OG at 4 °C.
In some experiments it was decided to measure the uptake of FITC-dextran as 
this polymer had been used for transport studies in previous chapters (see Chapters 4 
and 5). For cells incubated with this polymer, a general increase in cell-associated 
fluorescence was seen at both 37 °C and at 4 °C, over time. There was little 
difference in cell associated fluorescence at these two temperatures.
6.4 DISCUSSION
To measure the transport of sPAcA3o, and PAMAM generation 3.5 dendrimers 
across rat intestinal tissue, as well as to track the uptake of these molecules by Caco- 
2bbc cells, each polymer was fluorescently labelled with OGcad using EDC/sulfo-NHS 
coupling reactions. For PAMAM generation 3.5 dendrimers, the conjugation reaction 
was carried out as described by Izzo (2004), though there currently appears to be no 
data on the conjugation of OGcad to PAcA in the literature. All the same, (see Figure 
6.1) the reactions for both polymers were optimised. Calculations were made to give 
a 1.0 mole % OG-loading for PAcA3o, and a 1.5 mole % OG-loading for PAMAM 
generation 3.5 dendrimers (one OG unit per dendrimer).
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Figure 6.11 (a, b & c) PD-10 column chromatography elution profiles for PAMAM- 
OG stock solution at t = 0 min (panel a), or from the donor chamber (panel b) or 
recipient chamber (panel c) at t = 60 min.
192
Ce
ll 
as
so
cia
ted
 
flu
or
es
ce
nc
e 
Ce
ll 
as
so
cia
ted
 
flu
or
es
ce
nc
e
CHAPTER 6: Uptake and transport of polymer-OG conjugates
301
Key;.
PAcA30-OG (4 °C) 
—■— PAcA30-OG (37 °C)
25-
20 -
15-
Time (min)
Key:
—♦— FITC-dextran (4 °C) 
FITC-dextran (37 °C)
35i
30-
25-
20 -
10 -
Time (min)
Figure 6.12 (a & b) Uptake of PAcA3o-OG (1 mg/mL; panel a), and FITC-dextran (1
mg/mL; panel b) by Caco-2BBe cells over 60 min. The data shown are n =3 ± SEM.
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Though the conjugation of sPAcA30 and PAMAM 3.5 dendrimers was 
successful, and a relatively small amount of free OG remained in the dialysed 
polymers (Figure 6.2b and 6.4b respectively, and Table 6.1), the amount of polymer- 
bound OG according to UV/Vis analysis was not as had been calculated (Table 6.1). 
Nevertheless, using the UV/Vis spectrums of each polymer, the quantity of PAMAM 
3.5-OG required to match the OG content in 1 mg/mL of PAcA3o-OG was calculated. 
The required quantity of PAMAM 3.5-OG was found to be double (2.06 mg/mL) that 
of PAcA30-OG (1 mg/mL), and these polymer concentrations were used for transport 
studies.
Possible mechanisms o f polymer transport
The transport of polymers across cellular barriers depends upon their size, 
charge and lipophilicity. Although an in-depth study on the exact mechanisms of 
P A cA 3o-O G  and PAMAM 3.5-OG transport was not possible here due to time 
constraints, the vertical diffusion system served to measure the permeation of the 
fluorescent polymers across rat intestinal tissue, whilst flow cytometry was used to 
assess whether the polymers were taken up by endocytosis.
In the vertical diffusion system, the transfer of both polymers was greater in the 
Bas-»Ap direction across rat intestinal tissue with or without Peyer's patches, and 
this observation is in accordance with the literature. For example Kriwet and Kissel
(1996) have shown that basally applied microparticles of PAcA enhance the transport 
of sulforhodamine in Caco-2 cells by 30 x compared to microparticles applied 
apically. It was suggested that this result was due to the chelation of extracellular 
Ca2+. El-Sayed et al., (2003b) have shown that the transport of PAMAM 3.5 
dendrimers across Caco-2 cells is greater in the Bas—*Ap direction. For PAMAM 
generation 2 dendrimers, studies with the P-gp substrate paclitaxel, have shown that 
the greater rate of Bas->Ap transport is not likely to be due to efflux by this protein 
from the apical cell surface where it resides.
Furthermore, the observations made here differ from those seen previously in 
Chapter 5, where it was found that sPAcA3o, but not PAMAM 3.5 seemed to enhance 
FITC-dextran transport only in the Ap-»Bas direction. However, it is important to 
note that these results are not inconsistent as they measure different parameters.
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Unlike PAMAM 3.5, which is globular and approximately 4.5 nm in size 
(Wiwatanepatepee e t  a l . , 2000), the hydrodynamic radius o f PAcA3o is not known. 
Still, it can be expected to be large, as the polymer is linear and has a high molecular 
weight. Therefore the transport o f  PACA30-OG is likely to have been limited to the 
endocytic pathway, and this was reflected in the transport pattern seen from vertical 
diffusion chamber experim ents (Figure 6 .8 ). A slow  lag-time in PACA30-OG 
transport was seen in transport in both Ap-»Bas and Bas-^Ap directions across tissue 
with or without Peyer’s patches (Figure 6 .8 ). This was followed by a linear increase 
in fluorescence in the recipient chamber. Some o f  this fluorescence (26 %) was due 
to the transport o f  free OG. Indeed, a similar transport pattern has been seen for 
numerous water soluble, neutral, hydrophilic polymers such as 125I-labelled PVP, 125I- 
labelled poly(N-vinylpyrrolidone-co-maleic anhydride) (NVPMA) (Pat_ e t  a l. , 1994), 
and I-labelled HPMA copolymers (Cartilidge e t  a l . , 1986), when measured across 
the rat intestine using the everted gut sac model. These polymers were taken up by 
fluid-phase endocytosis.
In contrast to the above, anionic NVPM A (Pat_ e t  a l . , 1994) and to a greater 
extent anionic PAMAM generation 2.5 and 3.5 dendrimers (Wiwatanapatepee e t  a l., 
2 0 0 0 ) have shown greater transport rates across rat intestinal tissue, though this was 
not the case in the studies conducted here. The transport o f  PAMAM 3.5-OG across 
rat intestinal tissue was relatively low  compared to that seen for PACA30-OG. Hardly 
any PAMAM 3.5-OG was transported across the rat intestinal tissue during the 60 
min incubation, and PD -10 analysis show ed that a large percentage o f  the 
fluorescence (56 %) found in the recipient chamber was that o f  free OG (Figure 6.11). 
PAMAM 3.5-OG was less stable during the 60 min incubation with the rat intestinal 
tissue than PACA30-OG. It was also not stable during storage (-20 °C), and this may 
explain the low fluorescence output o f  the polymer compared to PACA30-OG in the 
experiments conducted (Figures 6.9 and 6.11). The instability o f  this polymer could 
have been the result o f  improper storage. When received from the manufacturers, the 
polymer was kept under nitrogen gas, however after having been conjugated to OG it 
was not. Nevertheless the polym er was kept for only a short time under these 
conditions (1  week) before it appeared to stick to the container it was held in.
It was because o f  this, that flow  cytometry was not conducted with the 
PAMAM 3.5-OG dendrimers. However, it would have been interesting to do this, as
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in theory it is possible that the polymers were being recycled by the tissue. 
Wiwatanapatepee et al., (2000) have shown that these polymers have a low rate of 
accumulation in rat intestinal tissue, and Xyloxiannis (2004) has shown that dendritic 
hybrid polymers (PEG-poly(ester) dendrons) can be rapidly exocytosed from cells, 
after internalisation, in a similar manner to naturally recycled macromolecules such as 
the transferrin receptor (Dautry-Varsat et al., 1983). It would have been interesting to 
have tested this theory using this polymer.
Nevertheless, flow cytometry was conducted with PAcA30-OG conjugates, and 
also with FITC-dextran (MW = 4,000 Da). For PAcA3o-OG-incubated cells, at both 
-4 and 37 °C only a small difference in cell associated fluorescence was seen (Figure 
6.12a). Therefore it can be concluded that PAcA3o-OG was binding to the cells, and 
little was being taken up by endocytosis. Similar results were also seen when the 
cells were incubated with FITC-dextran (Figure 6.12b). However, the fluorescence 
of FITC is pH-dependent (see Figure 5.1), and thus if the polymer was endocytosed, 
the fluorescence would drop as the pH inside the vesicles descreased (i.e. when 
endosomes become lysosomes).
However the results from flow the cytometry experiments were difficult to 
interpret, and contradict the results observed in the vertical diffusion system, which 
suggest both PAcA3o-OG (Figure 6.8) and FITC-dextran (Chapter 4) were being 
taken up by rat intestinal tissue by endocytosis. This was probably due to the nature 
of the cells used. If time had allowed it would have been beneficial to have repeated 
this study using a different cell line. The problems of using Caco-2BBe cells for this 
work were: (i) Firstly, as mentioned in the introduction to this chapter, Caco-2BBe 
cells require several weeks in culture in order to differentiate into mature, brush- 
border expressing enterocyte monolayers. They should also be grown on filters. If 
time had permitted, it would have been good to have grown these cells in this manner, 
and to have investigated polymer transport (in parallel to the vertical diffusion 
system), using fluorescence microscopy, and the measurement of TEER. (ii) 
Secondly, as the cells were clumped together, and had to be separated using a needle, 
the cells were likely to have been damaged. This could be seen during flow 
cytometry, as a high number of small granular particles (broken cells) were picked up 
by the laser, and appeared on the dot plot for each sample ran. They were gated 
around the population of viable cells, though it should be noted however that in most
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around the population of viable cells, though it should be noted however that in most 
cases this population was difficult to distinguish.
In summary, a simple schematic diagram depicting the possible cellular 
transport mechanisms it was thought PACA30-OG and PAMAM 3.5-OG would 
exploit is given in Figure 6.13. PAcA with its large hydrodynamic radius, linear 
structure and high molecular weight, is limited to the transport across the tissue via 
endocytic mechanisms. If indeed taken up by the cells, the fate of the polymer would 
then be targeted to lysosomes for degradation, or to be exocytosed (transcytosis). 
PAMAM 3.5-OG dendrimers could be transported across the tissue paracellularly or 
transcellularly (in accordance with literature, see Chapter 5 for review), or could be 
recycled. Flow cytometry suggests they are binding (most probably non-specifically) 
to the cells membrane.
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Figure 6.13 Schematic diagram showing the possible polymer transport mechanisms 
of polymer-OG conjugates.
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7.1 General comments
The columnar cells lining the GI tract (epithelial cells), the vasculature 
(endothelial cells), and not least the blood brain barrier provide a significant obstacle 
limiting effective oral bioavailability and drug delivery. These tissues constitute not 
only a physical barrier, but also a biochemical one, due to the presence of cytochrome 
p450 drug metabolising enzymes (e.g. CYP3A), and ABC efflux transporters such as 
P-gp. Moreover, oral delivery via the GI tract is also hampered by pH, extracellular 
enzymes, mucus and luminal fluid, making this region the most daunting for delivery.
The last four decades of research have sought to design ’safe' drug delivery 
systems, such as particulate or soluble carriers (Table 7.1) that can efficiently 
overcome these barriers, to deliver therapeutic doses of poorly absorbed (low 
molecular) drugs and macromolecules, particularly peptides and proteins. In parallel, 
research has been ongoing to develop polymer therapeutics for use as biologically 
active polymeric drugs, polymer-protein conjugates and polymer-drug conjugates. 
Since 1990 a growing number of such systems have entered routine clinical use 
(Duncan, 2003; Duncan, 2006). The initial aim of this project was to identify 
biologically active soluble polymers (some are even approved as excipients) that 
might be tailored (molecular weight and chemical characteristics) so that they would 
quickly promote significant local paracellular or transcellular drug delivery.
Reflections on the results observed during this study
A library of linear (alginate, HA, sHA, PAcAs) and dendritic (PAMAM) 
polymer architectures were chosen for these studies, in the hope that they would 
facilitate improved transient FITC-dextran transfer, across rat intestinal tissue. Each 
polymer selected was anionic, and was chosen based on information gleamed from 
the literature (as reviewed in Chapter 5, section 5.1). They were either (i) able to 
induce cytokine release from cells in vitro (i.e. alginate, HA, PAcAs), (ii) 
mucoadhesive (HA, PAcA), (iii) able to enhance paracellular transport across 
epithelial barriers (HA, PAcA, PAMAM dendrimers), or (iv) in the case of PAMAM 
dendrimers, can also transverse both epithelial and endothelial barriers by extremely 
rapid and efficient mechanisms (Wiwatanapatepee et al., 2000; El-Sayed et al, 
2003a; El-Sayed et al, 2003b).
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Table 7.1 Carriers currently used for drug delivery
Particle-type carriers Soluble carriers
Liposomes Plasma proteins
Lipid particles Peptides
Microspheres Polysaccharides
Nanoparticles Monoclonal antibodies
Polymeric micelles
Polymeric systems such as PEI that
complex DNA (polyplexes)
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Initially it was thought these polymers would interact with rat intestinal tissue 
at the cellular level, and increase FITC-dextran transfer directly, perhaps by 
inhibiting P-gp or physically widening TJ (Figure 7.1). It was also hoped that they 
would trigger local biochemical changes, caused by the modulation of Ca2+ 
concentration or the release of cytokines and/ or chemokines (Figure 7.1). Indeed, 
these polymers could also enhance transcytosis, and could certainly be used to 
permeabilise endothelial barriers as well (Figure 7.1). It is important to note that to 
date, no studies have systemically investigated the ability of acknowledged 
polymeric drug delivery systems to modulate permeability, by eliciting local 
cytokine release, and from this point of view, the scope of this project was very 
novel.
Although in many ways the results obtained in this study were negative, in that 
they did not highlight particular polymers that might be further optimised as 
permeabilising agents, able to promote transient oral delivery, each series of 
experiments did produce interesting data highlighting the opportunities and 
challenges of research in this difficult, but important field.
Cytotoxicity experiments showed that the polymers chosen for this work were 
non-toxic at concentrations up to 1 mg/mL. When incubated with various cell lines 
(DU937, RAW 246.7 and B16F10), the non-toxic concentrations of polymers did not 
induce TNF-a, IFN-y or IL-2 release, except for HA, and the positive cytotoxic 
control, PEI (Chapter 3). In the vertical diffusion chamber, rTNF-a, rlFN-y or rIL-2 
added at physiological levels did not show any effects on the transport of FITC- 
dextran, whilst at non-physiological concentrations (ng/mL) rlFN-y appeared to 
enhance it, however this effect was not significant (Chapter 4). Likewise, at 
concentrations of 1 mg/mL, polymers did not significantly enhance FITC-dextran 
transport across rat intestinal tissue in the vertical diffusion system (Chapter 5), 
though sPAcA30 and HA showed a slight increase. When fluorescently labelled, 
sPAcA3o seemed to be transported across the tissue by transcellular mechanisms in 
the vertical diffusion system (Chapter 6).
Although the polymers used in this study did not appear to enhance 
permeability, it also appears that no significant progress has been made in the drug 
delivery field over the last four years either.
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Progress in identifying agents able to permeabilise cellular barriers
Over the last four years the most interesting studies investigating methods to 
improve permeability across cellular barriers (intestine, blood-brain barrier, eye) 
have involved the use of TJ permeation enhancers, such as fatty acids (reviewed in 
Cano-Cebrian et al., 2005), and more recently toxins such as zonula occludin toxin 
(Zot) (Motlekar et a l, 2006), and Clostridium perffingens enterotoxin (Kondoh et al., 
2006), or thiolated polymers such as trimethylated chitosan (Thanou et a l, 2001). 
The effects of these molecules are reversible. Methods previously used to increase 
permeability include the use of fatty acids, calcium chelators, surfactants and bile 
salts, which can also operate by opening TJs (i.e. calcium chelators, fatty acids and 
some bile salts), or by increasing the fluidity of the cell membrane (i.e. surfactants, 
medium chain fatty acids and other bile salts). Nonetheless, the use of all the above 
is often linked to toxicity, and as yet, no single permeation enhancer is effective for 
the delivery of macromolecules. As such they are not widely used in oral 
formulations.
7.2 Thoughts regarding methods used and future experiments
Use o f  vertical diffusion chamber
Most of the research carried out on absorption-enhancing compounds, have 
been limited by the use of models that are non-physiological i.e. cell monolayers. 
Though Caco-2 and other cell lines are adequate for initial screening tests, they are 
poor predictors of in vivo performance. In much the same way, models that use 
isolated tissues such as the vertical diffusion chamber, are also poor predictors of in 
vivo performance for a variety of reasons including a lack of blood flow and luminal 
fluid. However they provide a method that is one step closer to the in vivo system.
In transport experiments the control rate of FITC-dextran transfer in the vertical 
diffusion system was highly variable (see Chapter 4 and Chapter 5), thus it was 
difficult to decipher differences in the transport of this marker mediated by the 
polymers or cytokines that were added (Chapter 4 and Chapter 5). This factor raises 
the question; is the vertical diffusion system a useful model for measuring transport?
The variability seen in the vertical diffusion system was largely due to 
variations in the animals used (see Chapter 4, section 4.4 for full discussion). Like 
man, Sprauge Dawley rats are outbred and thus (unlike cell monolayer models), the 
vertical diffusion chamber accounts for differences between individuals. However, 
this method is fraught with difficulties as discussed in Chapter 4 (section 4.4).
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It would have been interesting to have used another transport model, such as the 
everted gut sac method for this work as a comparison, however from the results 
observed in these studies, this would have been unnecessary.
Evaluation o f cytokine release - technical challenges
The difficulty in testing for the release o f  cytokines is that their half-life is so 
short (min). They may also bind to the polymers used, or the polymers may bind to 
the immunoglobulins in the ELISA plates, thus interfering with the assays (Chapter 
3). Furthermore, there is also the possibility that the polymer stocks could contain 
LPS, and this could lead to false-positive results. However, when trying to test for 
contamination, the polymers interfered with the LAL assay. It is also difficult to 
know which cell lines to use for these studies. Cells that are directly involved in the 
immune response i.e. leukocytes are the main cytokine producers, thus with this in 
mind, some transport experiments were conducted with Peyer’s patch containing 
tissues. It was thought that the T- and B-cells held in the patches would be more 
responsive to the cytokines used for these studies (Chapter 4). However, no increase 
in FITC-dextran transport was seen across these tissues (Chapter 4 and Chapter 5).
It is also difficult to know which cytokines to select and test for. A better way 
to test for cytokine release would have been to use cytokine arrays, modified ELISA 
assays, in which the release o f  several cytokines could have been depicted from a 
single sample o f  culture media from the polymer-incubated cells 
(www.RnDSystem.com). N ot only could this be used to measure the release o f a 
range o f  cytokines from the cells, but it could also be used to measure the induction 
o f  cytokine release over more time points. On another note, gene profiling could also 
have been used to investigate the responses o f  the cells towards the polymers 
investigated. It would also have been interesting to also examine the effect o f these 
polymers on other leukocytes such as T- and B-cells as found in Peyer’s patches.
7.3 Will the use of biologically active polymers ever be safe enough??
Cytokines generally modulate the permeability o f  cells by affecting the cellular
distribution o f TJ proteins (see Figure 1.4). Great interest has been focused on the
structure and cellular regulation o f  TJ in the last few  years (as reviewed in Chapter 1,
section 1.5.1), and a more in-depth knowledge o f  this physical barrier has recently
come to light. TN F-a (Chapter 1, section 1.7.3) and IFN-y (Chapter 1, section 1.7.2)
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both decrease (among others) the levels of ZO-1 from the TJ, and in doing so, 
reversibly decrease the TEER in Caco-2 and other intestinal cell lines, in a matter of 
h (as discussed in Chapter 4, section 4.4). The production of either cytokine is 
known to be elicited by polymers such as alginate, HA and PAcA from cells in vitro 
(Table 1.2).
Taking this data into account, not only did the idea of using these molecules to 
transiently enhance drug delivery seem plausible, but it was also thought that 
polymers capable of inducing them could be used to improve anticancer or antiviral 
therapies. Indeed, provoking a local cytokine cascade, would limit the toxicity 
problems observed with intravenous administration of cytokines such as IL-2 
(Chapter 1, section 1.7.1).
However, caution has to be taken when working with immunologically active 
molecules. Only recently (on the 13th March, 2006), a clinical trial in London, with 
the superagonist monoclonal antibody, TGN 14 12, served only to underline the 
difficulty in working with medicines that may tip the delicate balance of the host's 
immune system. Six healthy volunteers became violently ill, suffering multiple organ 
failure, and were admitted to intensive care only minutes after receiving an injection 
of the drug. TGN 14 12 was developed by TeGenero (Germany) to fight autoimmune 
disease (i.e. multiple sclerosis, rheumatoid arthritis) and leukaemia 
(www.tegenero.com). It functions by binding the CD28 receptor on T-cells, causing 
T-cell proliferation, without the involvement of the TCR as is required for natural T- 
cell activation (see Chapter 1, section 1.2.2, Figure 1.3).
In mice, rats, rabbits and monkeys, TGN 14 12 has demonstrated the ability to 
stimulate T-cell proliferation without apparent toxicity. In the human clinical trial, a 
flood of cytokines released by activated T-cells, was thought to be responsible for the 
drugs toxicity (reviewed by Bhattacharya and Coghlan, 2006). As mentioned earlier 
(Chapter 1, section 1.1.1), a similar fate occurred during Phase I clinical trials with 
DIVEMA in the 1960's.
7.5 Final thoughts
As an increasing number of therapeutic molecules are becoming available with
time (especially protein and peptide drugs through advancements in genetic
engineering), there is an impending need to find new ways to transiently
permeabilise endothelial and epithelial barriers. The benefits for drug delivery via
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this method include (i) the abolishment of injections, leading to increased patient 
compliance, (ii) cheaper drug manufacturing costs, as they would not need to be 
produced under strict sterile conditions, and (iii) a decreased need for trained 
professionals to administer them. Therefore, the design of novel permeation 
enhancers would be advantageous for the biomedical industry.
However, much research has to be made on trying to identify safe ways to 
permeabilise these barriers transiently. Although the polymers chosen for this study 
showed no inherent biological activity regarding cytokine release (except for HAs), 
or the ability to modulate FITC-dextran transport across rat intestinal tissue, evidence 
in the literature suggests otherwise, and it was difficult to validate the hypothesis of 
this work with the models used here. Perhaps the experiments conducted here need 
refining i.e. longer incubation times could be used, and different models could be 
employed.
As this project bridges several disciplines and the possibility of further studies 
are endless. I am sure with time a new class of successful biologically active 
polymeric drugs will be found.
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Appendix
Investigating the use of Biologically Active Polymers as a Means of 
Transiently Permeabilising the Intestinal Barrier
K. Phelps and R. Duncan
Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King 
Edward VII Avenue, Cardiff CF10 3XF, UK.
E-mail: Phelpskd@,cf.ac.uk
Numerous linear, water-soluble polymers (particularly polyanions) are biologically active and 
can induce cytokines, such as tumour necrosis factor-alpha (TNF-a), interferon-gamma (IFN- 
y) and interleukin-2 (IL-2), from cells depending on their molecular weight (MW), 
composition or salt form. The proinflammatory cytokines TNF-a and IFN-y are able to 
permeabilise epithelial barriers by affecting the protein composition of the tight junction 
(Walsh et al., 2000). The aim of this work is to identify polymers that will promote enhanced 
drug delivery due to their inherent ability to stimulate TNF-a IFN-y and IL-2 release, and 
therefore transiently permeabilise epithelial barriers. Several linear polyanions already used 
as excipients, including alginic acid, hyaluronic acid, sodium hyaluronate and polyacrylic 
acid (MW 30 kDa, 100 kDa, or 450 kDa), were chosen as the first library to investigate. 
Branched polymers, including polyamidoamine (PAMAM) generation 3.5 and the polycation 
polyethylenimine, PEI (MW 750 kDa), were also studied.
Finally, isolated rat intestine (the half cell model) was used to investigate the ability of 
polymers or cytokines to modulate the transport of the paracellular marker, FITC-dextran 
(MW 4 kDa). Initially, polymer cytotoxicity was investigated in B16F10 murine melanoma 
and ECV304 human endothelial-like cells using the MTT assay (Mosmann, 1983) after 1 h or 
72 h incubation times. Nontoxic concentrations of polymers (0.1-100 mg/mL) were then 
added to DU937 human macrophage-like cells for 24 h, or to B16F10 (0.1 and 1 mg/mL), or 
to 246.7 (1 mg/mL) murine raw monocyte/macrophage cells, for 1 h, to test their ability to 
induce TNF-a, IFN-y and IL-2 release. Cytokine release was assayed using human and 
murine sandwich-ELISA assays. Effects of IFN-y, TNF-a, IL-2 or polymers on apical to 
basal or basal to apical FITC-dextran transport, across rat jejunal tissue (with or without 
Peyer’s patches), was measured with the vertical diffusion system (Grass & Sweetana, 1988) 
over 1 h. Viability of the tissue was assessed during these experiments by measuring lactate 
dehydrogenase (LDH) release. Polyanions showed little cytotoxicity towards B16F10 cells 
and ECV304 cells at 72 h except polyacrylic acid of MW 100 kDa in both cell lines, and 450 
kDa in B16F10. PEI was cytotoxic even at low concentrations. Decreasing the incubation 
time to 1 h reduced polymer cytotoxicity (IC50 > 1 mg/mL) with the exception of PEI (IC50 
0.04 mg/mL). Highest amounts of TNF-a IL-2 and IFN-y release from B16F10 and 246.7 
cells were seen with PEI (1 mg/mL). Sodium hyaluronate induced TNF-a release (1675- 
2500 pg/mL) from DU937 cells in a concentration-dependent manner. In transport studies, 
FITC-dextran transfer was greatest in the apical to basal direction, and in the absence of 
Peyer’s patches. Apically applied TNF-a (30, 45, 60 pg/mL) tended to enhance FITC-dextran 
transport in a concentration-dependent manner. The polyacrylic acids (MW 100 kDa and 450 
kDa) and alginates (1 mg/mL) showed no increase in apical to basal FITC-dextran transport 
across non-Peyer’s patch tissue. Polyacrylic acid sodium salt (MW 30 kDa), appeared to 
induce an increase in transport.
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